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ABSTRACT OF THE DISSERTATION 
The Role of Schwann Cell Mitochondrial Metabolism in Schwann Cell Biology and 
Axonal Survival 
by 
Andreu Viader 
 
Mitochondrial dysfunction has emerged as a common cause of peripheral 
neuropathies. While the role of neuronal and axonal mitochondria in peripheral nerve 
disease is well appreciated, whether Schwann cell (SC) mitochondrial deficits contribute 
to peripheral neuropathies is unclear. Greater insight into the biology and pathology of 
SC mitochondrial metabolism could be relevant to the treatment of peripheral 
neuropathies, particularly because SCs critically support axonal stability and function as 
well as promote peripheral nerve regeneration. The present thesis investigates the 
contribution of SC mitochondrial deficits to disease progression in peripheral 
neuropathies as well as the gene regulatory network that drives the SC regenerative 
response after injury and in disease states.    
We describe the generation and characterization of the first mouse model useful in 
directly interrogating the contribution of SC mitochondrial dysfunction to peripheral 
neuropathy. These mice (Tfam-SCKOs) were produced through the tissue-specific 
deletion of the mitochondrial transcription factor A gene (Tfam), which is required for 
mtDNA transcription and replication. Interestingly, induction of SC-specific 
mitochondrial dysfunction did not affect SC survival; instead, these deficits resulted in a 
severe, progressive peripheral neuropathy characterized by extensive axonal degeneration 
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that recapitulated critical features of human neuropathy. Mechanistically, we 
demonstrated that SC mitochondrial dysfunction activates a maladaptive integrated stress 
response and causes a shift in lipid metabolism away from new lipid biosynthesis towards 
increased lipid oxidation. These alterations in lipid metabolism caused the early depletion 
of key myelin lipid components as well as a dramatic accumulation of acylcarnitine lipid 
intermediates. Importantly, release of acylcarnitines from SCs was toxic to axons and 
induced their degeneration. Our results show that normal mitochondrial function in SCs 
is essential for maintenance of axonal survival and normal peripheral nerve function, 
suggesting that SC mitochondrial dysfunction contributes to human peripheral 
neuropathies. Moreover, our work identifies alterations in SC lipid metabolism and the 
accumulation of toxic lipid intermediates as novel mechanisms driving some of the 
pathology in peripheral neuropathies associated with mitochondrial dysfunction. 
Tfam-SCKO mice showed a severe deficiency in their ability to remyelinate 
peripheral nerve axons after injury. To gain insight into the highly orchestrated process of 
SC-mediated support of axonal regeneration, we also investigated the transcriptional and 
post-transcriptional gene regulatory program that drives the SC regenerative response. 
We profiled the expression of SC microRNAs (miRNAs) after peripheral nerve lesions as 
well as characterized the injury response of SCs with disrupted miRNA processing and 
showed that SC miRNAs modulated the injury response largely by targeting positive 
regulators of SC dedifferentiation/proliferation. SC miRNAs cooperated with 
transcriptional regulators to promote rapid and robust transitions between the distinct 
differentiation states necessary to support nerve regeneration. Moreover, we identified 
miR-34a and miR-140 as regulators of SC proliferation and myelination. We then used a 
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novel computational approach to infer the gene regulatory network involved in this SC 
injury response and gain insight on cooperative regulation of this process by transcription 
factors and miRNAs.  
Together, the results described in the present thesis represent a significant 
increase in our understanding of how mitochondrial abnormalities specifically in SCs 
contribute to clinical impairment in patients with peripheral neuropathy. Moreover, the 
mechanistic characterization of lipid metabolism abnormalities in SCs following 
mitochondrial dysfunction elucidates potentially important therapeutic targets.  Finally, 
our analysis of the transcriptional and post-transcriptional gene regulatory network 
involved in the SC regenerative response also provides valuable insight that could be 
harnessed to help restore normal nerve function in patients with peripheral neuropathy.  
 
 
 
 
 
 
 
 
 
 
 
 
v 
 
ACKNOWLEDGEMENTS 
This dissertation is the result of a number of years of work and would not have 
been possible without many people that helped and supported me along the way. First I 
would like to thank my advisor Dr. Jeffrey Milbrandt. Over the past five years Jeff has 
provided me with the guidance, the means, and the freedom to pursue exciting projects. 
Jeff has been instrumental to my scientific development and I could not have asked for a 
better mentor. 
 I am also grateful to my thesis committee members Dr. Robert Schmidt, Dr. 
Robert Baloh, Dr. Aaron DiAntonio, Dr. Rakesh Nagarajan, Dr. Timothy Miller and Dr. 
Peter Crawford for their time, advice, and contribution to my progress. Much of this work 
would not have been possible without the help of some fantastic collaborators including 
Dr. Judy Golden, Dr. Kui Yang, Dr. Richard Gross, Elizabeth Jin-Wright, Dr. Robert 
Heuckeroth, Daniel Hunter, and Dr. Dennis Dietzen. Dr. Li-Wei Chang and Dr. Michael 
Kiebish were particularly important colleagues and great friends both in and out of the 
lab.  
I would also like to thank all of the current and past members of the Milbrandt lab 
for their support and friendship. I especially thank Dr. Jason Gustin for welcoming me 
into the lab and teaching me the basics of studying Schwann cells and peripheral nerves; 
Dr. Yo Sasaki, Dr. Jufang Chang, Dr. Biplab Dasgupta, Dr. Craig Press, Dr. Bin Zhang, 
Dr. Albert Misko and Dr. Vohra Bhupinder for invaluable discussions about new 
experiments and results; Amy Strickland, Timothy Farhner, Nina Pachenco, Tasha 
Crawford, Kelli Simburger, Amber Neilson, Anita Soteres and Mary Akin for helping 
vi 
 
with a number of experiments and for keeping in motion all the pieces that it takes to 
carry out a dissertation project.  
I owe a great deal of gratitude to my parents, Emilio and Angels, and my sister 
Neus who have always been there for me in every way possible and have always given 
me their unconditional love. I would also like to acknowledge the tremendous support 
and encouragement I have received from my US/St Louis family and friends, especially 
Maureen and Jaime, who welcomed me into their family with arms wide open, and Justin 
and Maia, who made St. Louis feel a little more like a home away from home. 
Finally, I must thank my wife Meghan who has been the perfect travel companion 
in this journey. She has been extremely understanding of all the long hours spent in the 
lab, while keeping me grounded and showing me the importance of life outside science. I 
could not have done this without her and I look forward to a life full of adventures 
together. This work is dedicated to her.  
 
 
 
 
 
 
 
 
 
 
vii 
 
TABLE OF CONTENTS 
 
ABSTRACT OF THE DISSERTATION ........................................................................... ii 
ACKNOWLEDGEMENTS ................................................................................................ v 
TABLE OF CONTENTS .................................................................................................. vii 
LIST OF FIGURES AND TABLES................................................................................... x 
CHAPTER 1 
Introduction: Peripheral Neuropathy and the Role of Schwann Cell Metabolism in the 
Biology and Pathology of Peripheral Nerves...................................................................... 1 
Peripheral Neuropathies and their clinical impact .......................................................... 2 
Mitochondrial dysfunction as a common element in the diverse etiology of peripheral 
neuropathies .................................................................................................................... 2 
SC support of axonal stability and peripheral nerve function ......................................... 4 
SC regenerative response after peripheral nerve injury and in disease states ................. 7 
Existing evidence of the contribution of SC-specific mitochondrial derangements to the 
pathology of peripheral neuropathies .............................................................................. 7 
The polyol pathway as an example of SC metabolic abnormalities that drive some of 
the pathology in peripheral neuropathies ...................................................................... 10 
Thesis significance and organization ............................................................................ 11 
References ..................................................................................................................... 15 
CHAPTER 2 
Schwann Cell Mitochondrial Metabolism Supports Long-term Axonal Survival and 
Peripheral Nerve Function ................................................................................................ 22 
Abstract ......................................................................................................................... 23 
Introduction ................................................................................................................... 24 
Results ........................................................................................................................... 25 
Discussion ..................................................................................................................... 39 
Materials and Methods .................................................................................................. 44 
Acknowledgements ....................................................................................................... 53 
References ..................................................................................................................... 53 
Figures ........................................................................................................................... 61 
viii 
 
CHAPTER 3 
Mitochondrial Dysfunction-induced Abnormalities in Schwann Cell Lipid Metabolism 
Lead to Axonal Degeneration and Peripheral Neuropathy ............................................... 81 
Abstract ......................................................................................................................... 82 
Introduction ................................................................................................................... 83 
Results ........................................................................................................................... 84 
Discussion ..................................................................................................................... 93 
Methods ......................................................................................................................... 97 
Acknowledgments ......................................................................................................... 98 
References ................................................................................................................... 108 
Figures ......................................................................................................................... 114 
CHAPTER 4 
Differential Regional and Subtype-Specific Vulnerability of Enteric Neurons to 
Mitochondrial Dysfunction ............................................................................................. 129 
Abstract ....................................................................................................................... 130 
Introduction ................................................................................................................. 131 
Results ......................................................................................................................... 133 
Discussion ................................................................................................................... 142 
Materials and Methods ................................................................................................ 145 
Acknowledgments ....................................................................................................... 151 
References ................................................................................................................... 152 
Figures ......................................................................................................................... 158 
Tables .......................................................................................................................... 168 
CHAPTER 5 
microRNAs Modulate Schwann Cell Response to Nerve Injury by Reinforcing 
Transcriptional Silencing of Dedifferentiation-related Genes ........................................ 171 
Abstract ....................................................................................................................... 172 
Introduction ................................................................................................................. 173 
Results ......................................................................................................................... 175 
Discussion ................................................................................................................... 187 
Materials and Methods ................................................................................................ 191 
Acknowledgements ..................................................................................................... 202 
ix 
 
References ................................................................................................................... 203 
CHAPTER 6 
An Integrated Approach to Infer Transcription Factor and microRNA Regulatory 
Networks ......................................................................................................................... 225 
Abstract ....................................................................................................................... 226 
Introduction ................................................................................................................. 227 
Results ......................................................................................................................... 228 
Discussion ................................................................................................................... 240 
Methods ....................................................................................................................... 244 
Acknowledgements ..................................................................................................... 251 
References ................................................................................................................... 251 
Figures ......................................................................................................................... 260 
CHAPTER 7 
Conclusions and Future Directions ................................................................................. 275 
 
 
 
 
 
 
 
 
 
 
 
 
x 
 
LIST OF FIGURES AND TABLES 
 
Chapter 2 
Figure 1 ……………………………………………................................................... 61 
Figure 2 ……………………………………………................................................... 63 
Figure 3 ……………………………………………................................................... 66 
Figure 4 ……………………………………………................................................... 68 
Figure 5 ……………………………………………................................................... 70 
Figure 6 ……………………………………………................................................... 72 
Figure 7 ……………………………………………................................................... 74 
Figure 8 ……………………………………………................................................... 76 
Supplementary Figure 1……………………………................................................... 79 
Chapter 3 
Figure 1 ……………………………………………...................................................114 
Figure 2 ……………………………………………...................................................116 
Figure 3 …………………………………………….................................................. 118 
Figure 4 ……………………………………………..................................................120 
Figure 5……………………………....................................................................121 
Figure 6…………………………..............................................................................123 
Figure 7…………………………..............................................................................125 
Supplementary Figure 1………………………….................................................. 126 
Supplementary Figure 2………………………….................................................. 127 
Chapter 4 
Figure 1 …………………………………………….................................................158 
Figure 2 …………………………………………….................................................160 
xi 
 
Figure 3 …………………………………………….................................................162 
Figure 4 …………………………………………….................................................164 
Figure 5 …………………………………………….................................................166 
Table 1 …………………………………………….................................................168 
Table 2 …………………………………………….................................................169 
Table 3 …………………………………………….................................................169 
Table 4 …………………………………………….................................................170 
Chapter 5 
Figure 1 ……………………………………………................................................211 
Figure 2 ……………………………………………..................................................213 
Figure 3 …………………………………………….................................................216 
Figure 4 …………………………………………….................................................219 
Figure 5 …………………………………………….................................................222 
Chapter 6 
Figure 1 …………………………………………….................................................260 
Figure 2 …………………………………………….................................................262 
Figure 3 …………………………………………….................................................264 
Figure 4 …………………………………………….................................................266 
Figure 5 …………………………………………….................................................268 
Supplementary Figure 1…………………………….................................................270 
Supplementary Figure 2…………………………….................................................271 
Supplementary Figure 3…………………………….................................................273 
Supplementary Figure 4…………………………….................................................274 
 
 
1 
 
 
 
 
 
CHAPTER 1 
 
 
Introduction: Peripheral Neuropathy and the Role of Schwann Cell Metabolism in 
the Biology and Pathology of Peripheral Nerves 
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Peripheral Neuropathies and their clinical impact 
Peripheral neuropathy is a general term used to describe any disorder 
characterized by peripheral nerve abnormalities. These nerve abnormalities include 
electrophysiological deficits such as reduced nerve conduction velocity as well as 
structural changes like axonal degeneration or demyelination. Structural and functional 
nerve abnormalities in peripheral neuropathies cause the clinical impairment observed in 
individuals afflicted with these diseases and can lead to incapacitating pain, sensory loss, 
and debilitating muscle weakness (England and Asbury, 2004). With an overall 
prevalence of 2400 per 100 000 (2.4%), rising to 8000 per 100 000 (8%) in people older 
than 55 years (Hughes, 2002), peripheral neuropathies are a common cause of substantial 
morbidity. At the same time these diseases constitute a significant economic and societal 
burden. For example, the total annual health care costs in the US for diabetic neuropathy, 
the most common form of peripheral nerve disease in developed countries, were 
estimated to be between $4.6 and $13.7 billion in 2001 (Gordois et al., 2003). It is 
therefore imperative to develop new therapeutic interventions to effectively treat patients 
with peripheral neuropathy. Discovery of new therapies could be greatly facilitated by an 
increased understanding of the underlying pathophysiological mechanisms of peripheral 
nerve disease, which still remain incompletely understood.  
 
Mitochondrial dysfunction as a common element in the diverse etiology of 
peripheral neuropathies 
The term peripheral neuropathy encompasses a myriad of forms of peripheral 
nerve disease with very diverse etiologies. In the developed world, the most common 
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cause of peripheral neuropathy is diabetes mellitus (Hughes, 2002). Given the rising 
prevalence of diabetes worldwide due to the epidemic in obesity, the incidence of 
diabetic peripheral neuropathy is also expected to rise (Fernyhough et al., 2010). In the 
developing world, leprosy continues to be a major cause of neuropathy. A range of 
metabolic disorders, infectious agents, vasculitis, toxins, and drugs are other common 
systemic causes of peripheral neuropathy. Finally, immune abnormalities and genetic 
mutations are also responsible for a substantial portion of chronic neuropathies (Hughes, 
2002). 
Despite this apparent etiological diversity, mitochondrial derangements have 
emerged as a common cause of many types of peripheral neuropathy. Ultrastructural 
morphological abnormalities of mitochondria, which are commonly associated with 
organelle dysfunction, have been reported in the nerves of patients with diabetic 
neuropathy as well as in animal models of the disease (Fernyhough et al., 2010; 
Kalichman et al., 1998). Dorsal root ganglion neurons in animal models of diabetes also 
show decreased mitochondria respiratory chain enzyme activities and overall 
mitochondrial respiration (Chowdhury et al., 2010). Similarly, metabolic and 
morphological mitochondrial abnormalities are also present in the nerves of patients and 
animal models of neuropathy associated with HIV/AIDS as well as with antiretroviral or 
chemotherapeutic treatment (Flatters and Bennett, 2006; Lehmann et al., 2011; Lewis and 
Dalakas, 1995). Moreover, the recent identification of disease-causing mutations that 
affect mitochondrial proteins and function in patients with inherited forms of peripheral 
neuropathy (known as Charcot-Marie-Tooth disease, CMT) has further confirmed central 
role of mitochondrial derangements in the pathophysiology of peripheral nerve disease 
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(Niemann et al., 2006). The need to elucidate the manner in which mitochondrial 
dysfunction underlies progression of peripheral nerve disease is thus well appreciated.  
To date much effort has been devoted to elucidating the role of neuronal and 
axonal mitochondria in peripheral neuropathies (Baloh, 2008). A growing body of 
evidence, however, has shown that Schwann cells (SCs), the main glial cell type in the 
peripheral nervous system, are essential to supporting axonal survival and peripheral 
nerve function (Chen et al., 2003; Meyer zu Horste et al., 2007; Reddy et al., 2003). 
These cells are also critical for nerve regeneration to occur after injury and during disease 
processes (Geuna et al., 2009). Moreover, glia are increasingly recognized as key 
contributors to the pathophysiology of neurodegenerative diseases traditionally thought to 
be neuron autonomous (Ilieva et al., 2009). The development of effective therapies for 
treatment of peripheral neuropathies will therefore need to address the contribution of SC 
mitochondrial dysfunction to disease progression. 
 
SC support of axonal stability and peripheral nerve function 
SCs are the main glial cell type in the peripheral nervous system (PNS) and they 
cover most of the surface of all axons in peripheral nerves. SCs are best known for their 
role in peripheral nerve myelinogenesis, during which individual SCs wrap around single 
axons, establish the boundaries for the formation of the nodes of Ranvier, and deposit the 
myelin sheath (Sherman and Brophy, 2005). SCs provide in this way the insulation and 
clustering of ion channels required for rapid, saltatory transmission of action potentials. 
Of the four types of SCs found in the mature nervous system, however, only myelinating 
SCs (MSCs) are involved in the formation of the myelin sheath. The majority of SCs in 
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the PNS are in intimate contact with neurons but do not form myelin (Corfas et al., 2004). 
This suggests that the role of SCs in the PNS extends beyond the assembly and 
maintenance of myelin. 
A number of studies have now established a critical role for SCs in the 
preservation of axonal function and survival. Chen et al.(Chen et al., 2003) showed that 
disruption of ErbB receptor-mediated communication between axons and non-
myelinating SCs (NMSCs) causes degeneration of unmyelinated axons and progressive 
sensory neuropathy. Similarly, perisynaptic SCs (PSCs), a second type of non myelin-
forming SCs, are essential for the long-term survival of axon terminals at the 
neuromuscular junction (Reddy et al., 2003). MSCs are also vital for the maintenance of 
axonal integrity.  Axonal degeneration ensues when the interactions between MSCs and 
axons are perturbed, as is presumably the case in axonopathies caused by mutations in the 
MSC-specific myelin protein zero (P0) (Bienfait et al., 2006; Shy, 2006), as well as in 
virtually all demyelinating neuropathies (Shy et al., 2002). In these situations, damage to 
axons is not caused by the loss of myelin itself since axonal degeneration and 
demyelination can be pharmacologically uncoupled (Meyer zu Horste et al., 2007). Long-
term support of axonal integrity is, therefore, a primary function of all SCs separate from 
the role of some SCs in the formation and maintenance of myelin. 
The mechanisms and cellular machinery underlying SC preservation of axons still 
remain largely unknown. It is currently believed that this glial support requires axonal 
engulfment and a molecular apparatus that includes some myelin-related components 
(Nave and Trapp, 2008). This notion stems from the observation that in the central 
nervous system (CNS), where oligodendrocytes (OLs) also preserve axonal integrity 
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independent of myelin (Griffiths et al., 1998; Lappe-Siefke et al., 2003), mutations in 
some myelin proteins cause axonal loss (Griffiths et al., 1998) while others cause severe 
dysmyelination without signs of axonal degeneration (Griffiths et al., 1998; Inoue et al., 
1981; Rosenbluth, 1980). It is not clear, however, whether the same molecular machinery 
is at work in the PNS and how it may apply to MSCs and NMSCs.  
Trophic support of axons through neurotrophic factors has also been hypothesized 
as a potential mechanism behind glia-mediated axonal maintenance. While the role of 
glia-derived neurotrophins during development, myelinogenesis, and remyelination has 
been described in detail (Rosenberg et al., 2006), there is little experimental evidence of 
continuous glial trophic support of mature axons. Further work is necessary before a role 
for SC-derived neurotrophins in axonal preservation can be asserted.  
Metabolic support of axons by ensheathing cells is also a likely but poorly 
understood mechanism of axonal preservation. For example, SCs may support axons 
through the transfer of metabolites or by helping axons eliminate certain toxic species, as 
is the case between CNS neurons and astrocytes (Benarroch, 2005; Magistretti, 2006). 
This type of metabolic support by axon ensheathing glia has not been well analyzed, but 
may be particularly relevant in the context of neuropathies associated with mitochondrial 
dysfunction. Disruption of the putative SC metabolic support of axons following 
abnormalities in SC mitochondrial metabolism could potentially drive some of the 
pathology of peripheral neuropathies.  
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SC regenerative response after peripheral nerve injury and in disease states 
Besides being essential to support axonal survival and normal peripheral nerve 
function under physiological conditions, SCs are also critical for nerve regeneration to 
occur during pathological processes. In the peripheral nervous system, SCs surrounding 
damaged axons undergo an injury response that enables the long distance regeneration of 
these axons. SCs have the striking ability to dedifferentiate and revert back to an 
immature-like state following axonal loss (Jessen and Mirsky, 2008). After a transient 
phase of proliferation, dedifferentiated SCs help support axonal regeneration by clearing 
myelin debris, forming tubular structures known as bands of Bungner, and upregulating 
the synthesis of a number of neurotrophic factors. As peripheral axons regenerate, SCs 
re-differentiate to form mature Remak bundles or new myelin sheaths, helping to restore, 
in this way, peripheral nerve function (Geuna et al., 2009). Greater insight into this highly 
orchestrated process of SC-mediated support of axonal regeneration could be harnessed 
to improve the treatment of peripheral and central neurodegenerative diseases 
characterized by axonopathy, including diabetic neuropathy (Coleman, 2005).  
 
Existing evidence of the contribution of SC-specific mitochondrial derangements to 
the pathology of peripheral neuropathies 
As described above, SCs have a primary role in supporting axonal function and 
survival (Chen et al., 2003; Meyer zu Horste et al., 2007; Reddy et al., 2003) and in 
enabling peripheral nerve repair in disease processes (Geuna et al., 2009). Given this 
critical involvement of SCs in the maintenance of peripheral nerves, mitochondrial 
dysfunction specifically in these glia is likely to cause some of the pathophysiological 
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changes that lead to clinical impairment in people with peripheral neuropathies. In fact, a 
growing body of literature implicates glial dysfunction in a number of neurodegenerative 
diseases traditionally thought to be neuron cell autonomous. Expression of disease-
causing mutant proteins specifically in glial cells has been shown to alter disease onset 
and progression in transgenic mouse models of amyotrophic lateral sclerosis (Boillee et 
al., 2006; Wang et al., 2009; Yamanaka et al., 2008) and Parkinson’s disease (Yazawa et 
al., 2005) among others (For review see Ilieva et al., 2009). The contribution of SC 
mitochondrial abnormalities to the pathology observed in peripheral nerve diseases, 
however, has remained largely unexplored.  
Attempts to address how SC mitochondrial deficits may play a role in peripheral 
neuropathy have been limited by the fact that the mechanisms that disrupt mitochondrial 
function in neuropathic nerves presumably affect all cells and not just SCs. Moreover, 
neuropathies associated with mitochondrial dysfunction can display a range of 
presentation that make it difficult to establish what cell type is primarily involved. This is 
particularly clear in the case of inherited neuropathies caused by mutations in 
ubiquitously expressed mitochondrial proteins, such as ganglioside-induced 
differentiation associated protein 1 (GDAP1). GDAP1 is a protein that localizes to the 
outer mitochondrial membrane and regulates mitochondrial fission (Niemann et al., 
2005). This process is essential to normal mitochondrial function because it regulates the 
number, morphology, and localization of these organelles, as well as their ability to 
exchange intraorganelle content and to carry out apoptosis (Detmer and Chan, 2007). 
GDAP1 mutations that lead to a reduction or loss of mitochondrial fission have now been 
identified in CMT patients. These patients can suffer from demyelinating, intermediate or 
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axonal forms of CMT (Niemann et al., 2005). Given that GDAP1 is expressed both in 
SCs and neurons, the degree to which SC mitochondrial dysfunction contributes to the 
diverse pathology observed in these CMT patients remains to be established.  
Evidence from peripheral neuropathy-prone mitochondriopathies, however, first 
suggested that mitochondrial dysfunction specifically in SCs may be a major driving 
force in the development of both myelin and axonal degeneration. Studies reviewing the 
nerve pathology in mitochondrial disorder patients with clinically apparent signs of 
peripheral neuropathy found that most mitochondrial abnormalities were localized to SCs 
(Bouillot et al., 2002; Schroder, 1993). Enlarged mitochondria with an amorphous matrix, 
distorted cristae, or containing paracrystalline material were predominantly found in SCs, 
particularly those surrounding unmyelinated axons. Similar observations have been 
reported in patients suffering from polyneuropathies associated with diabetes and 
HIV/AIDS (Kalichman et al., 1998; Schroder, 1993). SC-mediated nerve regenerative 
plasticity is also severely compromised in diabetic neuropathy (Kennedy and Zochodne, 
2005), further highlighting the potential importance of SC-specific metabolic 
abnormalities in the context of peripheral nerve disease. Therefore, the generation of 
novel models of peripheral neuropathy secondary to mitochondrial dysfunction that allow 
the examination of pathological processes specifically in SCs could greatly aid the 
development of new therapeutic strategies.  
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The polyol pathway as an example of SC metabolic abnormalities that drive some of 
the pathology in peripheral neuropathies 
The notion that understanding how SC mitochondrial dysfunction contributes to 
peripheral neuropathies could be therapeutically relevant is supported by earlier work 
examining the polyol pathway in diabetic neuropathy. This pathway represents an 
example of a metabolic abnormality that primarily affects SCs yet causes some of the 
pathology present in diabetic neuropathy. The polyol pathway is an alternative catabolic 
pathway that converts glucose to sorbitol. This pathway is normally not very active 
because aldose reductase, the first enzyme in the pathway, has a lower affinity for 
glucose than the glycolytic enzyme hexokinase. In normal nerves, therefore, most glucose 
is converted to glucose-6-phosphate instead of sorbitol. Increased intracellular glucose in 
diabetic peripheral nerves, however, saturates hexokinase and increases the flux through 
the polyol pathway. A high “flux” rate of glucose through the polyol pathway is thought 
to deplete cofactors such as NADPH and NAD+, thus causing peripheral nerve 
pathology. Appreciable increases in intracellular sorbitol concentrations may also lead to 
some tissue toxicity through an increased osmotic effect (for review see Tomlinson and 
Gardiner, 2008). 
 Interestingly, aldose reductase was found to be mainly expressed in SCs 
(Ludvigson and Sorenson, 1980). The pathology present in diabetic nerves secondary to 
increased activity of the sorbitol pathway may therefore primarily reflect abnormal 
metabolism in SCs. Overexpression of aldose reductase specifically in SCs was in fact 
shown to worsen pathophysiolgocial alterations present in a mouse model of diabetes 
(Song et al., 2003). Aldose reductase inhibitors have been successfully used to treat 
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animal models of diabetic neuropathy and somewhat promising results have been 
achieved in human clinical trials (Tomlinson and Gardiner, 2008). Importantly these 
results emphasize the potential of targeting metabolic abnormalities that may primarily 
affect SCs as a way to treat peripheral neuropathies.  
 
Thesis organization and significance 
Mitochondrial dysfunction has emerged as a common cause of peripheral 
neuropathies, a heterogeneous group of disorders characterized by peripheral nerve 
abnormalities and associated with substantial morbidity (Hughes, 2002). The need to 
elucidate the manner in which mitochondrial dysfunction underlies progression of 
peripheral nerve disease is thus well appreciated; to date much effort has been devoted to 
clarifying the role played by neuronal/axonal mitochondria (Baloh, 2008). The 
contribution of SC-specific mitochondrial deficits to the pathophysiology of peripheral 
neuropathy, however, has remained largely unexplored. Greater insight into the biology 
and pathology of SC mitochondrial metabolism could be relevant to the treatment of 
peripheral neuropathies, particularly because SCs critically support axonal stability and 
function as well as peripheral nerve regeneration (Chen et al., 2003; Meyer zu Horste et 
al., 2007; Reddy et al., 2003). The present thesis addresses the contribution of 
mitochondrial deficits specifically in SCs to disease progression in peripheral nerve 
disease. We also explore the gene regulatory network that is important for peripheral 
nerve regeneration after injury and in disease states.    
In the first part of the thesis (Chapter 2) we describe the generation and 
characterization of the first mouse model useful in directly interrogating the contribution 
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of SC mitochondrial dysfunction to peripheral neuropathy (Viader et al., 2011a). These 
mice, Tfam-SCKOs, were produced through the tissue-specific deletion of the 
mitochondrial transcription factor A gene (Tfam), which is required for mtDNA 
transcription and replication and when excised induces progressive defects in the 
mitochondrial electron transport chain (Larsson et al., 1998). Interestingly, induction of 
SC-specific mitochondrial dysfunction did not affect SC survival; instead, these deficits 
resulted in a severe, progressive peripheral neuropathy characterized by extensive axonal 
degeneration that recapitulated critical features of human neuropathy. These results 
showed that mitochondrial function in SCs is essential for maintenance of axonal survival 
and normal peripheral nerve function, suggesting that SC mitochondrial dysfunction 
contributes to human peripheral neuropathies.  
Having established the relevance of the characterization Tfam-SCKO mice to 
understanding and potentially treating peripheral neuropathies, we next focused on 
discovering the mechanisms underlying the nerve pathology in these mice. In Chapter 3 
(manuscript in preparation), we show that SC mitochondrial dysfunction activates a 
maladaptive integrated stress response and causes a shift in lipid metabolism away from 
new lipid biosynthesis towards increased lipid oxidation. These alterations in lipid 
metabolism caused the early depletion of key myelin lipid components that likely account 
for the severe demyelination that characterizes the late pathology in Tfam-SCKO mice. 
Moreover, increased lipid oxidation resulted in a dramatic accumulation of acylcarnitine 
lipid intermediates, particularly as mitochondrial dysfunction worsened. Importantly, we 
found that these lipid intermediates could be released from SCs and were toxic to axons, 
inducing them to degenerate. Our results identify alterations in SC lipid metabolism and 
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accumulation of toxic lipid intermediates as a novel mechanism driving some of the 
pathology of peripheral neuropathies associated with mitochondrial dysfunction.  
During our investigation of mice lacking Tfam-specifically in SCs, we 
inadvertently deleted Tfam from enteric neurons and glia and generated mice with 
disrupted mitochondrial metabolism in the enteric nervous system (Tfam-ENSKOs; 
Viader et al., 2011b). This was of interest because mitochondrial dysfunction is a central 
mediator of disease progression in diverse neurodegenerative diseases that often present 
with prominent gastrointestinal abnormalities. Given the lack of animal models to study 
the role of mitochondrial deficits in ENS neurodegeneration and gastrointestinal 
dysfunction, we carried out a phenotypic characterization of the Tfam-ENSKO mice. 
Interestingly, these mice showed that mitochondrial defects differentially affected 
specific subpopulations of enteric neurons and regions of the gastrointestinal tract. This 
regional and subtype-specific variability in susceptibility to mitochondrial defects 
resulted in an imbalance of inhibitory and excitatory neurons that caused a severe 
gastrointestinal pseudo-obstruction phenotype in Tfam-ENSKO mice. Mitochondrial 
dysfunction, therefore, is likely to be an important driving force of neurodegeneration in 
the ENS and contribute to gastrointestinal symptoms in people with neurodegenerative 
disorders.   
Tfam-SCKO mice showed a severe deficiency in their ability to remyelinate 
peripheral nerve axons after injury. To gain insight into the highly orchestrated process of 
SC-mediated support of axonal regeneration, the last part of this thesis investigates the 
transcriptional and post-transcriptional gene regulatory program that drives the SC 
regenerative response (Chapter 5, Viader et al., 2011c; Chapter 6, Chang et al., 2011). 
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Since at the time we started this work it was unclear whether injury-induced changes in 
SCs were orchestrated post-transcriptionally by microRNAs (miRNAs), we initially 
profiled the expression of SC miRNAs after peripheral nerve lesions and characterized 
the injury response of SCs with disrupted miRNA processing. We found that SC miRNAs 
modulated the injury response largely by targeting positive regulators of SC 
dedifferentiation/proliferation. SC miRNAs cooperated with transcriptional controls to 
promote rapid and robust transitions between the distinct differentiation states necessary 
to support nerve regeneration. Moreover, we identified miR-34a and miR-140 as 
regulators of SC proliferation and myelination. Having identified miRNAs as important 
modulators of the SC regenerative response, we used a novel computational approach to 
infer the integrated transcription factor (TF) and miRNA regulatory network involved in 
this SC process. Further analysis of regulatory network motifs in this SC injury response 
network provided insight on cooperative regulation of this process by TFs and miRNAs.  
Together, the results described in the present thesis represent a significant 
increase in our understanding of how mitochondrial abnormalities specifically in SCs 
contribute to the disease progression and clinical impairment in patients afflicted with 
peripheral neuropathy. Furthermore, the mechanistic characterization of the lipid 
metabolism abnormalities that occur in SCs following mitochondrial dysfunction 
provides new potentially important therapeutic targets.  Finally, our analysis of the 
transcriptional and posttranscriptional regulatory networks involved in the SC 
regenerative response also give new valuable insight that could be harnessed to restore 
normal nerve function in patients with peripheral neuropathy.  
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CHAPTER 2: 
 
 
Schwann Cell Mitochondrial Metabolism Supports Long-term Axonal Survival and 
Peripheral Nerve Function 
 
 
 
 
 
 
 
Adapted from: Viader A, Golden JP, Baloh RH, Schmidt RE, Hunter DA, Milbrandt J. 
(2011). Schwann cell mitochondrial metabolism supports long-term axonal survival and 
peripheral nerve function. J Neurosci 31(28): 10128-10140.  
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Abstract 
Mitochondrial dysfunction is a common cause of peripheral neuropathies. While 
the role of neuron and axonal mitochondria in peripheral nerve disease is well 
appreciated, whether Schwann cell (SC) mitochondrial deficits contribute to peripheral 
neuropathies is unclear. Here we examine how SC mitochondrial dysfunction affects 
axonal survival and contributes to the decline of peripheral nerve function by generating 
mice with SC-specific mitochondrial deficits. These mice (Tfam-SCKOs) were produced 
through the tissue-specific deletion of the mitochondrial transcription factor A gene 
(Tfam), which is essential for mitochondrial DNA (mtDNA) transcription and 
maintenance. Tfam-SCKOs were viable but, as they aged, they developed a progressive 
peripheral neuropathy characterized by nerve conduction abnormalities as well as 
extensive muscle denervation. Morphological examination of Tfam-SCKO nerves 
revealed early preferential loss of small unmyelinated fibers followed by prominent 
demyelination and degeneration of larger-caliber axons. Tfam-SCKOs displayed sensory 
and motor deficits consistent with this pathology. Remarkably, the severe mtDNA 
depletion and respiratory chain abnormalities in Tfam-SCKO mice did not affect SC 
proliferation or survival. Mitochondrial function in SCs is therefore essential for 
maintenance of axonal survival and normal peripheral nerve function, suggesting that SC 
mitochondrial dysfunction contributes to human peripheral neuropathies.  
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Introduction 
Peripheral neuropathies are a heterogeneous group of disorders characterized by 
peripheral nerve abnormalities. With an incidence of up to 8% in elderly populations, 
peripheral neuropathies are a common cause of substantial morbidity and constitute a 
significant economic and societal burden (Hughes, 2002). The etiology for these diseases 
is varied, ranging from vascular and metabolic irregularities to genetic mutations. Despite 
this apparent diversity, mitochondrial derangements have emerged as a common cause of 
many types of peripheral neuropathy. A number of mutations that affect mitochondrial 
function are now thought to be responsible for several forms of inherited neuropathies 
(Niemann et al., 2006). Similarly, diabetic neuropathy, the most prevalent form of 
peripheral nerve disease, is also associated with abnormalities in mitochondrial 
morphology and metabolism (Fernyhough et al., 2003). With the hope of developing new 
therapies, therefore, much effort is being devoted to understanding how mitochondrial 
deficiencies influence nerve function.  
In recent years, significant progress has been made in elucidating the role of 
axonal mitochondria in peripheral neuropathies (Baloh, 2008). Peripheral nerve axons, 
however, do not function in isolation. SCs, the main glial cell type in the PNS, are 
intimately associated with all peripheral nerve axons and are essential for their long-term 
preservation and survival (Chen et al., 2003; Reddy et al., 2003; Meyer zu Horste et al., 
2007). Mitochondrial dysfunction in SCs is thus likely to participate in the disease 
progression in peripheral neuropathies. In fact, pathological mitochondria in neuropathic 
nerves are often localized to SCs (Schroder, 1993; Kalichman et al., 1998). The 
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contribution of SC mitochondrial dysfunction to the pathology observed in peripheral 
nerve diseases, however, is poorly understood and remains largely unexplored. 
With the goal of understanding whether SC mitochondrial abnormalities affect 
axonal survival and contribute to the decline of patients suffering from peripheral nerve 
diseases, we generated mice with impaired mitochondrial function exclusively in SCs. 
These Tfam-SCKO mice were generated through the tissue-specific deletion of the 
mitochondrial transcription factor A gene (Tfam), which is required for mtDNA 
transcription and replication (Larsson et al., 1998). Here we show that mitochondrial 
function in SCs is essential for maintenance of axonal survival and normal peripheral 
nerve function. Importantly, SC mitochondrial dysfunction alone recapitulated a number 
of critical features of human neuropathies. Remarkably, the severe mtDNA depletion and 
respiratory chain abnormalities in Tfam-SCKO mice did not affect SC survival. SC 
mitochondrial dysfunction, therefore, is a likely contributor to the impairment of patients 
suffering from peripheral neuropathies. 
 
Results 
Schwann cell-specific disruption of the Tfam gene 
To study how mitochondrial dysfunction affects SCs and their ability to support 
long-term axonal survival, we generated mice with disrupted mitochondria only in SCs 
(Tfam-SCKOs). For this purpose we used a previously developed mouse with loxP-
flanked Tfam alleles (Tfam
loxP
) (Larsson et al., 1998) (Fig. 1a). TFAM is a nuclearly-
encoded mitochondrial protein that is essential for mtDNA maintenance, copy number 
regulation and transcription (Larsson et al., 1998; Ekstrand et al., 2004). Previous reports 
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have shown that the deletion of Tfam in Tfam
loxP
 homozygous mice that express cre-
recombinase in a tissue of interest results in severe tissue-specific mtDNA depletion and 
mitochondrial respiratory chain deficiency (Larsson et al., 1998; Wang et al., 1999; Silva 
et al., 2000; Sorensen et al., 2001; Wredenberg et al., 2002). This makes the tissue-
specific deletion of Tfam an effective way to induce mitochondrial dysfunction in a 
selected population of cells.   
We mated Tfam
loxP
 mice to mice that express cre-recombinase under the control 
of the P0 promoter (P0-Cre) (Feltri et al., 1999). P0-Cre mice are well-established to 
induce specific recombination of floxed genes in peripheral myelinating and non-
myelinating SCs starting at E13.5-14.5, but not in any other central or peripheral neuron 
or glia (Feltri et al., 1999; Feltri et al., 2002). We confirmed this selectivity by crossing 
P0-Cre mice with Cre-inducible Rosa26-YFP reporter animals. Indeed, YFP fluorescence 
was visible in most sciatic nerve SCs but not in axons or perineurial cells. Similarly, YFP 
could also be seen in most dorsal root ganglia SCs (satellite cells) but not in DRG 
neurons (Fig. 1b). In agreement with previous reports, therefore, P0-Cre induced selective 
recombination in most peripheral SCs.  
The observed P0-Cre-mediated excision of Tfam in SCs was highly efficient.  
Analysis of Tfam mRNA and protein levels from Tfam-SCKO sciatic nerve extracts 
showed an 80% reduction compared to littermate controls (Fig. 1c and d). Considering 
that an estimated 15% of endoneurial cells are P0-Cre negative fibroblast and 
macrophages (King RH, 2005) and that nerve extracts also contain some perineurial and 
endothelial cells, the actual excision rate of Tfam in SCs was probably near complete. 
Given the high selectivity and efficiency of the P0-promoter driven expression of cre-
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recombinase, we conclude that the mating of Tfam
loxP
 to P0-Cre mice resulted in animals 
that lacked Tfam specifically in SCs. 
 
SC mtDNA depletion and respiratory dysfunction in Tfam-SCKOs  
To determine the functional effect of deleting Tfam in SCs, we next assessed 
mtDNA copy number and transcript level in Tfam-SCKO sciatic nerves. Consistent with 
the essential role of Tfam in the maintenance, replication and transcription of mtDNA 
(Larsson et al., 1998; Ekstrand et al., 2004), as well as with previous reports describing 
tissue-specific Tfam knock-out mice (Larsson et al., 1998; Wang et al., 1999; Silva et al., 
2000; Sorensen et al., 2001; Wredenberg et al., 2002), total mtDNA content was found to 
be significantly reduced in Tfam-SCKO nerves compared to control animals (Fig. 2a). 
Similarly, transcripts of two different mitochondrially-encoded proteins (mt-ND2 and mt-
Cox1) were also severely depleted in the sciatic nerves of Tfam-SCKO animals (Fig. 2b). 
As expected, no differences in the transcript levels of nuclearly-encoded mitochondrial 
proteins were observed (Fig. 2b).  
The mitochondrial genome encodes 13 subunits that are essential components of 
complexes I, III, IV and V of the electron transport chain. The depletion of mtDNA and 
mitochondrially-encoded transcripts following Tfam excision has been previously shown 
to induce severe respiratory chain deficiency (Larsson et al., 1998; Wang et al., 1999; 
Silva et al., 2000; Sorensen et al., 2001; Wredenberg et al., 2002). To examine the 
dysfunction of SC mitochondria in Tfam-SCKO mice we first assessed respiratory chain 
enzyme activities in the sciatic nerves of 2 month old animals. At this age, Tfam has 
already been efficiently excised in sciatic nerve SCs and mtDNA content and transcripts 
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have been severely depleted (See Fig. 1c and d and Fig. 2a and b). Mitochondria isolated 
from Tfam-SCKO sciatic nerves showed a 60% reduction in COX activity (complex IV), 
which contains critical mtDNA-encoded subunits (Fig. 2c). As expected, the activity of 
SDH (complex II), which is fully nuclearly encoded, showed no significant change in 
mitochondria isolated from Tfam-SCKO sciatic nerves (data not shown). 
To further confirm the disruption of SC mitochondria in Tfam-SCKO mice, we 
next used high-resolution respirometry to measure mitochondrial respiration under 
different substrates in permeabilized 2 month old Tfam-SCKO sciatic nerves. Respiration 
induced by substrates delivering electrons to complex I (pyruvate+malate), was 
significantly impaired in Tfam-SCKO sciatic nerves compared to littermate controls. 
Similarly, respiration induced by the convergent transport of electrons entering at 
complexes I and II (using pyruvate+malate+succinate as substrates), which best 
corresponds to the mitochondrial substrate supply in vivo (Gnaiger, 2009), was also 
significantly reduced in Tfam-SCKO sciatic nerves compared to littermate controls. 
These reductions in mitochondrial respiration in Tfam-SCKO nerves are likely explained 
by defects in complexes I, III and IV as these complexes contain mtDNA-encoded 
subunits. Respiration induced by electrons entering at the level of complex II remained 
unchanged in Tfam-SCKO nerves, which is explained by the fact that complex II 
contains only nuclearly-encoded subunits (Fig. 2d).  
It should be emphasized that while the functional deficits described above were 
measured from whole Tfam-SCKO sciatic nerves, they are a reflection of the mtDNA-
depletion and mitochondrial dysfunction taking place specifically in SCs. The high 
specificity of the P0-cre mediated excision of Tfam ensures this (Fig. 1b). Moreover, 
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COX enzymatic staining, which reflects respiratory chain activity in individual cells, 
showed reduced staining intensity in the cell bodies of SCs in Tfam-SCKO sciatic nerves 
(Fig. 2e). Finally, electron microscopy of Tfam-SCKO nerves revealed abundant 
abnormal, enlarged mitochondria, sometimes with distorted cristae, specifically in SC but 
not in axons (Fig. 2f). Together, our results confirm that by deleting Tfam specifically in 
SCs we were able to generate a mouse with disrupted mitochondrial metabolism only in 
peripheral glia.  
 
Tfam-SCKOs develop a progressive degenerative peripheral neuropathy 
Despite severe mtDNA and transcript depletion as well as respiratory chain 
dysfunction in their SCs, Tfam-SCKO animals were born at the expected Mendellian 
ratios and survived to at least 12 months of age (the longest a Tfam-SCKO was allowed 
to survive before it was sacrificed). Tfam-SCKO animals developed normally and were 
indistinguishable from their control littermates up to 3 months of age. Starting at 3-4 
months of age, however, Tfam-SCKOs showed signs of muscle weakness and gait 
abnormality. Tfam-SCKOs exhibited abnormal limb clasping, mild tremors, impaired 
coordination and developed a characteristic “swimming-gait”.  These deficits 
progressively worsened so that by 8 months of age, most Tfam-SCKOs were often unable 
to support themselves on their hind legs (Fig. 3a). Such motor abnormalities are 
indicative of peripheral nerve disease and have been previously described in other mouse 
models of peripheral neuropathy (Le et al., 2005; Ryu et al., 2007; Baloh et al., 2009).  
Reduced peripheral nerve conduction velocity is a hallmark and diagnostic marker 
of diabetic as well as other mitochondria-related neuropathies (Arezzo and Zotova, 
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2002). To further characterize the peripheral nerve deficits in Tfam-SCKOs we 
performed nerve conduction studies both on pre-symptomatic and symptomatic mice. 
Nerve conduction velocity was significantly reduced in Tfam-SCKO animals as early as 
2 months of age and this deficit persisted over time (Fig. 3c). Moreover, Tfam-SCKO 
mice displayed marked temporal dispersion at 4 months of age (Fig. 3b and d). Both 
these findings are suggestive of a progressive demyelinating phenotype in Tfam-SCKO 
mice. 
 Interestingly, electromyography (EMG) of Tfam-SCKOs showed occasional 
fibrillation potentials and fasciculations at 2-3 months of age, which became prominent at 
4 months and continued to worsen with increasing age (Fig. 3e and data not shown). 
These EMG findings reflect loss of muscle fiber innervation and spontaneous firing of 
motor units, and are often seen in human nerve diseases involving motor axon loss. Thus, 
our EMG results indicated a progressive axonal degeneration phenotype in Tfam-SCKO 
mice. This was confirmed by muscle histology, which revealed abundant denervated 
atrophic muscle fibers (Fig. 3f). SC-specific mitochondrial dysfunction caused, therefore, 
a progressive peripheral neuropathy characterized by both demyelination as well as 
axonal degeneration.  
 
Tfam-SCKOs display early preferential loss of small unmyelinated fibers 
To examine in detail the peripheral nerve abnormalities in Tfam-SCKOs we 
performed histological and electron microscopy analysis of Tfam-SCKO sciatic nerves at 
different ages. Tfam-SCKO nerves initially developed normally and for the first 2-3 
weeks of life there were no obvious differences between Ctrl and Tfam-deficient nerves 
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(data not shown). As early as 1 month of age, however, Tfam-SCKO nerves started to 
display signs of pathology. Interestingly, we found that these early abnormalities 
preferentially affected, and were initially limited to, small-caliber unmyelinated fibers (C 
fibers) (Fig. 4a-e) 
Small caliber fibers are normally associated with non-myelinating SCs, such that 
a single SC wraps around multiple axons to form a Remak bundle. The Remak bundle is 
delimited by a basement membrane and individual axons are kept separate from one 
another inside it by a thin extension of SC cytoplasm (Fig. 4e-1). At 1 month, the 
structure of Remak bundles in Tfam-SCKO nerves was clearly disrupted (Fig. 4d and e). 
Unmyelinated axons within a Remak bundle were often found touching one another and 
interspersed by pathological SC processes known as Bands of Bungner (Fig. 4e-2). 
Moreover, degeneration of unmyelinated axons was extensive and evidenced by free-
floating, excess basement membrane surrounding empty spaces previously occupied by 
axon bundles (Fig. 4e-2, 3). Precise quantification of small fiber loss in the nerves of 
Tfam-SCKO mice, however, was not possible because of the difficulty of distinguishing 
abnormal unmyelinated axons from SC processes forming Bands of Bungner. Note that, 
at this age (1 month old), large-caliber myelinated fibers (A fibers) in Tfam-SCKO 
nerves appeared normal (Fig. 4a-c). 
The unmyelinated fibers in Tfam-SCKO nerves quickly deteriorated and by 2 
months of age most non-myelinating SCs were associated with unstructured, 
degenerating Remak bundles. These bundles contained few intact axons and were often 
filled with phagocytic vesicles and membranous debris, indicative of axonal degeneration 
(Fig. 4e-4). We confirmed the early degeneration of unmyelinated fibers observed in 
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Tfam-SCKO sciatic nerves by quantifying C fiber density in the epidermis. Somatic C 
fibers are primarily high-threshold nociceptors that terminate in the epidermis (Kennedy 
and Wendelschafer-Crabb, 1993). In neuropathies characterized by loss of small 
unmyelinated fibers, skin denervation is one of the initial signs of pathology and 
correlates with disease severity (Ebenezer et al., 2007). While we did not observe 
differences in epidermal fiber density at one month of age, we found a significant 
decrease in skin innervation in 2 month old Tfam-SCKO mice (Fig. 4f and g). This was 
again in contrast to large myelinated fibers, which at this age were just beginning to show 
initial signs of pathology (Fig. 5a). Overall numbers of dorsal root ganglion neurons in 
L3, whose axons project to the sciatic nerve, were comparable in 2 month old Tfam-
SCKO and Ctrl mice (average total # of neurons Ctrl= 7048 +/- 186; Tfam-SCKO= 
7381+/- 211.3; n=3 mice per genotype). Similarly, TUNEL and cleaved caspase 3 
immunostaining of the dorsal root ganglion neurons whose axons project to the sciatic 
nerve (levels L3-L5) showed no signs of cell death in either 2 or 4 month old Tfam-
SCKOs (data not shown). The degeneration of small unmyelinated fibers in the nerves of 
Tfam-SCKO mice was, therefore, a primary pathological event and was not secondary to 
neuronal death. 
 Together, our results show that Tfam-SCKO mice initially suffered early 
preferential loss of small unmyelinated fibers, suggesting that these fibers are most 
sensitive to SC mitochondrial dysfunction. The temporal progression of fiber loss in 
Tfam-SCKO nerves is particularly interesting because early preferential loss of small 
unmyelinated fibers has been reported in polyneuropathies associated with diabetes and 
HIV/AIDS (Kennedy et al., 1996; McArthur et al., 2005), diseases in which 
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mitochondrial dysfunction is known to occur (Fernyhough et al., 2003; Dalakas et al., 
2001)  
 
Loss of large caliber myelinated fibers in older Tfam-SCKOs  
While Tfam-SCKOs suffered an early preferential loss of small unmyelinated 
fibers, these mice also developed deficits in large caliber myelinated axons as they aged. 
Toluidene blue stained plastic sections of 2 month old Tfam-SCKO sciatic nerves showed 
early signs of axonal degeneration (Fig. 5a). This observation was confirmed by electron 
microscopic examination, which revealed a few axons undergoing active demyelination 
and Wallerian degeneration (data not shown). Note, however, that at this age there was 
not a significant decrease in the number of myelinating profiles in Tfam-SCKO nerves 
(Fig. 5b).  
Severe axonal loss became prominent in Tfam-SCKOs by 4 months (Fig. 5a-c). 
At this age, the number of myelinating profiles in Tfam-SCKO nerves was greatly 
reduced compared to control littermates (Fig. 5b). Degeneration of myelinated axons 
continued to progress as Tfam-SCKO mice aged and by 8 months of age the number of 
myelinating profiles in these animals was less than 40% that of control littermates (Fig. 
5a, b and c-3). Electron micrographs confirmed the severity of the axonal degeneration in 
Tfam-SCKO nerves, revealing large portions of endoneurium completely devoid of axons 
(Fig. 5c). Similarly, numerous axons undergoing degeneration were also visible. Detailed 
morphometric analysis (Hunter et al., 2007) showed no differences in the size distribution 
of myelinated axons in Tfam-SCKO nerves compared to control littermates at different 
ages, indicating that myelinated fibers of all calibers were susceptible to degeneration 
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(Fig. 5d). As in the case of small unmyelinated fibers, the degeneration of myelinated 
fibers was not secondary to neuronal death since no TUNEL or cleaved caspase 3 
positive motor neurons were observed in the spinal cords of either 2 or 4 month old 
Tfam-SCKOs (data not shown).  
At 4 months demyelination was also widespread in Tfam-SCKO nerves. At this 
age, large caliber axons without any myelin were a prominent pathological feature (Fig. 
5c). Examination of osmicated teased fibers from 4 month old Tfam-SCKO nerves 
confirmed the presence of segmental demyelination (Fig. 5e). Consistent with 
demyelination, SCs actively digesting myelin debris were present in Tfam-SCKO nerves 
at this age (Fig. 5c-4). Occasionally, axons surrounded by abnormally thin myelin were 
also observed. Thin myelin was, however, not characteristic, and in fact there was no 
difference in the overall g-ratio between Tfam-SCKO and control nerves at different ages 
(data not shown). Overall, these results show that extensive axonal degeneration and 
demyelination ensue when SC mitochondria are disrupted. Normal SC mitochondrial 
function is therefore essential for maintaining the interaction between myelinating SCs 
and axons.  
 
Tfam-SCKOs have behavioral deficits consistent with early loss of unmyelinated 
fibers followed by extensive degeneration of myelinated axons 
To determine the physiological effects and confirm the temporal progression of 
the pathology observed in Tfam-SCKO nerves, we carried out a battery of sensorimotor 
tests in 2 and 4 month old animals. Behavioral tests that primarily assess the function of 
small unmyelinated C fibers were expected to show deficits in both 2 and 4 month old 
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Tfam-SCKO mice. On the other hand, behavioral paradigms looking mainly at the 
function of large myelinated fibers were predicted to show differences only in 4 month 
old Tfam-SCKO mice.  
Small unmyelinated C-fibers have a primary role in nociception. To examine the 
physiological effect of the early C-fiber loss observed in Tfam-SCKOs we assessed their 
sensitivity to a noxious heat stimulus. When a noxious radiant heat stimulus was applied 
to the hind paw (Hargreaves test), Tfam-SCKOs displayed a longer withdrawal latency 
than their control littermates. As expected, this reduced sensitivity to noxious heat stimuli 
was detectable in 2 month old animals and persisted as these mice aged (Fig. 6a). 
We also tested innocuous mechanical sensitivity in 2 month old Tfam-SCKOs 
using the von Frey test. Innocuous mechanical sensitivity is another form of 
somatosensation but, unlike nociception, it is primarily mediated by myelinated fibers. 
Interestingly, 2 month old Tfam-SCKO animals showed no deficits in the von Frey test 
compared to wild type littermate controls (average withdrawal threshold Ctrl=0.86 g +/- 
0.08g; Tfam-SCKO=1.0g  +/- 0.05g; n=4 mice per genotype). The results from these 
somatosensory studies supported the pathological observations indicating early 
preferential loss of small unmyelinated fibers in Tfam-SCKO mice.  
Given that the axons of motor neurons are large myelinated fibers, we next 
determined whether the pathology observed in Tfam-SCKO nerves caused any 
abnormalities in motor function. As predicted, no motor deficits were detected in 2 month 
old Tfam-SCKOs (Fig 6b and c). 4 month old Tfam-SCKO animals, however, spent 
significantly less time on an accelerating rotarod (Fig. 6d) as well as on an inverted 
screen (Fig. 6b), indicating abnormal coordination and muscle weakness. The results 
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from these motor studies are consistent with the observation that large-caliber axons are 
not affected in Tfam-SCKO mice until later in the disease. Together, our results confirm 
that Tfam-SCKO mice initially suffered early preferential loss of small unmyelinated 
fibers followed by extensive loss of large-caliber myelinated axons.  
 
SC mitochondrial dysfunction does not compromise SC survival 
To determine whether the axonal loss and demyelination observed in Tfam-SCKO 
animals was simply the result of SC death we assessed changes in SC numbers in the 
nerves of these animals. Remarkably, we found no differences in the number of SC nuclei 
between Tfam-SCKO sciatic nerve and littermate controls up to 8 months of age (Fig. 7a 
and b). Moreover, by crossing Tfam-SCKO mice to Cre-inducible Rosa26-YFP reporter 
animals we were able to confirm that, at all ages examined, Tfam-deficient SCs present in 
Tfam-SCKO nerves (identified by their excision-dependent YFP fluorescence) remained 
viable (Fig. 7a and c).  These results indicate that the survival of Tfam-deficient SCs was 
not compromised despite severe mtDNA depletion and respiratory chain abnormalities.  
Consistent with the viability of Tfam-SCKO SCs, we did not detect any 
differences in TUNEL staining, a marker of cell death, between Tfam-SCKO sciatic 
nerve and controls at different ages (Fig. 7a and d). Similarly, staining with an antibody 
that recognizes the proliferation marker phospho-histone 3 showed no changes in 
proliferation that could compensate for the potential loss of Tfam-deficient SCs in Tfam-
SCKO nerves (data not shown). The pathology observed in Tfam-SCKOs, therefore, was 
not due to the loss of SCs. Together, our findings indicate that normal mitochondrial 
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function is not required for SC survival, but is essential for maintenance of axonal 
survival and normal peripheral nerve function.  
 
Tfam deficient SCs support axonal regeneration but fail to remyelinate following 
injury 
 Schwann cells play a critical role in promoting axonal regeneration following 
peripheral nerve injury. Upon degeneration of peripheral axons, SCs in the distal stump 
undergo an orchestrated process that helps support axonal regeneration (Geuna et al., 
2009). To determine whether disrupting mitochondrial function affects the ability SCs to 
support axonal regeneration, we studied the response of these cells after peripheral nerve 
crush injury in 2 month old Ctrl and Tfam-SCKO mice. At this age, the peripheral nerves 
of Tfam-SCKOs show modest pathology that is mainly limited to unmyelinated fibers yet 
mitochondrial function has already been severely disrupted (see above).  
We first looked at the initial response of SCs to axonal degeneration by assessing 
changes in SC proliferation and in their ability to break down existing myelin. Within the 
first few days after losing contact with axons SCs de-differentiate and start to proliferate 
(Geuna et al., 2009). Immunostaining of nerves harvested 4 days after injury distal to the 
site of crush using a phopho-histone 3 antibody showed no impairment in the ability of 
Tfam-deficient SCs to proliferate following axonal loss (Fig. 8a and b). Nerve 
regeneration also depends on the ability of SCs to break down existing myelin and 
remove the resulting debris. This process starts immediately after injury and takes place 
over a period of 3-6 weeks (Geuna et al., 2009). We did not observe differences in the 
amount of myelin debris present in Ctrl and Tfam-SCKO nerves 3 weeks after injury, 
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suggesting that disruption of mitochondrial function in SCs does not interfere with their 
ability to break down and remove myelin following axonal degeneration (Fig. 8c).  
We next studied the ability of Tfam-deficient SCs to support axonal regeneration 
by analyzing toluidene blue stained plastic sections of Tfam-SCKO and Ctrl nerves 
collected distal to the site of crush 3 weeks after injury. At this time, we found that 
substantial axonal regeneration and SC remyelination had already taken place in Ctrl 
nerves (Fig. 8d). In Tfam-SCKO nerves, however, we observed a striking decrease in the 
number of myelinated fibers (Fig. 8d). Interestingly, examination of Tfam-SKO nerves 
by electron microscopy revealed that this decrease in myelinated profiles was not due to 
the inability of Tfam-deficient SCs to support axonal re-growth. In fact, the total number 
of fibers (myelinated and unmyelinated) distal to the crush site was equivalent between 
Ctrl and Tfam-SCKO nerves 3 weeks after injury (Fig. 8e and f). Moreover, the majority 
of regenerated axons in Tfam-SCKO nerves 3 weeks after injury were associated with 
SCs in the typical 1 to 1 ratio (Fig. 8g1-4). Tfam-deficient SCs, however, failed to form 
mature myelin. Given that the proportion of axons of large enough caliber to induce 
myelination (larger than 1 m in diameter) was not different between Ctrl and Tfam-
SCKOs (Fig. 8h), the inability of Tfam-deficient SCs to myelinate is likely a direct 
consequence of their disrupted mitochondrial metabolism.  
Regenerated Remak bundles were also absent in Tfam-SCKO nerves compared to 
Ctrl littermates 3 weeks after crush injury. Instead, we observed pathological bundles of 
unorganized unmyelinated axons interspersed by Bands of Bungner (Fig. 8g-5,6), similar 
to those present in 2 month old Tfam-SCKO mice prior to injury. We conclude that 
disrupting SC mitochondrial function does not affect the ability of these glia to de-
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differentiate, proliferate or support axonal regeneration following injury. Normal SC 
mitochondrial metabolism, however, is essential for SCs to form mature myelin and 
Remak bundles, suggesting that the formation and maintenance of these mature structures 
poses a high metabolic challenge. 
 
Discussion 
In the present study we describe the generation and characterization of mice with 
disrupted mitochondrial function only in SCs. We found that the induction of SC-specific 
mitochondrial dysfunction did not affect the survival of these cells but resulted in a 
severe, progressive peripheral neuropathy characterized by extensive axonal 
degeneration. SC mitochondrial dysfunction, therefore, disrupts the axo-glial interactions 
required for the long-term support of axons and is a likely contributor to the clinical 
impairment of patients suffering from peripheral neuropathies. 
Mitochondrial dysfunction is a common cause of peripheral neuropathies. An 
extensive body of literature has now addressed how neuronal/axonal mitochondria may 
contribute to the pathology observed in these diseases (Niemann et al., 2006; Baloh, 
2008). The results described above show for the first time that disrupted mitochondrial 
function specifically in SCs can itself also cause axonal degeneration and peripheral 
nerve disease. These findings are consistent with observations in patients suffering from 
polyneuropathies associated with diabetes, HIV/AIDS, and mitochondrial disorders, in 
which most nerve mitochondrial abnormalities are localized to SCs (Schroder, 1993; 
Kalichman et al., 1998).  
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Moreover, the Tfam-SCKO mice generated in our study recapitulated a number of 
critical pathological features of human peripheral neuropathies. Disrupting mitochondrial 
metabolism specifically in SCs was sufficient to induce both axonal degeneration as well 
as demyelination. Tfam-SCKOs also displayed distal weakness and sensory deficits, two 
common problems in human patients. Finally, Tfam-SCKOs suffered preferential early 
loss of unmyelinated C fibers followed by the degeneration of large-caliber myelinated 
axons. This was of particular interest because preferential loss of small-caliber 
unmyelinated fibers is characteristic of peripheral and optic neuropathies associated with 
systemic diseases such as diabetes or with exposure to environmental toxins (Kennedy et 
al., 1996; McArthur et al., 2005; Sadun, 2002). Together, our results indicate that SC 
mitochondria are underappreciated contributors to the abnormalities observed in 
peripheral neuropathies. Furthermore, key pathological features commonly encountered 
in human peripheral nerve disease can potentially be explained by SC-specific 
mitochondrial dysfunction. 
The findings described in the present paper are consistent with a growing body of 
literature that implicates glial dysfunction in a number of neurodegenerative diseases 
traditionally thought to be cell autonomous. This is best exemplified by amyotrophic 
lateral sclerosis (ALS), a disease characterized by premature death of motor neurons 
which is sometimes linked to dominant mutations in the antioxidant protein superoxide 
dismutase 1 (SOD1) (Rosen et al., 1993). While neuronal expression of mutant SOD1 in 
transgenic mouse models of ALS was found to be important for the initial timing of 
disease onset (Boillee et al., 2006; Yamanaka et al., 2008; Wang et al., 2009), expression 
in microglia cells (Boillee et al., 2006; Wang et al., 2009) and astrocytes (Yamanaka et 
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al., 2008) was found to significantly contribute to disease progression. Similarly, in a 
mouse model of Parkinson’s disease, oligodendrocyte-specific overexpression of the 
disease-related protein -synuclein resulted in neurodegeneration (Yazawa et al., 2005). 
A central role for glia in diseases such as Huntington’s, spinocerebellar ataxia or 
Alzheimer’s has also been reported (For review see Ilieva et al., 2009). The development 
of effective therapies for peripheral neuropathies and neurodegenerative disorders, 
therefore, will need to address the contribution of SCs and other glia to disease 
progression.  
An unexpected finding of our work was that severe mtDNA depletion and 
respiratory chain abnormalities in the SCs of Tfam-SCKO mice did not affect their 
survival. This observation suggests that SCs have an adaptable energy metabolism and 
that their survival and ATP production are not fully dependent on mitochondrial function. 
Previous studies looking at the effect of Tfam deletion in a number of tissues have indeed 
reported cell-specific metabolic changes that take place following the Tfam deletion-
induced disruption of the electron transport chain. For example, following the muscle-
specific deletion of Tfam, myocytes increased their mitochondrial mass to compensate for 
any deficiencies in their respiratory chain (Wredenberg et al., 2002).  Cardiomyocytes, on 
the other hand, were reported to switch to a primarily glycolytic metabolism in response 
to the heart-specific excision of Tfam (Hansson et al., 2004). Some of these adaptations 
likely account for the limited or largely delayed cell death observed in several tissue-
specific Tfam KOs (Larsson et al., 1998; Wang et al., 1999; Silva et al., 2000; Sorensen 
et al., 2001; Wredenberg et al., 2002). Specific metabolic adaptations following Tfam 
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depletion-induced mitochondrial dysfunction may also explain why SC viability was not 
affected in Tfam-SCKO mice. 
 SCs have, in fact, been hypothesized to be largely glycolytic and rely on the non-
oxidative catabolism of glucose to meet their energy needs (Pellerin and Magistretti, 
2003). This idea is supported by the observation that in explant systems SCs take up a 
disproportionately large amount of glucose (Vega et al., 2003). The fact that disruption of 
mitochondrial energy metabolism in Tfam-SCKO mice did not affect SC survival 
provides indirect support for this hypothesis. Our current knowledge of the basic energy 
metabolism and requirements of SCs, however, is still very rudimentary. Future work 
aimed at understanding the metabolic changes that take place in SCs following Tfam 
deletion-induced respiratory chain deficiency should provide valuable insight into both 
the biology and pathology of SCs. 
Following peripheral nerve injury, SCs undergo a process of de-differentiation, 
proliferation, and formation of tubular structures known as bands of Bungner, which 
together with their production of neurotrophic factors, helps support axonal regeneration 
(Geuna et al., 2009). Interestingly, we found that Tfam depletion-induced mitochondrial 
dysfunction did not interfere with the ability of SCs to perform these duties and support 
axonal re-growth. However, Tfam-deficient SCs failed to re-differentiate and form 
mature Remak bundles and myelin sheaths after having promoted axonal regeneration. 
The high metabolic challenge posed by the reconstruction of these mature structures, 
therefore, appears to require an undisturbed SC mitochondrial anaplerotic metabolism. 
Elucidation of deficiencies in the intermediate metabolism of Tfam-SCKOs could thus 
provide new targets whose manipulation may promote the remyelination and the 
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restoration of normal nerve function in patients suffering from mitochondrial-related 
peripheral neuropathies.   
SCs have a primary role in supporting axonal function and survival (Chen et al., 
2003; Reddy et al., 2003; Meyer zu Horste et al., 2007), yet the mechanisms and cellular 
machinery underlying SC preservation of axons still remain largely unknown. Others 
have hypothesized that glial support requires axonal ensheathment as well as some 
myelin-related proteins. Trophic support of axons through neurotrophic factors has also 
been postulated as a potential mechanism behind glia-mediated axonal maintenance. 
Metabolic support of axons by ensheathing cells is also a likely but poorly understood 
mechanism of axonal preservation (Nave and Trapp, 2008). For example, SCs may 
support axons through the transfer of metabolites or by helping axons eliminate certain 
toxic species, as is the case between CNS neurons and astrocytes (Benarroch, 2005). Our 
results show that SC mitochondria are essential for the SC-mediated support of axonal 
function and survival. Given the central role of mitochondria in cellular energy and 
anaplerotic metabolism, we speculate that the axonal degeneration in Tfam-SCKOs 
reflects a disruption of SC-mediated metabolic support of axons. The preferential loss of 
small unmyelinated fibers early in the Tfam-SCKO disease process would then reflect a 
greater dependence of these fibers on SC metabolic support. Consistent with this 
hypothesis, unmyelinated axons have been found to be more energetically demanding 
than myelinated axons and are estimated to consume 2.5-10 fold more energy per action 
potential generated (Wang et al., 2008).  
In summary, Tfam-SCKOs are, to our knowledge, the first SC-specific metabolic 
mutant that recapitulates some of the pathology of human peripheral neuropathies. These 
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mice demonstrate that SC-specific mitochondrial dysfunction can be sufficient to cause 
both demyelination and axonal degeneration. Our study also provides evidence that SC 
mitochondria help maintain the axo-glial interactions required for the long-term support 
of axons. A greater understanding of SC mitochondria and how to prevent their 
dysfunction is, therefore, relevant to the treatment of patients suffering from peripheral 
neuropathies. 
 
Materials and Methods 
Matings of transgenic animals: All animal experiments were carried out in compliance 
with institutional animal protocols. Tfam
loxP/loxP
 mice in a pure C57Bl6 background 
(Larsson et al., 1998) were crossed to P0-Cre mice also in a pure C57Bl6 background 
(Feltri et al., 1999). Compound heterozytoges (P0-Cre 
+/-
, Tfam
+/loxP
) were then 
backcrossed to homozygous Tfam
loxP/loxP 
to generate the Tfam-SCKO mice (P0-Cre 
+/-
, 
Tfam
loxP/loxP
) and their Ctrl littermates (P0-Cre 
-/-
, Tfam
loxP/loxP
). Tfam
loxP/loxP
 mice were 
also crossed to homozygosity to Rosa26-YFP reporter mice. Tfam
loxP/loxP
/Rosa26-YFP
+/+
 
were then crossed to P0-Cre mice using an analogous breeding scheme. Tfam
loxP/loxP
 
genotyping was carried out as previously described (Larsson et al., 1998).  
 
Immunohistochemistry and cell quantification: The following primary and secondary 
antibodies were used:
 
rabbit anti-GFP (1:1000, Invitrogen), chicken anti-GFP (1:1000, 
Aves), rabbit anti-βIII tubulin (1:1000, Covance), rabbit anti-phospho histone 3 (1:200, 
Millipore), rabbit anti-Kv1.1 (1:100, Abcam), rabbit anti-Nav1.6 (1:100, Millipore), 
mouse anti-Caspr (1:1000, gift from Dr. Elior Peles, Weizmann Institute of
 
Science, 
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Rehovot, Israel), anti-rabbit Cy3 (1:500, Jackson ImmunoResearch Laboratories), 
streptavidin conjugated Cy3 (1:500, Jackson ImmunoResearch Laboratories), anti-rabbit 
Alexa 488 (1:500, Jackson ImmunoResearch Laboratories), and anti-chicken Alexa 488 
(1:500, Jackson ImmunoResearch Laboratories).   
For immunohistochemical analysis of sciatic nerves, nerves were dissected, 
immersion fixed in 4% paraformaldehyde for 2 h, rinsed with PBS, and cryoprotected in 
30% sucrose. Sciatic nerves were then embedded in Tissue-Tek OCT Compound (Sakura 
Finetek) and sectioned at 6 m. For analysis of DRGs, mice were transcardially perfused 
with 4% paraformaldehyde. The entire spinal cord was then dissected, post-fixed in PFA 
overnight, rinsed in PBS and cryoprotected in 30% sucrose. After cryoprotection DRGs 
were dissected, embedded in Tissue-Tek OCT Compound, and sectioned at 6 m. For 
analysis of foot pads, foot pad skin was removed from the plantar surface of the hindpaw,
 
immersion fixed in Zamboni's fixative for 2 h, rinsed with PBS,
 
and cryoprotected in 30% 
sucrose.
 
Skin was sectioned at 30 µm in a plane perpendicular to
 
the skin surface. For 
analysis of teased nerve fibers, mouse sciatic nerves were dissected and incubated in 4% 
paraformaldehyde in PBS for 30 min at room temperature. The nerves were washed three 
times in PBS for 5 min and de-sheathed, and bundles of nerve were dissected with fine 
needles in PBS on Fisherbrand Superfrost/Plus microscope slides. Slides were air dried 
for at least 2hrs at room temperature and stored at -20°C until staining.  
All frozen sections were immunostained by post-fixing in ice-cold acetone at -
20°C for 10 min and blocking in 10% horse serum (DRG and foot pads) or 5% fish skin 
gelatin (sciatic nerve and teased fibers) in PBS-0.2% Triton for 1 h at room temperature. 
Sections were then incubated with primary antibody diluted in blocking buffer overnight 
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at 4°C. Secondary antibody incubation was performed at room temperature for 1 h also in 
blocking buffer. TUNEL staining was performed as previously described (Grinspan et al., 
1996).  After all stainings, sections were mounted with Vectashield Mounting Medium 
with DAPI (Vector Laboratories) for microscopic visualization. Images were captured 
using an upright microscope equipped
 
for epifluorescence microscopy (Nikon 80i; 
CoolSnapES camera)
 
and were processed using MetaMorph, Image-J and Gimp software
 
using global adjustments in brightness and contrast.
  
All cell number quantifications were carried out by counting the cells of interest 
in 4 randomly selected regions in longitudinal nerve sections from each animal assessed 
(at least 3 mice per genotype at each age) at a 20x magnification. Epidermal innervation 
density was quantified by tracing the dermal–epidermal border and determining the 
number of fibers that crossed this borders as previously described (Golden et al., 2010).
 
 
 
Western Blotting: Sciatic nerves were isolated, desheathed in PBS, and immediately 
frozen in liquid nitrogen. Lysates were prepared by homogenizing the tissue by 
sonication in a buffer containing  150 mM sodium chloride, 50 mM Hepes, 1% NP-40, 
1mM EDTA, 1mM sodium fluoride, 1mM sodium orthovanodate, and complete protease 
inhibitor cocktail (Roche Applied Science). The lysates were clarified by centrifugation 
at 14,000 rpm for 10 min and quantified using the MicroBCAProtein Assay kit (Pierce). 
For Western blotting, the proteins were separated by SDS-PAGE and transferred to a 
PVDF membrane (Millipore). Membranes were blocked in 5% milk in 0.5% TBS-Tween 
and incubated overnight with the appropriate primary antibody. Following incubation 
with secondary antibodies conjugated to HRP (GE Healthcare), membranes were 
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developed with SuperSignal West Dura substrate (Pierce). The primary antibodies used 
were rabbit anti-Tfam (1:4000, Dr. Nils-Goran Larsson), mouse anti-Porin 31HL (ab2) 
(1:200, Calbiochem) and mouse anti-tubulin (1:1000, Sigma). The secondary antibodies 
used were anti-mouse and anti-rabbit HRP (1:5000; Jackson ImmunoResearch 
Laboratories). 
 
RNA and DNA preparation and quantitative real-time PCR: Sciatic nerves were 
harvested from Tfam-SCKO mice at different ages and immediately frozen in liquid 
nitrogen. For RNA isolation, tissue was homogenized in Trizol reagent (Invitrogen) and 
total RNA prepared according to the manufacturer’s protocol. For DNA isolation, tissue 
was digested and DNA isolated using DNeasy Blood and Tissue Kit (Qiagen) according 
to the manufacturer’s protocol. DNA and RNA concentration were quantified using an 
ND-1000 spectrophotometer (Nanodrop Technologies).  
For RNA qRT-PCR cDNA was reverse transcribed from total RNA using M-
MLV reverse transcriptase (Invitrogen). qRT-PCR was performed using a SYBR green-
based detection system on a 7700 Sequence Detector instrument (Applied Biosystems) as 
described previously (Nagarajan et al., 2001). Glyceraldehyde-3-phosphate 
dehydrogenase expression was used to normalize samples and obtain relative expression 
values that were used to calculate fold changes. mtDNA content was also quantified by 
qRT-PCR using a SYBR green-based detection system on a 7700 Sequence Detector 
instrument (Applied Biosystems) in a similar way as described previously (Nagarajan et 
al., 2001). Instead of cDNA, however, 15ng of total DNA were used per reaction. Primers 
that recognized a region unique to the mitochondrial genome were used to determine the 
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mtDNA content relative to a serial dilutions standard curve. mtDNA content values were 
normalized to nuclear DNA content as determined by a set of primers directed to the 
genomic locus of Smrt1. DNA and RNA qRT-PCR primer sequences were as follows 
(5’-3’): Tfam: F, CAGGAGGCAAAGGATGATTC; R, 
ATGTCTCCGGATCGTTTCAC; GAPDH:
 
F, TGCCCCCATGTTTGTGATG; R, 
TGTGGTCATGAGCCCTTCC; mt-ND2: F, CGCCCCATTCCACTTCTGATTACC; R, 
TTAAGTCCTCCTCATGCCCCTATG. mt-Cox1: F, 
GAACCCTCTATCTACTATTCGG; R, CAAGTCAGTTTCCAAAGCCT. SDHB: F, 
TGTAGAGAAGGCATCTGTGG ; R, CGTAGAAGTTACTCAAATCAGGG. mtDNA: 
F, AAGTCGTAACAAGGTAAGCA;  R, ATATTTGTGTAGGGCTAGGG. Nuc.DNA: 
F, GGGTATATTTTTGATACCTTCAATGAGTTA; R, 
TCTGAAACAGTAGGTAGAGACCAAAGC 
 
Mitochondrial isolation, respiratory enzyme activity measurements, and 
respirometry: For mitochondrial isolation, 4 sciatic nerves were dissected, desheathed, 
mechanically dissociated, digested with collagenase for 20 min and pooled together in 2 
ml of homogenization buffer (HM) containing 0.22 M mannitol, 70 mM sucrose, 10 mM 
Tris-HCl, 0.5 mM EDTA, 1mM EGTA and 0.5%
 
delipidated BSA. Nerves were 
homogenized for about 2 minutes (12 strokes) using a Teflon-glass homogenizer turning 
at 200 rpm. The homogenate was then centrifuged at 800xg for 10 min. The clarified 
supernatant was centrifuged at 8,000xg for 10 min and the pellet was resuspended in 1ml 
of HM buffer without BSA and spun once more at 7,500xg. The resulting pellet was 
resuspended in 250 l of HM buffer without BSA. The protein concentration of the 
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resuspended mitochondrial fractions was determined using a MicroBCAProtein Assay kit 
(Pierce). Five micrograms of protein from these mitochondrial preps were used to 
measure complex II and complex IV activity spectrophotometrically as previously 
described (Birch-Machin and Turnbull, 2001).  
 For high resolution respirometry 2 sciatic nerves were dissected, briefly digested 
with collagenase for 10 min, then desheathed and fluffed using a pair of fine forceps. At 
this point, nerve respiration was measured in a 2-ml chamber using and OROBOROS 
Oxygraph 2k (Oroboros) as previously described (Mancuso et al., 2010).  
 
Surgical procedure: Mice were anesthetized by intraperitoneal injection of 2-2-2
 
tribromoethanol at a dose of 500 mg/kg. The sciatic nerve was exposed at the hip and a 
reproducible crush injury was created by using #5 jeweler’s forceps for 30 sec. The site 
of injury was marked with a single 10-0 nylon epineural suture. Nerve lesions were 
produced on the right side
 
and the contralateral nerve was left intact and served as the
 
uninjured control. At the appropriate time nerves were harvested and processed for 
histology.  
 
Nerve light and electron microscopy and morphometry: Sciatic nerves from Ctrl and 
Tfam-SCKO mice at different ages were dissected and placed in 3% glutaraldehyde 
overnight. After washing with phosphate buffer, nerves were postfixed in 1% osmium 
tetraoxide in phosphate buffer overnight at 4°C. Specimens were then dehydrated in 
graded alcohols and embedded in 100% epoxy (Araldite 502). One-micrometer-thick 
plastic embedded sections were prepared and stained with toluidene blue for light 
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microscopy. For electron microscopy, thin sections were prepared, stained with uranyl 
acetate and lead citrate, and photographed with a JEOL (Akishima) 1200 electron 
microscope. All nerves underwent qualitative assessment of neural architecture followed 
by detailed histomorphometric analysis carried out as previously described (Hunter et al., 
2007). 
 
Nerve electrophysiology and electromyography: Electrophysiology and 
electromyography were performed on mice at 2, 4 and 8 months of age using a Viking 
Quest electromyography machine (Nicolet) as previously described (Baloh et al., 2009). 
Briefly mice were anesthetized with avertin, and placed on a heating pad. For nerve 
electrophysiology subcutaneous platinum subdermal EEG electrodes 0.4 mm diameter, 
12 mm length (Viasys) were used. Stimulating electrodes were placed just above the left 
ankle and the left sciatic notch for nerve stimulation. Recording electrodes were placed in 
the footpad. Evoked CMAPs were obtained using supramaximal stimulation, and distance 
between the two sites of stimulating electrodes was used to calculate conduction velocity. 
For EMG recordings a 27-gauge, Teflon-coated, monopolar needle electrode with a 70 × 
500 μm recording surface (PRO-37SAF; Electrode Store) was used. A 29-gauge 
reference needle electrode (GRD-SAF; Electrode Store) was inserted subcutaneous in 
close approximation to the recording electrode. A subdermal ground electrode was placed 
on the back. The recording electrode was inserted into the tibialis anterior (TA) or 
gastrocnemius/soleus muscles, and spontaneous electrical activity was recorded for 90 s.  
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Muscle histology: Gastrocnemius muscles were dissected fresh, immediately frozen in 
isopentane cooled in liquid nitrogen. Cryostat sections of gastrocnemius muscle were cut 
at 10 m onto slides and stained with hematoxylin and eosin. 
 
Nerve Cytochrome oxidase staining: Sciatic nerves were dissected fresh, placed in 
Tissue-Tek OCT Compound, and immediately frozen in isopentane cooled in liquid 
nitrogen. Tissue was then sectioned at 6 m. Sections were placed in an incubating 
solution containing sucrose (100mg/ml), 3,3'-diaminobenzidine tetrahydrochloride 2 
(DAB, 0.6 mg/ml), sodium phosphate buffer  (final concentration 0.05 M), catalase 3 (2.6 
g/ml), and cytochrome c (1.6 mg/ml) for 60 minutes at room temperature. After 
incubation, sections were washed 3 times with deionized water, dehydrated in a series of 
ascending alcohols and cleared with xylene, and mounted using permount.  
 
Behavioral testing: Behavior testing was performed using male and female Tfam-SCKO 
mice and littermate controls at 2 and 4 months of age. The experimenter was blind to
 
the 
genotypes of the mice during data acquisition. Noxious heat sensitivity (Hargreaves test) 
was determined as previously described (Golden et al., 2010). Briefly, the thermal 
threshold was determined by measuring the withdrawal
 
latency to a radiant heat source 
applied to the plantar surface
 
of the hindpaw in 5 separate trials for each hindpaw with a
 
15 min interval between trials. The withdrawal threshold was
 
determined by averaging 
the withdrawal latency obtained in each
 
of the trials. Mechanical sensitivity was 
determined using the von Frey test.
 
Beginning with the smallest filament and continuing 
from smallest
 
to largest, calibrated von Frey filaments were pressed to the
 
plantar surface 
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of the hindpaw until the filament just bent.
 
The withdrawal threshold is defined as the 
force that produces
 
a withdrawal response in 3 of 5 consecutive applications within
 
one 
trial. The threshold was determined in 3 trials per hindpaw
 
with a 15 min interval 
between trials. An accelerating rotarod was used to evaluate motor
 
coordination and 
balance. Five consecutive acceleration trials
 
were performed with a 5 min interval 
between trials as described
 
previously (Montana et al., 2009). Muscle strength was 
measured using an inverted screen test as previously described (Golden et al., 2010). 
 
Osmicated teased sciatic nerve fibers: Sciatic nerves were dissected and immersion 
fixed in 3% glutaraldehyde overnight. After washing with 0.1M phosphate buffer nerves 
were incubated in 1% osmium tetraoxide plus 1.5% potassium ferricyanide in 0.5 M 
phosphate buffer for 1 h. Nerves were washed in PBS followed by incubation in 33, 66, 
and 100% glycerol/PBS for 6 h each. Nerves were then treated with 0.6% sudan black 
dissolved in 70% ethanol at 25 °C for 30 minutes, rinsed with 70% ethanol and with 
water and then placed back in 100% glycerol. Nerves were teased in 100% glycerol and 
coverslipped for imaging. 
 
Statistical analysis: All values are expressed as mean ± SEM. If not stated
 
otherwise, p 
values were determined by unpaired, two-tailed
 
Student's t test. All statistical analyses 
were performed using
 
Microsoft Excel 2007. 
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Figures  
Figure 1: P0-Cre deletes Tfam from SCs specifically and efficiently in Tfam-SCKO 
mice. a) Diagram of the targeted Tfam locus in Tfam
loxP
 mice. When Tfam
loxP
 mice are 
crossed with mice that express Cre recombinase under the control of the P0 promoter, 
exons 6 and 7 of Tfam are excised to produce Tfam
–
 mice. b)  YFP fluorescence in SCs 
(arrowheads) of longitudinal sciatic nerve sections (ScN), as well as satellite SCs 
(arrowheads) in DRGs (DRG) of Rosa26-YFP/P0-Cre mice. P0-Cre induces 
recombination specifically in SCs and excision-dependent YFP fluorescence is localized 
to regions of SC cytoplasm but not to axons (Tuj1 and stars; note non-overlapping Tuj1 
and YFP staining) or DRG neuron cell bodies (stars). Scale Bars: top and bottom panels 
100 m, middle magnified panel 50 m. c) qRT-PCR results showing efficient depletion 
of Tfam mRNA in Tfam-SCKO sciatic nerves. Tfam mRNA levels in the sciatic nerve of 
1 month old Tfam-SCKOs were decreased by 60% (p=0.001, two-tailed Student’s t-test) 
compared to Ctrl littermates. By 2 months of age Tfam mRNA levels were reduced by 
85% (p=0.002, two-tailed Student’s t-test) compared to Ctrl littermates. Reported values 
are normalized to GAPDH; error bars, SEM; n=2 pools of 3 mice run in 3 independent 
experiments. d) Western blot showing efficient depletion of Tfam protein in the sciatic 
nerves of Tfam-SCKO mice compared to Ctrl littermates by 2 months of age.  
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Figure 2: SC-specific excision of Tfam induces mtDNA and transcript depletion and 
respiratory dysfunction in Tfam-SCKOs. a) qRT-PCR results showing depletion of 
mtDNA content in the sciatic nerves of Tfam-SCKO mice compared to littermate Ctrls. 
mtDNA content was significantly reduced by 50% (p=0.01, two-tailed Student’s t-test) in 
2 month old Tfam-SCKO sciatic nerves compared to Ctrl nerves. Reported values are 
normalized to nuclear DNA content; error bars, SEM; n=3 mice per genotype run in 2 
independent experiments. b) qRT-PCR results showing depletion of mitochondrially-
encoded electron transport chain subunit transcripts (mt-ND2 and mt-Cox1) in Tfam-
SCKO sciatic nerves. mRNA levels of these subunits were decreased 85% (p=0.02, two-
tailed Student’s t-test) in 2 month old Tfam-SCKO sciatic nerves compared to Ctrl 
littermates. In contrast, transcripts of nuclearly-encoded electron transport chain subunits 
(nuclear SDHB) are not depleted in Tfam-SCKO sciatic nerves. Reported values are 
normalized to GAPDH; error bars, SEM; n=2 pools of 3 mice run in 3 independent 
experiments. c) Respiratory chain enzyme activity measured from mitochondria isolated 
from the sciatic nerves of 2 month old Tfam-SCKO nerves and Ctrl littermates. COX 
activity (complex IV), which contains critical mtDNA-encoded subunits, is reduced 65% 
(p<0.01, two-tailed Student’s t-test) in Tfam-SCKO mice. Error bars, SEM; n=3 pools of 
2 mice per genotype. d) Mitochondrial respiration in 2 month old Tfam-SCKO and 
littermate Ctrl permeabilized sciatic nerves measured using high resolution respirometry. 
Respiration induced by substrates delivering electrons to complex I (pyruvate+malate) is 
reduced by 35% (p=0.04, two-tailed Student’s t-test) in Tfam-SCKO sciatic nerves 
compared to littermate controls. Respiration induced by the convergent transport of 
electrons entering at complexes I and II (using pyruvate+malate+succinate as substrates) 
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is decreased by 25% (p=0.04, two-tailed Student’s t-test) in Tfam-SCKO sciatic nerves 
compared to littermate Ctrls. Respiration induced by substrates delivering electrons to 
complex II alone (succinate), which is fully nuclearly-encoded, was not significantly 
changed in Tfam-SCKO nerves compared to littermate Ctrls. Error bars, SEM; n=5 mice 
per genotype. e) COX enzymatic staining of 4 month old Ctrl and Tfam-SCKO sciatic 
nerves. The intense COX staining that localizes to SCs in Ctrl nerves (arrowheads) is 
largely lost in Tfam-SCKO nerves, indicating mitochondrial dysfunction specifically in 
this cell type. f) Electron micrographs of Tfam-SCKO sciatic nerves show abundant 
abnormal enlarged mitochondria (arrowheads), often with distorted cristae. Aberrant 
mitochondria are mainly found in SCs, while axonal mitochondria show no 
morphological abnormalities (arrows). Pathological mitochondria are visible as early as 1 
month in Tfam-SCKO nerves (top 3 panels) and become more abundant as these mice 
age (bottom panels from 4 month old mice). Scale bars: 500 nm 
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Figure 3: Tfam-SCKOs develop a progressive degenerative peripheral neuropathy. 
a) Photograph of end-stage Tfam-SCKO mouse (≈8 months old). At this stage Tfam-
SCKOs display a characteristic “swimming-gait” and are unable to support themselves on 
their hind legs. b) Typical nerve conduction trace from a 4 month old Tfam-SCKO mouse 
showing marked temporal dispersion. Scale bars 1ms and 1 mV. c, d) 
Electrophysiological studies of Tfam-SCKO mice show that, as early as 2 months of age, 
these mice have significantly reduced nerve conduction velocity (c, p<0.001, two-tailed 
Student’s t-test) compared to littermate Ctrls. This deficit persists in 4 month old animals 
(c, p<0.001, two-tailed Student’s t-test), which also have severe temporal dispersion as 
shown by an increased response duration (d, p <0.001, two-tailed Student’s t-test). These 
findings indicate segmental demyelination. Error bars, SEM. N=4 mice per genotype at 
each age. e) Typical electromyography traces from a 4 month old Tfam-SCKO mouse 
showing fibrillation (arrowheads) and fasciculations (arrows), common findings in 
diseases involving motor axon loss, indicative of muscle fiber denervation and motor unit 
degeneration/regeneration. These findings were never present in Ctrl littermates. Scale 
bars 50 ms, 500 V f) Hematoxylin and eosin stain of the gastrocnemius muscle from a 
Ctrl and a Tfam-SCKO mouse showing scattered and grouped muscle fiber atrophy 
(arrowheads). This is characteristic of motor axon degeneration. Scale bar 50 m. 
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Figure 4: Tfam-SCKOs display early preferential loss of small unmyelinated fibers. 
a-c) Toluidene blue stained plastic sections of 1 month old Tfam-SCKO sciatic nerve and 
littermate Ctrls (a) show that at this age there are no differences in the number of 
myelinated fibers (b) or the extent of myelination (g-ratio, axon area/fiber area) (c). Scale 
bar 25 m. Error bars, SEM. n=4 mice per genotype. d) Electron micrographs of 1 month 
old Ctrl and Tfam-SCKO sciatic nerves show that while large myelinated fibers are 
mostly normal in Tfam-SCKO mice at this age (arrows), the structure of Remak bundles 
(arrowheads) is largely abnormal. Scale bar 2 m. e 1-4) Compared to Ctrl littermates 
(1), unmyelinated axons in Tfam-SCKO Remak bundles are  found touching one another 
(2, 4, stars) and interspersed by pathological SC processes known as Bands of Bungner 
(2, arrowheads). Free-floating excess basement membrane (2, 3, arrows) enclosing SC 
cytoplasm (3, star) with few or no axons left, indicative of extensive degeneration of 
unmyelinated axons, is also visible. By 2 months of age most non-myelinating SCs are 
associated with unstructured, degenerating Remak bundles, containing abnormal axons 
(4, star) and filled with phagocytic vesicles and membranous debris (4, arrowhead). Scale 
bar 500 nm. f) Representative photographs of epidermal fiber innervation (arrowheads) in 
the foot pads of 2 month old Tfam-SCKO and littermate Ctrl mice. Scale bar, 10 m g) 
Quantification of fiber density in the epidermis shows a 30% decrease in Tfam-SCKO by 
2 months of age (p=0.02, two-tailed Student’s t-test), indicating early degeneration of 
small unmyelinated C-fibers. Results reported are normalized to per unit area. Error bars, 
SEM; n=3 mice per genotype at each age.  
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Figure 5: Degeneration of large caliber myelinated fibers in older Tfam-SCKOs. a, 
b) Toluidene blue stained plastic sections of Tfam-SCKO sciatic nerves and littermate 
Ctrls at different ages (a) and quantification of total number of myelinated profiles per 
nerve (b). At 2 months, some initial signs of axonal degeneration are apparent 
(arrowhead) in Tfam-SCKO nerves, but at this age there are no differences in the number 
of myelinated fibers (b). By 4 months there is prominent axonal degeneration, as shown 
by a significant decrease (p>0.001, two-tailed Student’s t-test) in the total number of 
myelinated profiles in Tfam-SCKO nerves. Axonal degeneration worsens by 8 months of 
age (p>0.001, two-tailed Student’s t-test). Scale bar 25 m. Error bars, SEM.  n=4 mice 
per genotype at each age. c 1-4) Electron micrographs of Tfam-SCKO nerves at different 
ages confirm that large myelinated fiber degeneration becomes prominent by 4 months of 
age (2) and worsens by 8 months (3), as shown by large portions of endoneurium 
completely devoid of axons (stars). By 4 months of age actively demyelinating and 
degenerating axons filled with membranous debris (arrowheads) are also common in 
Tfam-SCKO nerves (4).By this age segmental demyelination as shown by large caliber 
axons without myelin is also prominent (2-4, arrows). This type of pathology is not 
visible in Ctrl nerves (1). Scale bar, 2 m. d) Fiber size distribution analysis in Tfam-
SCKO and Ctrl littermate nerves at different ages. No differences in fiber size 
distribution are evident despite severe axonal degeneration, indicating that myelinated 
fibers of all calibers are susceptible to degeneration. Error bars, SEM. n=4 mice per group 
at each age e) Osmicated teased fibers from 4 month old Tfam-SCKO nerves confirm the 
presence of segmental demyelination. Scale bar 25 m.  
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Figure 6: Tfam-SCKOs have behavioral deficits consistent with early loss of 
unmyelinated fibers followed by extensive degeneration of myelinated axons a) 2 
month old Tfam-SCKOs are less sensitive to an applied noxious heat stimulus than Ctrl 
littermates (p<0.01, two-tailed Student’s t-test), as shown by an increased withdrawal 
latency, which indicates loss of unmyelinated C-fiber nociceptors. This deficiency 
persists in 4 month old Tfam-SCKO mice (p<0.01, two-tailed Student’s t-test). b-d) At 2 
months of age, consistent with the early preservation of large myelinated motor axons, 
Tfam-SCKOs do not display significant motor deficits as shown by the inverted screen 
test (b) or accelerating rotarod (c). 4 month old Tfam-SCKOSs, however, spend 
significantly less time on an inverted screen (p<0.01, two-tailed Student’s t-test) (b) and 
accelerating rotarod (p<0.01, two-tailed Student’s t-test) (d), motor deficits that indicate 
the loss of large myelinated fibers by this age. Error bars, SEM. N=4 mice per genotype 
at each age.  
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Figure 7: SC mitochondrial dysfunction does not compromise SC survival. a, b) 
Nuclear staining (a Dapi) and quantification (b) shows that there is no difference in the 
number of SC nuclei between Tfam-SCKO and Ctrl sciatic nerves at different ages. a, c) 
Quantification of Rosa-YFP immunofluorescence (a YFP/DAPI, c) in Tfam-SCKO/Rosa-
YFP nerves at different ages shows that the majority of SCs are Tfam-deficient at all 
ages. a, d) Quantification of TUNEL immunohistochemistry (a Tunel/DAPI, d) of Tfam-
SCKO and Ctrl littermate shows no differences in the number of TUNEL positive cells at 
different ages, indicating that SCs are able to survive despite the disruption in their 
mitochondria. Scale bar 100 m. Error bars, SEM. n=3 mice per genotype at each age.  
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Figure 8: Tfam-deficient SCs support axonal regeneration but fail to remyelinate 
following injury. a, b) Phospho-histone 3 (PH3) immunostaining (a) and quantification 
(b) shows that there is no difference in the number of proliferating SCs (arrowheads) 
between Tfam-SCKO and Ctrl sciatic nerves 4 days after crush injury. Scale bar 100 m. 
Error bars, SEM. n=at least 3 mice per genotype. c) Quantification of the amount of 
myelin debris present in Ctrl and Tfam-SCKO nerves 3 weeks after crush injury shows 
no impairment in the ability of Tfam-deficient SCs to break down existing myelin. Error 
bars, SEM. n=3 mice per genotype. d) Quantification of the number of myelinated 
profiles in Ctrl and Tfam-SCKO nerves 3 weeks after crush distal to the site of injury 
shows a significant decrease (p<0.001, two-tailed Student’s t-test) in the number of 
myelinated profiles formed by Tfam-deficient SCs following injury. Error bars, SEM. 
n=3 mice per genotype. e) Electron micrographs of Ctrl and Tfam-SCKO nerves 3 weeks 
after crush depicting the inability of Tfam-deficient SCs to form mature myelin even 
though they are capable of supporting axonal regeneration. Scale bar, 2 m. f) 
Quantification of the total number of fibers (myelinated and unmyelinated) distal to the 
site of injury 3 weeks after crush shows no differences between Tfam-SCKO and Ctrl 
nerves, confirming that Tfam-deficient SCs are able to support axonal regeneration. Error 
bars, SEM. n=3 mice per genotype g) Electron micrographs of Ctrl (1) and Tfam-SCKO 
(2-4) large caliber fibers distal to the site of injury 3 weeks after crush showing that while 
Tfam-deficient SCs are capable of ensheathing axons and forming 1 to 1 associations 
with them (arrowheads, axons; arrows, SCs) they are not able to form mature myelin. 
Regenerating Remak bundles are present in Ctrl nerves (5) but are absent in Tfam-SCKO 
nerves (6; arrowheads, axons; arrows, SCs). h) Proportion of axons larger than 1 m is 
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similar between Tfam-SCKO and Ctrl nerves following injury and cannot explain the 
absence of myelin in Tfam-SCKO nerves.  
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Supplementary Figure 1: Tfam-SCKOs initially develop and myelinate normally. a-
c) Toluidene blue stained plastic sections of 2 week old Tfam-SCKO sciatic nerve and 
littermate Ctrls (a) show that at this age there are no differences in the number of 
myelinated fibers (b) or extent of myelination (c) (g-ratio, axon area/fiber area). Scale bar 
25 m. Error Bars, SEM. n= 3 mice per genotype d,e) Electron micrographs from 2 week 
old Tfam-SCKO sciatic nerve and littermate Ctrls confirm that myelin (d) as well as 
nodes of Ranvier  initially develop normally. N, node; Mv, microvilli; Pn, paranode; 
arrowheads, paranodal loops.  Scale bar 2 m (d) and 500 nm (magnified panels)(e). f) 
Immunostaining of teased nerve fibers from 3 week old Tfam-SCKO and Ctrl mice with 
antibodies against nodal (Nav1.6), paranodal (Caspr) and juxtaparanodal (Kv1.1) markers 
confirm that nodal architecture initially develops normally in these mice. Scale bar 50 
m. 
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CHAPTER 3: 
 
 
Mitochondrial Dysfunction-induced Abnormalities in Schwann Cell Lipid 
Metabolism Lead to Axonal Degeneration and Peripheral Neuropathy  
 
 
 
 
 
 
 
Adapted from: Viader A, Sasaki Y, Yang K, Gross RW, Milbrandt J. (2011). 
Mitochondrial dysfunction-induced abnormalities in Schwann cell lipid metabolism lead 
to axonal degeneration and peripheral neuropathy. Submitted.  
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Abstract 
Mitochondrial dysfunction is a common cause of peripheral neuropathy. Much 
effort has been devoted to examining the role played by neuronal/axonal mitochondria, 
but how mitochondrial deficits in peripheral nerve glia (Schwann cells, SCs) contribute to 
peripheral nerve diseases remains unclear. Here, we investigate a mouse model of 
peripheral neuropathy secondary to SC mitochondrial dysfunction (Tfam-SCKOs). We 
show that disruption of SC mitochondria activates a maladaptive integrated stress 
response and causes a shift in lipid metabolism away from fatty acid synthesis toward 
oxidation. These alterations in SC lipid metabolism result in depletion of important 
myelin lipid components as well as in extensive accumulation of acylcarnitines, an 
intermediate of fatty acid -oxidation. Importantly, we show that acylcarnitines are 
released from SCs and induce axonal degeneration. Altered SC lipid metabolism 
accompanied by toxic accumulation of lipid intermediates is thus an underlying 
pathological mechanism in mitochondria-related peripheral neuropathies.  
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Introduction 
Mitochondrial metabolic irregularities are a common culprit in diverse 
neurodegenerative diseases and are key pathological contributors to peripheral 
neuropathy. Mitochondrial dysfunction is thought to be largely responsible for the 
peripheral nerve deficits that afflict up to 50% of all people with diabetes and can lead to 
incapacitating pain, sensory loss, and debilitating muscle weakness 1. Similarly, a number 
of mutations in mitochondrial proteins have now been identified as the cause of several 
forms of inherited neuropathies known as Charcot Marie Tooth (CMT) 2. The need to 
elucidate the manner in which mitochondrial dysfunction underlies progression of 
peripheral nerve disease is thus well appreciated; to date much effort has been devoted to 
clarifying the role played by neuronal/axonal mitochondria 3.  
Glial cells, the main non-neuronal cell component of the nervous system, are 
involved in virtually every aspect of nervous system function 4. Moreover, glia are 
increasingly recognized to influence neurodegenerative diseases traditionally thought to 
be neuron autonomous (e.g. amyotrophic lateral sclerosis) 5. Schwann cells (SCs), the 
glial cells in the peripheral nervous system (PNS), intimately associate with all peripheral 
nerve axons to support their long-term preservation and function 6-8. Moreover, SCs are 
also essential for peripheral nerve repair after axonal damage 9. Interestingly, SCs from 
nerves of patients with neuropathy often present with abnormal mitochondria 10, 11. Given 
this critical involvement of SCs in the maintenance of peripheral nerves and the role of 
mitochondria in cell energy and anaplerotic metabolism, mitochondrial dysfunction in 
these glia is likely to contribute to disease progression of peripheral neuropathies. 
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With the goal of understanding whether SC mitochondrial abnormalities affect 
axonal survival and peripheral nerve function we recently generated mice (Tfam-SCKOs) 
with disrupted mitochondrial metabolism exclusively in SCs 12. Using this novel model of 
peripheral neuropathy, the present work demonstrates that SC mitochondrial dysfunction 
activates a maladaptive integrated stress response and causes a shift in lipid metabolism 
away from new lipid synthesis towards increased fatty acid oxidation. This metabolic 
alteration results in early depletion of myelin lipid components as well as a large 
accumulation of acylcarnitine lipid intermediates. Importantly, we show that 
acylcarnitines are released from SCs and induce axonal degeneration. Altered SC lipid 
metabolism accompanied by the toxic accumulation of lipid intermediates is thus an 
underlying mechanism of axonal degeneration and demyelination in peripheral 
neuropathies and constitutes a potentially important therapeutic target.  
 
Results  
Energy depletion does not drive nerve pathology in Tfam-SCKO mice  
To directly interrogate the contribution of SC mitochondrial dysfunction to 
peripheral neuropathy, we recently generated mice (Tfam-SCKOs) with impaired 
mitochondrial function exclusively in SCs 12. These mice were produced through the 
tissue-specific deletion of the mitochondrial transcription factor A gene (Tfam), which is 
required for mtDNA transcription and replication and when excised induces progressive 
defects in the mitochondrial electron transport chain 13. Interestingly, induction of SC-
specific mitochondrial dysfunction did not affect SC survival; instead, these deficits 
resulted in a severe, progressive peripheral neuropathy characterized by extensive axonal 
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degeneration that recapitulated critical features of human neuropathy. Tfam-SCKO 
nerves displayed early morphological abnormalities and preferential loss of small 
unmyelinated C fibers (starting at 1-2 months of age, Fig. 1a) followed by the 
degeneration of large-caliber myelinated axons (starting at 3-4 months of age, Fig 1b and 
c) 12. Extensive demyelination was apparent at late stages of the disease (Fig 1b). 
Consistent with this nerve pathology, Tfam-SCKO mice developed progressive distal 
weakness and sensory deficits 12, common symptoms in patients with peripheral 
neuropathy.  
Having established the utility of the Tfam-SCKO mouse model in understanding 
and potentially treating peripheral neuropathies, we explored causal mechanisms of the 
nerve pathology in these mice. We focused on identifying processes that drive disease 
progression in 2 month old Tfam-SCKOs, an age when SC mitochondrial function is 
already disrupted yet Tfam-SCKO nerves display only limited, early pathological 
changes (Fig 1c) 12. All experiments described below were carried out on mice this age. 
We first determined the energy status of Ctrl and Tfam-deficient SCs, because clinical 
deficits in diseases associated with mitochondrial dysfunction are often assumed to be 
directly related to depletion of cellular energy levels. Surprisingly, HPLC measurement 
of nerve adenylate pools and determination of the Adenylate Energy Charge (EC), an 
index used to measure cellular energy status (see methods) 14, revealed only a very slight 
energy reduction (≈8%) in Tfam-SCKO nerves (EC Ctrl=0.812 +/- 0.009; EC Tfam-
SCKO=0.747 +/-0.008; p<0.001; Fig. 1d). Increased mitochondrial content and 
glycolysis in Tfam-deficient SCs (Supplementary Fig.1), two metabolic adaptations that 
often follow mitochondrial deficits 15, 16, likely account for this relative preservation of 
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energy levels in Tfam-SCKO nerves. When we assessed the activation status 
(phosphorylation at Thr172) of the cellular energy sensor AMP-activated protein kinase 
(AMPK) 17, we observed no differences between Ctrl and Tfam-SCKO nerves (Fig. 1e 
and f). This indicates that Tfam-deficient SCs do not experience a significant energy 
depletion to an extent that is likely responsible for the pathology observed in the nerves 
of these mice. 
 
Mitochondrial dysfunction activates a maladaptive stress response and shifts the 
balance of lipid metabolism in SCs 
In an attempt to identify other potential disease-causing processes, we carried out 
gene expression profiling of 2 month old Ctrl and Tfam-SCKO nerves. This analysis 
uncovered the upregulation of a number of genes activated by the integrated stress 
response (ISR), including Chop10, Asns, and Trib3, in SCs with disrupted mitochondrial 
metabolism (data not shown). The ISR is an evolutionarily conserved, “stress”-activated, 
gene expression program controlled by the phosphorylation of translation initiation factor 
2 (eIF2) 18. Importantly, previous studies examining neuropathy models induced by 
mutations in structural myelin proteins have shown that activation of the ISR by 
endoplasmic reticulum (ER) accumulation of the mutant proteins is particularly 
maladaptive to SCs 19. Thus, we first used qRT-PCR to confirm the activation of ISR in 
Tfam-SCKOs nerves and verified the upregulation of ISR target genes (Fig 2a). 
Moreover, Western blot analysis showed hyper-phosphorylation of eIF2in Tfam-SCKO 
nerves compared to Ctrl (Fig. 2b), further establishing the activation of ISR following SC 
mitochondrial dysfunction.  
87 
 
To ensure that ISR activation in Tfam-SCKO nerves was a primary effect of 
mitochondrial defects in Tfam-deficient SCs, we treated SCs in vitro with mitochondrial 
inhibitors (e.g. FCCP, antimycin, oligomycin) and examined the effect on the activity of 
the pathway. Application of mitochondrial inhibitors on SCs in vitro also increased 
phosphorylation of eIF2 (Fig. 2c) and induced ISR target genes (Fig. 2d). These results 
suggest that the activation of the ISR in Tfam-SCKO nerves was a consequence of SC 
mitochondrial deficits. Note, however, that unlike previous reports on other mouse 
models of neuropathy 19, activation of the ISR in Tfam-SCKOs was not associated with 
ER stress or an unfolded protein response (UPR). Levels of activated PERK (as 
determined by its phosphorylation), the main ER-stress sensor known to induce ISR 18, 
were not elevated in Tfam-SCKO nerves (Fig. 2e). Similarly, IRE-1, a second ER stress 
sensor normally activated by the UPR 18, was not engaged either in Tfam-SCKO nerves 
or in cultured SCs treated with mitochondrial inhibitors (as determined by splicing of the 
IRE-1 target Xbp-1; Fig. 2f). Therefore, SC mitochondrial electron transport chain 
deficits activate ISR through a process that is distinct from ER-stress. Maladaptive 
activation of the ISR in SCs by a variety of stressors may thus be a central pathological 
mechanism common to different forms of peripheral neuropathy.   
The downstream cellular processes initiated by the ISR that are maladaptive to 
SCs are unclear. Recent reports have linked activation of this pathway to a decrease in 
expression of lipid biosynthesis genes 20 as well as alterations in intermediate lipid 
metabolism 21. Moreover, increased expression of the ISR target gene Trib3, which we 
found to be highly upregulated in Tfam-SCKO nerves, shifts the balance of fatty acid 
metabolism away from lipogenesis and toward oxidation in muscle and fat cells 22. Given 
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the central role of lipids in the normal biology of SCs (e.g. myelin formation) (Chrast et 
al., 2010) and the importance of mitochondria to lipid metabolic reactions (e.g. as a 
source of intermediates), we hypothesized that nerve deficits in neuropathies modeled by 
Tfam-SCKO mice might be largely caused by alterations in SC lipid metabolism 
secondary to mitochondrial derangements. Consistent with this idea we found that 
differentially expressed genes in Tfam-SCKO vs. Ctrl nerves were enriched for targets 
involved in lipid metabolism. Lipid-related metabolic pathways were in fact over-
represented among differentially expressed genes in Tfam-SCKO nerves (Fig. 3a). qRT-
PCR confirmed that a number of genes critically involved in lipid synthesis were 
downregulated in Tfam-deficient SCs following mitochondrial dysfunction, including 
fatty acid synthetase (FASN) and HMG-CoA reductase (HMGCR) (Fig. 3b). Moreover, 
we found that Acetyl-coA carboxylase (ACC) phosphorylation, which inhibits the 
activity of this enzyme (Fig. 3c), was increased 3-fold in Tfam-SCKO nerves compared 
to Ctrls (Fig. 3d and e). ACC supplies malonyl-coA required for lipid biosynthesis and as 
such critically regulates the balance between lipid synthesis vs. oxidation (Fig. 3c) 23. 
Increased phosphorylation of ACC in Tfam-SCKO nerves and decreased expression of 
lipid synthetic genes is consistent with a shift in lipid metabolism away from new lipid 
synthesis and towards increased lipid oxidation. Together, these results show that 
mitochondrial dysfunction in SCs activates a maladaptive stress response and remodels 
SC lipid metabolism.  
 
SC mitochondrial dysfunction causes depletion of myelin lipids and accumulation of 
fatty acid oxidation intermediates 
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The signs of altered lipid metabolism in SCs with disrupted mitochondria 
prompted us to examine in more detail the implications of these changes for the 
pathology observed in Tfam-SCKO nerves. To this end, we analyzed the lipid 
composition of 2 month old Ctrl and Tfam-SCKO nerves using multidimensional mass 
spectrometry-based shotgun lipidomics. This method provides a comprehensive 
description of alterations in cellular lipids by identifying and quantifying individual lipid 
molecular species in a high-throughput fashion from a database of over 36,000 potential 
lipid molecular species 24. Among all the different lipid classes examined, cerebrosides 
and sulfatides were the only lipid classes showing a depletion in 2 month old Tfam-
SCKO nerves compared to Ctrls, with a 30% and a 40% reduction respectively (Fig. 4a 
and b, Supplementary Fig. 2a). In peripheral nerves, cerebrosides and sulfatides are 
almost exclusively produced by SCs and are particularly enriched in myelin; together 
they represent almost 30% of all lipid content in peripheral myelin 25. The depletion of 
these two important myelin glycosphingolipids from Tfam-SCKO nerves is in agreement 
with our observations suggesting that mitochondrial dysfunction in SCs results in a 
metabolic shift away from lipid biosynthesis. Moreover, sulfatide and cerebroside 
depletion disrupts saltatory conduction of action potentials by increasing myelin fluidity 
and interfering with the maintenance of SC-axon contacts 26-28. The reduction of myelin 
lipid components induced by mitochondrial dysfunction may underlie the prominent 
demyelinating phenotype apparent in late stages of the disease in Tfam-SCKO mice (Fig. 
1b and d) 12. This is supported by the observation that depletion of sulfatides and 
cerebrosides preceded the extensive demyelination or reduction in expression of myelin 
proteins in Tfam-SCKO nerves (Fig.1b and c, Fig. 4c) 12. 
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 The most prominent alteration in lipid composition in 2 month old Tfam-SCKO 
nerves was a 25-fold increase in acylcarnitine species (Fig. 5a). This dramatic increase 
affected most long-chain acylcarnitines with some species being hundreds of times higher 
in Tfam-SCKO nerves compared to Ctrls (Fig. 5b, Supplementary Fig. 2b). 
Acylcarnitines are intermediates in the transport of fatty acyl groups across the 
mitochondrial membrane required for them to undergo mitochondria fatty acid -
oxidation, an important source of cellular energy and anabolic metabolites 29. Fatty acids 
longer than 10 carbon atoms are converted to acylcarnitines to be shuttled into the 
mitochondrial matrix, the site of -oxidation, where they are oxidized through repeated 
cycles of four enzymatic reactions that catalyze this process (Fig. 5c) 29. Increased 
acylcarnitine levels in Tfam-SCKO nerves, therefore, support our previous observations 
suggesting a shift away from lipid synthesis toward oxidation following SC 
mitochondrial deficits (Fig. 3). The severity of the acylcarnitine accumulation in Tfam-
deficient SCs, however, likely indicates that the increased shunting of lipids toward -
oxidation was accompanied by a decrease in the ability of SCs to oxidize them. The large 
presence of hydroxy-acylcarnitines (Fig. 5d) and reduced NAD
+
/NADH ratio in Tfam-
SCKO nerves (Fig. 5e), likely related to the inability of Tfam-deficient SCs to re-oxidize 
NADH as mitochondrial dysfunction worsened, suggests the inhibition of the rate 
determining step in -oxidation of fatty acids that is catalyzed by 3-hydroxyacyl CoA 
dehydrogenase. This step normally converts -hydroxy-acyl-CoA to keto-acyl-CoA  (Fig. 
5c); inhibition of this NAD
+
-dependent step of -oxidation (by a decreased NAD+/NADH 
ratio) leads to accumulation of the transient intermediate 3-hydroxy acyl CoA, which can 
then be converted to hydroxy-acylcarnitines (Fig. 5c) 30, 31.  
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The accumulation of acylcarnitine -oxidation intermediates can be toxic and has 
been observed to exacerbate pathological states 32. We hypothesized therefore that 
accumulation of acylcarnitines in Tfam-SCKO nerves may contribute to the neuropathy 
present in these mice. In fact, genetic diseases that inhibit fatty acid -oxidation and lead 
to a significant accumulation of acylcarnitines often present with severe forms of 
peripheral neuropathy 33, 34. Together, these results suggest that depletion of myelin lipid 
components and accumulation of toxic lipid intermediates in SCs with dysfunctional 
mitochondria are underlying pathological mechanisms in peripheral neuropathies. 
 
Acylcarnitines can be released from SCs and cause axonal toxicity 
Given the dramatic increase in acylcarnitine concentration in Tfam-SCKO nerves 
we examined the possibility that acylcarnitines cause the axonal degeneration observed in 
Tfam-SCKO mice. This amphiphilic metabolite adversely alters the properties of 
membranes and ion channels with devastating effects. In the heart, for example, 
acylcarnitine-mediated disruption of ion homeostasis can predispose the myocardium to 
lethal ventricular tachyarrhythmias and sudden death during ischemic episodes 35-37. 
Given the ability of acylcarnitines to cross the plasma membrane 29 and the intimate 
association between SCs and axons in peripheral nerves, we hypothesized that release of 
acylcarnitines from SCs onto the surrounding axons could alter axonal membrane 
properties and ion homeostasis and contribute to the severe axon degeneration phenotype 
in Tfam-SCKO nerves as well as in neuropathies that present with prominent axonal loss. 
 To test this hypothesis we first examined whether long-chain acylcarnitines are 
released from SCs onto surrounding axons. Two-month old Ctrl and Tfam-SCKO nerves 
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were cultured as explants for 2.5 days. At the end of this time, we measured the amount 
of long-chain acylcarnitines released from the nerves into the culture media. While Ctrl 
nerves released very low levels of long-chain acylcarnitines into the surrounding media, 
Tfam-SCKO nerves secreted 35-fold more long-chain acylcarnitines (primarily C16 and 
C18; Fig. 6a).  Remarkably, the buildup of long-chain acylcarnitines from a single Tfam-
SCKO nerve in 100 l of media reached up to ≈ 2 M within 2.5 days. Tfam-deficient 
SCs therefore not only accumulate acylcarnitines following mitochondrial dysfunction, 
but also release them in significant quantities onto surrounding axons.  
 We next assessed the ability of acylcarnitines to disrupt axonal membrane 
properties and ion homeostasis. We specifically focused on the effect of acylcarnitines on 
axonal calcium levels (Ca
2+
), since long-chain acylcarnitines have been previously shown 
to alter Ca
2+
 homeostasis in cardiac and skeletal muscle 37. Ca
2+
 is also important for 
axonal integrity and function; intra-axonal Ca
2+ 
elevation often leads to severe axon 
degeneration 38, and its homeostasis is disrupted in peripheral neuropathies 39. Acute 
application of palmitoyl-carnitine, one of the most highly increased acylcarnitine species 
in Tfam-SCKO nerves, caused a significant elevation of intracellular Ca
2+
 in cultured 
dorsal root ganglion (DRG) neurons loaded with the calcium dye Fluo-4 (Fig. 6b and c). 
This rise in intracellular Ca
2+
 took place within minutes after exposure to acylcarnitine, 
was dose-dependent, and was specific to acylcarnitines; application of the corresponding 
free fatty acid at the same concentrations exerted no comparable effect (Fig. 6b and c). 
The acute influx of Ca
2+
 after addition of palmitoyl-carnitine also caused significant 
axonal blebbing (Fig. 6b and d), which when severe enough results in axonal 
degeneration.  
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Finally, we explored the long-term effect of chronic exposure to moderate levels 
of acylcarnitines on axonal stability as this more likely recapitulates the situation in vivo. 
For these experiments we applied 25 M palmitoyl-carnitine onto DRG neurons daily for 
up to nine days; this concentration caused no immediate axonal degeneration when 
applied acutely and was close to the range of long-chain acylcarnitines released from a 
single Tfam-SCKO nerve cultured as an explant (Fig. 6a). Interestingly, axons were able 
to withstand exposure to 25 M palmitoyl-carnitine for up to four days. After four days, 
however, prominent axonal blebbing started to develop and axonal degeneration followed 
soon thereafter and progressively worsened (Fig. 6e and f). Note, that 12.5 M palmitoyl-
carnitine applied chronically resulted in axons of unhealthy appearance that displayed 
morphological abnormalities, but no statistically significant increase in the degeneration 
index of these axons was observed within the time frame of our experiments (data not 
shown). Together, these results demonstrate that the long-chain acylcarnitines that 
accumulate in SCs following mitochondrial dysfunction can be released out of these glia 
onto the surrounding axons. Moreover, exposure of axons to long-chain acylcarnitines 
can disrupt axonal membrane properties and ion homeostasis, compromising axonal 
stability over time.  
 
Discussion 
In the present study we have found that a lipid metabolic shift away from 
synthesis towards oxidation is induced in SC following mitochondrial dysfunction. This 
metabolic shift is induced, at least in part, by the activation of a conserved stress response 
(the ISR), which is maladaptive in SCs. We demonstrate that this shift in lipid 
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metabolism results in the depletion of important lipid myelin components, which 
preceded overt demyelination and is therefore a likely driver of this process in 
mitochondria-related neuropathies. Finally, we propose a novel mechanism by which 
lipid abnormalities in SCs can exacerbate axonal loss in peripheral neuropathies through 
the release of toxic long-chain acylcarnitines (Fig. 7). Disruption of SC lipid metabolism 
homeostasis secondary to mitochondrial dysfunction is thus a critical underlying 
pathological mechanism in peripheral neuropathies.  
Mitochondrial dysfunction is a common cause of peripheral neuropathies. We 
recently generated the first mouse model (Tfam-SCKOs) useful in directly interrogating 
the contribution of SC mitochondrial derangements to peripheral neuropathy, by 
disrupting mitochondria specifically in these glia 12. Interestingly, SC mitochondrial 
deficits in Tfam-SCKO mice did not affect the survival of these glia but instead resulted 
in a severe, progressive peripheral neuropathy characterized by extensive axonal 
degeneration that recapitulated critical features of human neuropathy 12. These results 
showed that normal mitochondrial function in SCs is essential for maintenance of the 
axo-glial interactions required for the long-term support of axons and normal peripheral 
nerve function. Importantly this work indicated that SC mitochondrial dysfunction may 
contribute to human peripheral neuropathies and that Tfam-SCKO mice, a new model of 
neuropathy secondary to SC mitochondrial dysfunction, could be useful in identifying 
causal pathophysiological mechanisms. 
The examination of Tfam-SCKO mice described above uncovered the activation 
of the ISR in Tfam-deficient SCs secondary to mitochondrial dysfunction. The ISR is an 
evolutionarily conserved, “stress”-activated, gene expression program centered on 
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phosphorylation of eIF2. Activation of this program is meant to promote a cellular 
stress-resistant state by global attenuation of protein synthesis, which reduces the ER load 
and diverts amino acids from energetically costly protein synthesis to other metabolic 
pathways 18. Activation of this program in SCs, however, has previously been shown to 
be particularly maladaptive. In a study examining a model of CMT caused by mutations 
to myelin protein zero (P0), the authors found that accumulation of mutant P0 in the ER 
activated the ISR as part of an UPR 19. Importantly, by blocking the induction of this 
pathway through the deletion of a key downstream mediator (Chop), the behavioral and 
pathological presentations of this disease model could be prevented 19. These and other 
studies have led to the notion that UPR-mediated activation of the ISR in SCs contributes 
to the pathology in myelin-related neuropathies 40. Activation of the ISR in Tfam-SCKO 
mice, however, was not associated with ER stress or an UPR. The maladaptive induction 
of the ISR in SCs may therefore be a central pathological mechanism common to 
different forms of peripheral neuropathy, including those associated with mutations to 
structural myelin proteins as well as metabolic abnormalities. Intriguingly, 
chemotherapeutic agents that cause neuropathy also activate the ISR in cultured cells 41, 
which highlights the fact that this maladaptive pathway in SCs could be operant in 
diverse forms of neuropathy.  
The downstream cellular processes initiated by the ISR that are maladaptive to 
SCs are unclear.  Activation of this pathway, however, has been linked to alterations in 
lipid metabolism that are characterized, overall, by a shift away from lipid synthesis and 
towards lipid oxidation 20-22. The results described above are consistent with a decreased 
shunting of fatty acids towards new lipid synthesis and a concomitant increase in fatty 
96 
 
acid oxidation in the nerves of Tfam-SCKO mice. Lipids play a crucial role in the normal 
biology of SCs; they are required for myelin assembly and maintenance, regulate the 
differentiation status of these glia, and may also be important for SC-mediated metabolic 
support of axons 42. The observed early shift in the lipid metabolism of Tfam-deficient 
SCs secondary to mitochondrial dysfunction is thus a likely cause of the phenotype in 
Tfam-SCKO mice. Given that abnormalities in peripheral nerve lipid composition are 
present in mitochondrial disorders 42, 43, our results suggests that alterations in SC lipid 
metabolism may be central pathological mechanisms of mitochondrial-related 
neuropathies. 
The shift in lipid metabolism of Tfam-deficient SCs resulted in depletion 
(sulfatides and cerebrosides) as well as in accumulation (acylcarnitines) of specific lipid 
molecular species. Both of these lipid alterations in Tfam-SCKO nerves are likely to 
participate in the subsequent neuropathy phenotype of these mice. The depletion of 
cerebrosides and sulfatides from Tfam-deficient SCs, which together represent almost 
30% of all myelin lipid content 25, likely underlie the prominent demyelinating phenotype 
apparent in late stages of disease in Tfam-SCKO mice 12. Moreover, given the central role 
of sulfatides and cerebrosides in maintaining axon-glial contact 27, 28, depletion of these 
glycosphingolipids could also drive some of the axon loss in Tfam-SCKO nerves by 
disrupting the ability of SCs to properly associate with and support axons. This axonal 
degeneration is likely exacerbated by the accumulation of acylcarnitines in Tfam-SCKO 
nerves following mitochondrial dysfunction. Accordingly, long-chain acylcarnitines 
accumulating in SCs could be released onto surrounding axons where they could disrupt 
axon membrane properties and induce axon degeneration. These results are consistent 
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with presentations of peripheral neuropathy in patients with genetic defects in fatty acid 
-oxidation that lead to a buildup of acylcarnitines 33, 34.  
In summary, Tfam-SCKO mice, a novel model of neuropathy secondary to 
mitochondrial dysfunction, have enabled us to examine for the first time the mechanisms 
by which deficits in mitochondrial metabolism in SCs specifically contribute to 
peripheral nerve diseases. Our work demonstrates that mitochondrial deficits activate a 
maldaptive stress response in SCs and cause a shift in the lipid metabolism of these glia. 
We provide evidence that the resulting early depletion of important lipid myelin 
components as well as the accumulation and release of toxic lipid intermediates from SCs 
drive the pathology observed in Tfam-SCKO mice. New therapeutic strategies that 
prevent the depletion of lipids that support axo-glial interactions as well as the 
accumulation of fatty acid intermediates with marked axonal toxicity may be useful in 
treating patients with diabetic neuropathy and other mitochondria-related peripheral 
nerve disorders. 
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Methods 
Matings of transgenic animals: All animal experiments were carried out in compliance 
with institutional animal protocols. Tfam-SCKO mice (P0-Cre 
+/-
, Tfam
loxP/loxP
) and Ctrl 
littermates (P0-Cre 
-/-
, Tfam
loxP/loxP
) were generated by crossing Tfam
loxP/loxP
 mice 13 to P0-
Cre mice 44. Mating and genotyping were carried out as previously described 12.  
 
Nerve histology and morphometry: Sciatic nerves from Ctrl and Tfam-SCKO mice at 
different ages were dissected and placed in 3% glutaraldehyde overnight. After washing 
with phosphate buffer, nerves were postfixed in 1% osmium tetraoxide in phosphate 
buffer overnight at 4°C. Specimens were then dehydrated in graded alcohols and 
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embedded in 100% epoxy (Araldite 502). One-micrometer-thick plastic embedded 
sections were prepared and stained with toluidene blue for light microscopy. For electron 
microscopy, thin sections were prepared, stained with uranyl acetate and lead citrate, and 
photographed with a JEOL (Akishima) 1200 electron microscope. All nerves underwent 
qualitative assessment of neural architecture followed by detailed histomorphometric 
analysis carried out as previously described 
45
. 
 
Metabolite measurements: For ATP, ADP, AMP, and lactate measurements sciatic 
nerves were excised from Ctrl and Tfam-SCKO mice, weighted, and metabolites 
extracted with 1M perchloric acid (10 to 1 volume : weight). Extracts were centrifuged 
and neutralized with 3 M potassium carbonate. For ATP, ADP and AMP determination, 
neutralized extracts were diluted 1:10 with potassium phosphate buffer and assayed by 
HPLC (Shimazu) using an LC-18T HPLC column (Supelco) at flow rate of 1 ml/min and 
the absorbance at 254 nm was recorded. Each elution peak was compared with standards 
for identification and quantification and levels were normalized to tissue weight. EC was 
defined as follows: EC=[ATP]+1/2[ADP])/([ATP]+[ADP]+[AMP]. Lactate levels were 
determined spectrophotometrically as previously described 
46
. NAD+, NADH+ and the 
NAD+/NADH ratio was determined using a CycLex NAD+/NADH colorimetric assay 
kit (MBL International) according to the manufacturer’s protocol. 
 
Western Blotting: Sciatic nerves were isolated, desheathed in PBS, and immediately 
frozen in liquid nitrogen. Lysates were prepared by homogenizing the tissue by 
sonication in a buffer containing  150 mM sodium chloride, 50 mM Hepes, 1% NP-40, 1 
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mM EDTA, 1 mM sodium fluoride, 1mM sodium orthovanodate, and complete protease 
inhibitor cocktail (Roche Applied Science). The lysates were clarified by centrifugation 
at 14,000 rpm for 10 min and quantified using the MicroBCA Protein Assay kit (Pierce). 
For Western blotting, the proteins were separated by SDS-PAGE and transferred to a 
PVDF membrane (Millipore). Membranes were blocked in 5% milk in 0.5% TBS-Tween 
and incubated overnight with the appropriate primary antibody. Following incubation 
with secondary antibodies conjugated to HRP (GE Healthcare), membranes were 
developed with SuperSignal West Dura substrate (Pierce). The primary antibodies for p-
AMPK AMPK p-ACC, ACC, and p-Perk were all raised in rabbit, used 1:1000 and 
purchased from Cell Signaling. We also used mouse anti-Porin (31HL, 1:1000, 
Calbiochem), mouse anti-actin (1:1000, Sigma), mouse anti-myelin basic protein (SMI 
94, 1:1000, Covance), and rabbit anti-myelin protein zero (1:1000, Sigma). The 
secondary antibodies used were anti-mouse and anti-rabbit HRP (1:5000; Jackson 
ImmunoResearch Laboratories). Optical density of the signals was determined using 
Image-J. 
 
RNA preparation and quantitative real-time PCR: Total RNA was isolated after 
homogenization (for sciatic nerves) or lysis (for cultured SCs) in Qiazol lysis reagent 
(Qiagen) using a miRNeasy Minikit (Qiagen) according to the manufacturer’s protocol. 
RNA concentration was quantified using an ND-1000 spectrophotometer (Nanodrop 
Technologies). mRNA was reverse transcribed from 100 ng of total RNA using qScript 
cDNA SuperMix (Quanta Biosciences). mRNA qRT-PCR was performed using a SYBR 
green-based detection system on a 7900 HT Sequence Detector instrument (Applied 
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Biosystems) as described previously 
47
. GAPDH expression was used to normalize 
samples and obtain relative expression values that were used to calculate percent 
changes. The sequences of the qRT-PCR primers used are as follows (5’-3’; mouse 
unless specified): ATF4: F, GGCTATGGATGATGGCTTGG, R, 
AATTGGGTTCACTGTCTGAGG; ATF4 (rat): F, CTTAAGCCATGGCGCTCTTC, R, 
TTGCTGGTATCGAGGAATGTG ; Chop: F, AAGTGCATCTTCATACACCACC, R, 
TTGATTCTTCCTCTTCGTTTCCTG; Chop (rat): F, CTGAGGAGAGAGTGTTCCAG, 
R, GTGTGGTGGTGTATGAAGATG; ASNS: F, GCCCAAGTTCAGTATCCTCTC, R, 
TAAATACATGCCCACAGATGCC; mthfd2: F, AATTAAGCGAACAGGCATTCCA, 
R, AGGATCGTGTGCTTCTTCAG; Trib3: F, CACTTTAGCAGCGGAAGAGG, R, 
GTGTAGCTCGCATCTTGTCC; Trib3 (rat): F, 
TGTCTTCAGCAACTGTGAGAGGACGAA, R, 
GTAGGATGGCCGGGAGCTGAGTAT; Srebp1: F, CATGCCATGGGCAAGTACAC, 
R, TGTTGCCATGGAGATAGCATCT; FASN: F, GGGTGCTGACTACAACCTCTCC, 
R, TGCACAGACACCTTCCCGTC; HMGCR: F, TGGTGGGACCAACCTTCTAC, R, 
GCCATCACAGTGCCACATAC; Acly: F, AGGAAGTGCCACCTCCAACAGT, R, 
CGCTCATCACAGATGCTGGTCA; ACC2: F, GGGCTCCCTGGATGACAAC,  R, 
TCTTCCGGGAGGAGTTCT; GAPDH: F, TGCCCCCATGTTTGTGATG, R, 
TGTGGTCATGAGCCCTTCC.   
 
Xbp-1 splicing RT-PCR: xbp-1 splicing in Ctrl and Tfam-SCKO nerves as well as in 
cultured SCs was determined from cDNA in a 25 l PCR reaction with a single 4 min 
94ºC denaturation cycle followed by 35 cycles of 94ºC for 10 s, 63ºC for 30 s, and 72ºC 
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for 30 s followed by separation of the unsplice (254 bp) and spliced (229 bp) XBP-1 RT-
PCR products on a 10 cm 2% agarose gel. Primers used were as follows (5’-3’) F: 
GGCCTTGTGGTTGAGAACCAGGAG; R: GAATGCCCAAAAGGATATCAGACTC. 
Explanted nerves maintained in 10% fetal bovine serum (FBS) supplemented with 2 mM 
L-glutamine and 100 ng/ml of nerve growth factor in the presence of 10 g/ml of 
tunicamycin served as a positive control for nerve samples.  
 
Microarray and computational analysis: total RNA samples were prepared by isolating 
and pooling RNA from at least 3 different 2 month old Tfam-SCKO and Ctrl mice. 
Replicates were prepared entirely independently from two separate pools of at least three 
animals each, 2 replicates were used. Total RNA concentration and purity was obtained 
from an absorbance ratio at 260 nm and 280 nm.  Total RNA quality was then determined 
by Agilent 2100 bioanalyzer (Agilent Technologies) according to manufacturer’s 
recommendations. RNA transcripts were amplified by T7 linear amplification 
messageAmp TotalPrep amplification kit (ABI-Ambion) using 400 ng of each total RNA 
sample. The amplified RNA samples (aRNA) were then cleaned with RNA columns and 
quantified on a spectrophotometer, and RNA quality was determined by Agilent 2100 
bioanalyzer (Agilent Technologies). 1500 ng of each aRNA were hybridized onto 
Illumina Mouse WG-6 v2.0 Expression Beadchips according to manufacturer’s 
recommendations. Arrays were scanned on an Illumina BeadArray Reader. Images were 
quantitated by Illumina Beadscan, v3 and the resulting data was imported into Illumina 
GenomeStudio software, where on-slide spot replicates were averaged and individual 
spot probe was reported. This signal intensity data was background subtracted and 
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quantile normalized in Illumina genome Studio. Probes having detection p-value>0.05 in 
all samples were removed and a two class unpaired SAM analysis was performed. 
Differentially expressed genes with at least 2.0 fold differential regulation between Tfam-
SCKO and Ctrl nerves at a false discovery rate (FDR) of 0.5% were selected for further 
analysis. Gene enrichment of metabolic pathway was examined using GeneGO (Genego 
Inc). 
 
Tissue and mitochondria Complex IV determination: nerve mitochondria were 
isolated and maximum complex IV activity determined as previously described 
12
. Tissue 
maximum Complex IV activity was determined using high resolution respirometry in an 
OROBOROS Oxygraph 2k (Oroboros) as previously described 
12, 48
.   
 
Nerve sample lipid extract preparation for mass spectrometric analysis: lipid 
extraction of nerve samples was performed essentially as described previously 
49
. Briefly, 
a protein assay on each nerve sample was performed by using BCA method with bovine 
albumin as standard. Lipid internal standards (approximately one for each lipid class) 
were added based on protein content of each nerve sample. The molecular species of 
internal standards (e.g., 
13
C4-16:0 carnitine, N-Pentadecanoyl-psychosine (N15:0 
Cerebroside), N-Hexadecanoyl-sulfatide (N16:0 sulfatide) were selected because they are 
either stable isotope labeled species or represent <0.1% of the endogenous cellular lipid 
mass as demonstrated by mass spectrometric analysis of the nerve lipid extract without 
addition of internal standards. A modified Bligh and Dyer procedure was used to extract 
lipids from each nerve sample as previously described 
49
 . Each lipid extract was 
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reconstituted in 200 l /mg of protein (which was the measured protein content 
aforementioned) in chloroform/methanol (1:1, v/v). A portion of each lipid extract (e.g., 
50 uL) was treated with LiOMe to hydrolyze phospholipids followed by washing with 
hexane as previously described 
50
.  The treated lipid samples were used for the analysis of 
the sphingolipidome of each nerve sample. The original and treated lipid extracts were 
flushed with nitrogen, capped and stored at -20°C until ESI/MS analysis, typically within 
one week. 
 
Lipidomic analysis of nerve lipid extracts by multi-dimensional mass spectrometry-
based shotgun lipidomics: a triple-quadrupole mass spectrometer (Thermo Fisher TSQ 
Quantum Ultra Plus) equipped with an automated nanospray apparatus (i.e., Nanomate 
HD, Advion Bioscience Ltd., Ithaca, NY) and Xcalibur system software were utilized in 
the study as previously described 
49
. Briefly, each originally-prepared lipid extract was 
diluted to < 50 pmol/uL with chloroform/methanol/isopropanol 1:2:4 (v/v/v) prior to 
direct infusion through a nanospray apparatus linked to the mass spectrometer for the 
analyses of phospholipids, lyso-phopholipids, acyl-carnitine, non-esterified fatty acids 
and triacylglycerols with or without the presence of a small amount of LiOH 
51
. Each 
LiOMe-treated lipid extract was properly diluted prior to infusion to the mass 
spectrometer for the analyses of sphingolipids (Jiang et al., 2007). Typically, a 2-min 
period and 2-5-min of signal averaging in the profile mode were employed for acquisition 
of each survey scan and each tandem MS scan, respectively. For tandem mass 
spectrometry, a collision gas pressure was set at 1.0 mTorr but the collisional energy was 
varied with the classes of lipids as previously described 
51
 . All the MS spectra and 
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tandem MS spectra were automatically acquired by a customized sequence subroutine 
operated under Xcalibur software. Each individual lipid species in a lipid class was 
identified using multi-dimensional mass spectrometry through building block analyses 
52
. 
The identified species were quantified using a two-step approach as previously described 
52
. 
 
Primary SC cultures and in vitro ISR induction: Primary rat SCs were cultured from 
sciatic nerves of postnatal day1 to day3 rat pups as previously described 47. For SC in 
vitro ISR induction assays, SCs were initially seeded onto collagen coated 24-well plates 
(~75,000 cells/well) in 10% FBS-DMEM media supplemented with 2 M forskolin and 
20 g/ml of bovine pituitary extract. 48 h later cells were switched to 1% FBS-DMEM 
media for 2 days to stop proliferation. At this point, SCs were treated with either vehicle, 
5 M FCCP, 2.5 M oligomycin, 10 M antimycin or 1 M tunicamycin. RNA or 
protein were isolated 24 h later. Reported results are from duplicate wells from at least 
three independent assays.  
 
Acyl-carnitine release measurements: To measure the ability of Tfam-deficient SCs to 
secrete long-chain acylcarnitines, nerves were explanted from Tfam-SCKO and Ctrl mice 
and maintained in 100 l of 10% fetal bovine serum (FBS) supplemented with 2 mM L-
glutamine and 100 ng/ml of nerve growth factor for 2.5 days. At this time, media was 
collected and immediately frozen in liquid nitrogen. Media was then analyzed for 
acylcarnitine species content (C2–C18 saturated, unsaturated, and hydroxylated) as butyl 
esters by direct flow injection and precursor ion scanning on an API 3200 LC-MS/MS 
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system (Applied Biosystems, Foster City, CA, USA). Quantitation was achieved using a 
cocktail of internal standards. Concentrations were normalized to tissue weight.  
 
DRG neuron culture and Fluo-4 imaging: mouse DRG neurons were isolated from E12 
embryos in DMEM (Sigma), dissociated by incubation in 0.25% trypsin, and resuspended 
(100 μl/embryo) in complete DRG medium: neurobasal medium (Invitrogen) containing 
2% B27 supplement (Invitrogen), 50 ng/ml of nerve growth factor (Harlan Laboratories), 
1 μM 5-fluoro-2′-deoxyuridine (Sigma), and 1 μM uridine (Sigma). Cells were then 
seeded onto either 24-well or 96-well cell cultures plates coated with poly-d-lysine 
(Sigma) and Laminin (Invitrogen) by spotting a single 0.5 l (96-well) or 2 l (24-well) 
droplet of the concentrated cell suspension, incubating for 15 min at 37 °C to allow 
neurons to adhere, then adding 100 μl (96-well) or 400 ul (24-well) of complete DRG 
media. All experiments were carried out 5-6 days after seeding. For calcium imaging 
experiments, neurons were incubated with the calcium indicator Fluo-4 AM (2 M, 
Invitrogen) for 30 min at 37 °C, washed by replacing half the media twice, then incubated 
for another 30 min to allow complete de-esterification of intracellular AM esters. 
Baseline fluorescence and phase images were taken at this point. Neurons were then 
treated either with vehicle, palmitoyl-carnitine (Sigma), or palmitate (Sigma) at the 
appropriate concentrations. Phase and fluorescence images were acquired every 15 
minutes for up to 6 hours using an Operetta imaging system equipped with an 
environmental chamber (Perkin Elmer).  To examine the effect of chronic acylcarnitine 
exposure, DRG neurons were treated daily for up to nine days with vehicle or with 
palmitoyl-carnitine at the appropriate concentration.  
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Automated analysis and quantification of images: Axon degeneration, axonal calcium 
accumulation, and calcium containing vacuole formation were quantified using ImageJ as 
follows. For axon degeneration, bright field images of axons were binarized and 
fragmented axons were detected using particle analyzer. The ratio of fragmented axon 
area against the total axon area was expressed as degeneration index.  Axonal calcium 
accumulation was quantified from the fluorescent images of axons loaded with Fluo-4 
calcium sensitive dye as described above. The fluorescent intensity of the pixels over the 
axon area (as determined from accompanying bright field images) were summed and then 
normalized by the total axon area. Palmitoyl-carnitine treated axons tend to form 
vacuoles containing high concentration of Ca
2+
 which are recognized as spherical 
structures with higher Fluo-4 intensity than surrounding axons. The total area of these 
vacuoles was expressed as a Fluo-4 blebbing index. This index was determined by first 
calculating the total Fluo-4 positive axon area. Then the area of calcium containing 
vacuoles was quantified using binarized Fluo-4 images threshold such that only vacuoles 
but not the rest of axons were recognized by a particle analyzer. The total vacuole area 
detected was normalized against total Fluo-4 positive area to give Fluo-4 blebbing index. 
Statistical analysis: All values are expressed as mean ± SEM. If not stated
 
otherwise, p 
values were determined by unpaired, two-tailed
 
Student's t test. All statistical analyses 
were performed using
 
Microsoft Excel 2007. 
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Figures 
Figure 1: SC mitochondrial dysfunction induces a progressive degenerative 
peripheral neuropathy that is not directly linked to energy depletion. a) Electron 
micrographs of 1 month old Ctrl and Tfam-SCKO sciatic nerve cross sections depicting 
early structural abnormalities of Remak bundles (SC surrounding multiple unmyelinated 
axons) and degeneration of unmyelinated axons (asterisk). A, axons; N, SC nucleus; C, 
SC cytoplasm. Scale bar 500 nm. b, c) Toluidene blue stained plastic sections of Tfam-
SCKO and Ctrl sciatic nerve cross sections (b) and quantification of total number of 
myelinated profiles per nerve (c) at different ages show prominent, progressive 
degeneration of large-caliber myelinated axons and demyelination starting at 3-4 months 
of age. Arrowheads (b) indicate axons surrounded by unusually thin myelin, a sign of 
demyelination. Arrow (c) indicates the point in the progression of the pathology for all 
mice used in later experiments; note that at this age nerves display only limited, early 
pathological changes with minimal axon loss and demyelination. Error bars, SEM. n=4 
mice per genotype at each age. *P<0.01 Scale bar 25 m. d) Adenylate energy charge in 
Tfam-SCKO nerves shows only a slight decrease in the energy levels of Tfam-deficient 
SCs compared to Ctrl nerves. Error bars, SEM. n=8 mice per genotype. *P<0.01 e, f) 
Immunoblot analysis (e) and quantification of band intensity (f) reveals no increase in the 
phosphorylation (activation) of the energy sensor AMPK in Tfam-SCKO nerves, 
indicating that energy depletion is an unlikely driver of nerve pathology in these mice. 
Error bars, SEM. n=4 mice per genotype.  
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Figure 2: SC mitochondrial dysfunction activates a maladaptive integrated stress 
response (ISR) independent of ER-stress. a) SC mitochondrial dysfunction upregulates 
the expression of ISR target genes in Tfam-SCKO nerves compared to Ctrl as measured 
by qRT-PCR. ATF4, activating transcription factor 4; Chop, DNA-damage inducible 
transcript 3; ASNS, asparagine synthetase; MTHFD2, methylenetetrahydrofolate 
dehydrogenase; TRIB3, tribbles homolog 3. Error bars, SEM. n=5 mice per genotype. 
*P<0.05 b) Immunoblot analysis shows increased phosphorylation of eIF2in Tfam-
SCKO vs. Ctrl nerves, confirming the activation of the ISR c) Immunoblot analysis 
shows that application of the mitochondrial inhibitor FCCP to cultured SCs increases 
phosphorylation of eIF2indicating that inhibition of the mitochondrial electron 
transport chain activates the ISR. d) Inhibition of mitochondrial respiration in cultured 
SCs with mitochondrial inhibitors upregulates the expression of ISR target genes as 
measured by qRT-PCR. Error bars, SEM. n=duplicate wells from 3 independent 
experiments. *P<0.05. e) Immunoblot analysis of the phosphorylation (activation) status 
of the ER-stress sensor Perk in Ctrl and Tfam-SCKO nerves shows no differences, 
indicating that ISR activation following SC mitochondrial deficits does not involve ER-
stress. f) Gel showing the absence of Xbp-1 splicing downstream of the activation of the 
ER-stress sensor Ire-1 in Tfam-SCKO nerves, or SCs treated with mitochondrial 
inhibitors, confirms that ISR activation induced by mitochondrial derangement is 
independent of ER-Stress. Tunicamycin treatment of sciatic nerves cultured as explants 
or of SCs, serves as a positive control for ER-stress.  
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Figure 3: SC mitochondrial dysfunction causes a shift in lipid metabolism away 
from lipid biosynthesis and toward fatty acid oxidation. a) Differentially expressed 
mRNAs in Tfam-SCKO nerves as determined by microarray analysis are enriched for 
genes involved in lipid metabolism pathways. The 10 pathways with most significant 
enrichment among differentially expressed genes in Tfam-SCKO nerves are shown.  b) 
qRT-PCR analysis confirms that a number of lipid synthesis related enzymes are 
downregulated in Tfam-SCKO vs. Ctrl nerves. SREBP1, sterol regulatory element 
binding transcription factor 1; FASN, fatty acid synthase; HMGCR, 3-hydroxy-3-
methylglutaryl-Coenzyme A reductase; ACLY, ATP citrate lyase; ACC2, acetyl-
Coenzyme A carboxylase beta (primarily localized to mitochondria). Error bars, SEM. 
n=5 mice per genotype. *P<0.05. c) Diagram depicting the regulation by acetyl-coA 
carboxylase (ACC) of the balance between fatty acid synthesis vs. oxidation and how it is 
altered by ACC’s phosphorylation status. d, e) Immunoblot analysis (d) and 
quantification of band intensity (e) show increased phospohorylation of ACC in Tfam-
SCKO nerves compared to Ctrls. Phosphorylation inhibits this central regulator of the 
balance between lipid synthesis vs. oxidation, indicating (together with gene expression 
results) a shift in lipid metabolism away from new lipid synthesis and towards increased 
lipid oxidation in SC following mitochondrial dysfunction. Error bars, SEM. n=4 mice 
per genotype. *P<0.05. 
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Figure 4: Abnormal lipid metabolism secondary to mitochondrial dysfunction 
results in depletion of myelin lipid components in Tfam-SCKO nerves. a, b) 
Lipidomic analysis revealed an early and significant depletion of two key myelin lipid 
components, cerebrosides (a) and sulfatides (b), in Tfam-SCKO vs. Ctrl nerves, likely 
accounting for the subsequent demyelination observed in these mice. Error bars, SEM. 
n=5 mice per genotype. *P<0.05. c) Immunoblot analysis reveals that sulfatide and 
cerebroside depletion precedes any decrease in expression of nerve myelin basic protein 
(MBP) and myelin protein zero (P0), making lipid depletion a potential driver of the later 
demyelination. 
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Figure 5: Abnormal lipid metabolism secondary to mitochondrial dysfunction 
causes severe accumulation of acylcarnitine fatty acid -oxidation intermediates in 
Tfam-SCKO nerves a, b) Lipidomic analysis shows a significant accumulation of long-
chain acylcarnitines (total, a) that affects most long-chain molecular species (b) in Tfam-
SCKO vs. Ctrl nerves. Error bars, SEM. n=5 mice per genotype. *P<0.05. c) Diagram 
depicting fatty acid -oxidation in the mitochondria. Long-chain fatty acids are converted 
to acylcarnitines to be shuttled into the mitochondrial matrix, the site of -oxidation, 
where they are oxidized through repeated cycles of four enzymatic reactions. Red text 
indicates the altered ratio of NAD/NADH
+
 in Tfam-SCKO nerves. Red stars indicate 
lipid intermediates accumulating in Tfam-SCKO nerves following mitochondrial 
dysfunction. Cpt1 and Cpt2: carnitine palmitoyltransferase 1 and 2; T outer: long-chain 
fatty acid transporter; T inner: carnitine-acylcarnitine translocase; Co-Ash: coenzyme A. 
d) Lipidomic analysis also shows the accumulation of hydroxy-acylcarnitine species 
(derived from 3-hydroxy acyl CoA) in Tfam-SCKO nerves, indicative of inhibition of the 
-oxidation reaction catalyzed by 3-hydroxyacyl CoA dehydrogenase. Error bars, SEM. 
n=5 mice per genotype. *P<0.05. e) Reduced NAD+/NADH ratio in Tfam-SCKO nerves. 
Error bars, SEM. n=6 mice per genotype. *P<0.05. 
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Figure 6: Long-chain acylcarnitines are secreted from SCs and alter axonal calcium 
homeostasis and stability. a) Explanted Tfam-SCKO nerves but not Ctrl nerves release 
long-chain acylcarnitines into surrounding culture media as measured by mass 
spectrometry. Error bars, SEM. n=6 mice per genotype. *P<0.05 b) Images depicting 
increased fluorescence intensity of the Ca
2+
 dye Fluo-4 after acute (30 min) application of 
palmitoyl-carnitine (PC), an acylcarnitine species highly increased in Tfam-SCKO 
nerves, shows that this lipid intermediate can disrupt axonal calcium homeostasis. Note 
that similar changes were not seen when the corresponding free fatty acid (Palmitate, P) 
was applied. Scale bar, 100 m c, d) Quantification of the effect of palmitoyl-carnitine on 
Fluo-4 intenstiy (c) and Ca
2+
 blebbing (d) shows that the effect of this lipid intermediate 
on axonal calcium is dose-dependent, and specific to acylcarnitines; application of the 
corresponding free fatty acid at the same concentrations exerted no comparable effect. 
Error bars, SEM. n=triplicate wells from 1 out of 3 representative experiments. *P<0.05. 
e) Images depicting a progressive increase in axonal degeneration following chronic 
application of 25 M palmitoyl-carnitine (PC) after 9 days of treatment. Scale bar, 100 
m f) quantification of the effect on axonal degeneration of chronic treatment with 25 
M palmitoyl-carnitine (PC) shows a significant, progressive increase in the axon 
degeneration index. Error bars, SEM. n=6 wells from 1 out of 2 representative 
experiments. *P<0.05.   
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Figure 7: Altered SC lipid metabolism accompanied by the toxic accumulation of 
lipid intermediates induces axonal degeneration and demyelination in 
mitochondria-related peripheral neuropathies. Diagram describing the proposed 
model for how a shift in lipid metabolism away from lipid synthesis and towards lipid 
oxidation secondary to SC mitochondrial dysfunction may contribute to the pathology in 
peripheral neuropathies. CB: cerebrosides; ST: sulfatides; AC: acylcarnitine 
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Supplementary Figure 1: Increased mitochondrial content and glycolysis help 
maintain cellular energy levels in Tfam-deficient SCs. a) Immunoblot analysis and 
quantification of band intensity (OD, optical density; b) of porin, a mitochondrial 
membrane protein that serves as a reliable marker of mitochondrial content, shows a 3-
fold increase in Tfam-SCKO vs Ctrl nerves. Error bars, SEM. n=3 mice per genotype. 
*P<0.05. b) Increased ratio of maximum complex IV activity per mg of tissue vs 
maximum complex IV activity per mg of mitochondria for Tfam-SCKOs confirms a 
higher mitochondrial content in these mice. Error bars, SEM. n= complex IV activity 
measured from 5 whole nerves and from 4 nerve mitochondria preparations. *P<0.05. c) 
Lactate levels in Tfam-SCKO nerves are greater than in Ctrl nerves, suggesting increased 
glycolysis. Error bars, SEM. n=8 mice per genotype. *P<0.05. 
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Supplementary Figure 2: Depletion of myelin lipid components and accumulation of 
acylcarnitine fatty acid -oxidation intermediates in Tfam-SCKO nerves a) 
Representative spectrum of sulfatide species detected in Ctrl and Tfam-SCKO nerves 
shows depletion of this lipid class in SCs following mitochondrial dysfunction. Asterisk 
marks one of the more depleted sulfatide species, m/z = 888.6, d18:1, N24:1. IS, internal 
standard. b)  Representative spectrum of acylcarnitine species detected in Ctrl and Tfam-
SCKO nerves depicts the dramatic accumulation of this lipid class in SCs following 
mitochondrial dysfunction. Asterisks mark two of the more increased acylcarnitines 
species m/z = 398.3, C16:1; m/z = 426.3, C18:1. IS, internal standard. 
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Abstract 
Mitochondrial dysfunction is a central mediator of disease progression in diverse 
neurodegenerative diseases that often present with prominent gastrointestinal 
abnormalities. Gastrointestinal dysfunction in these disorders is related, at least in part, to 
defects in the enteric nervous system (ENS). The role of mitochondrial deficits in ENS 
neurodegeneration and their relative contribution to gastrointestinal dysfunction, 
however, are unclear. To better understand how mitochondrial abnormalities in the ENS 
influence enteric neurodegeneration and affect intestinal function, we generated mice 
(Tfam-ENSKOs) with impaired mitochondrial metabolism in enteric neurons and glia 
through the targeted deletion of the mitochondrial transcription factor A gene (Tfam). 
Tfam-ENSKO mice were initially viable but, at an early age, they developed severe 
gastrointestinal motility problems characterized by intestinal pseudo-obstruction resulting 
in premature death. This gastrointestinal dysfunction was caused by extensive, 
progressive neurodegeneration of the ENS involving both neurons and glia. Interestingly, 
mitochondrial defects differentially affected specific subpopulations of enteric neurons 
and regions of the gastrointestinal tract. Mitochondrial deficiency-related neuronal and 
glial loss was most prominent in the proximal small intestine, but the first affected 
neurons, nitrergic inhibitory neurons, had the greatest losses in the distal small intestine. 
This regional and subtype-specific variability in susceptibility to mitochondrial defects 
resulted in an imbalance of inhibitory and excitatory neurons that likely accounts for the 
observed phenotype in Tfam-ENSKO mice. Mitochondrial dysfunction, therefore, is 
likely to be an important driving force of neurodegeneration in the ENS and contribute to 
gastrointestinal symptoms in people with neurodegenerative disorders.   
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Introduction 
Gastrointestinal dysfunction is a prevalent symptom in neurologic and systemic 
diseases associated with neurodegeneration. Constipation, for example, is the most 
widely recognized non-motor symptom in people with Parkinson’s disease (PD), the 
second most common neurodegenerative disorder in industrialized countries [1,2]. 
Decreased frequency of bowel movements is in fact one of the earliest signs of PD, 
predating the development of the classic motor symptoms, sometimes by many years [3-
5]. In addition, impaired gastric emptying is estimated to affect the majority of patients 
with PD and complicates treatment by interfering with levodopa absorption, which can 
only be absorbed once it reaches the small intestine (SI) [1,6,7]. Similarly, up to 75% 
people with diabetes mellitus, a systemic metabolic disease associated with progressive 
neuronal damage [8], experience a variety of gastrointestinal symptoms ranging from 
diarrhea to severe gastroparesis and constipation [9]. Gastrointestinal dysfunction in these 
neurodegenerative disorders is related, at least in part, to abnormalities and cell loss in the 
enteric nervous system (ENS) [9-11], the complex network of neurons and glia that 
innervates the gut and controls intestinal function. A better understanding of the 
pathophysiology of neurodegeneration within the ENS could therefore be relevant to the 
treatment of patients with diseases characterized by neuron loss with prominent 
gastrointestinal symptoms.  
Mitochondria are now thought to be critical mediators of disease progression in 
diverse disorders such as PD and diabetes. Studies primarily focusing on the central 
nervous system (CNS) have established that mitochondrial dysfunction is involved in 
both the initiation and propagation of disease processes that eventually result in neuron 
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death [12,13]. A growing body of evidence indicates that mitochondrial defects may 
similarly contribute to neurodegeneration in the ENS. Consistent with this notion, rodent 
models of PD induced by mitochondrial toxins are characterized by ENS pathology and 
cell loss, even at doses below those necessary to cause CNS pathology [14-17]. Indeed, 
the ENS appears to be particularly susceptible to mitochondrial dysfunction compared to 
other tissues. This is best exemplified by the fact that primary inherited mitochondrial 
disorders, a heterogeneous group of complex multisystem diseases, commonly include 
gastrointestinal symptoms. As is the case in PD, symptoms of gastrointestinal 
dysfunction can precede other presentations of mitochondrial deficits and, in some cases 
(e.g. mitochondrial neurogastrointestinal encephalomyopathy, or MNGIE) may be the 
most prominent manifestation of the disease [18]. The role of mitochondrial 
abnormalities in ENS neurodegeneration and its relative contribution to gastrointestinal 
dysfunction, however, remain poorly understood. 
With the goal of elucidating how mitochondrial abnormalities in the ENS 
contribute to enteric neurodegeneration and affect gastrointestinal function, we generated 
mice with impaired mitochondrial metabolism in neurons and glia of the ENS. These 
Tfam-ENSKO mice were generated by tissue-specific deletion of the gene encoding 
mitochondrial transcription factor A (Tfam), which is required for mitochondrial DNA 
(mtDNA) transcription and replication [19]. We show that normal mitochondrial function 
in the ENS is essential for the survival of both enteric neurons and glia as well as for 
maintenance of normal gastrointestinal motility. Interestingly, we found that 
mitochondrial dysfunction differentially affected specific subpopulations of enteric 
neurons and, most surprisingly, specific regions of the gastrointestinal tract. 
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Mitochondrial deficiency-related neuronal and glial loss was most prominent in the 
proximal SI, but nitrergic, inhibitory neurons were less severely affected in this region 
and, instead, were most affected in the distal SI. Interestingly, this regional and subtype 
variability of enteric neurons appears to directly correlate to the phenotype observed in 
Tfam-ENSKO mice, with dilation in the proximal SI and relative constriction in the distal 
SI. Mitochondrial dysfunction in the ENS and the regional- and subtype-specific 
vulnerabilities of enteric neurons are likely contributors to the gastrointestinal symptoms 
of patients suffering from some neurodegenerative disorders.  
 
Results 
Cre-mediated deletion of Tfam results in mitochondrial abnormalities in the ENS: 
To study how mitochondrial dysfunction in the ENS affects gastrointestinal 
function and contributes to enteric neurodegeneration, we generated mice with disrupted 
mitochondrial metabolism in both enteric neurons and glia (Tfam-ENSKOs). For this 
purpose we used a previously developed mouse with loxP-flanked Tfam alleles (Tfam
loxP
) 
[19]. Tfam is a mitochondrial protein encoded by nuclear DNA that is essential for 
mtDNA maintenance, copy number regulation and transcription [19,20]. Previous studies 
have shown that cre-mediated deletion of Tfam in Tfam
loxP
 homozygous mice results in 
severe tissue-specific mtDNA depletion and mitochondrial respiratory chain deficiency 
[19,21-25]. The tissue-specific deletion of Tfam is, therefore, an effective way to induce 
mitochondrial dysfunction in a selected population of cells.   
We mated Tfam
loxP
 mice to mice expressing cre-recombinase under the control of 
the Cnp1 promoter (CNP-Cre) [26]. Cnp1 encodes the enzyme 2′, 3′-cyclic nucleotide 3′-
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phosphodiesterase (CNP), a commonly used marker for myelin-forming glia. However, 
we inadvertently discovered that the Cnp1 promoter also drives the expression of cre-
recombinase in the ENS and thereby induces recombination in the majority of enteric 
neurons and glia. Consistent with this fortuitous observation, CNP has been reported to 
be highly expressed in gut neural crest stem cells [27]. Indeed, when we crossed CNP-
Cre mice with Cre-inducible Rosa26-YFP reporter animals, YFP fluorescence was visible 
in over 90% of enteric neurons and glia throughout the gut (Fig. 1a and b). 
Crossing of Tfam-ENSKO mice to Cre-inducible Rosa26-YFP reporter animals 
(YFP/Tfam-ENSKOs) showed that Tfam was efficiently excised in all enteric neurons 
and glia in which we observed Cnp1-mediated expression of cre-recombinase (as 
visualized by YFP fluorescence). When we isolated YFP-positive enteric neurons and 
glia from 7 week old YFP/Tfam-ENSKO mice, we could not detect the Tfam allele by 
RT-PCR analysis (Fig. 1c). Given the extent and high efficiency of the Cnp1 promoter-
driven expression of cre-recombinase, we conclude that the mating of Tfam
loxP
 to CNP-
Cre mice resulted in animals that lacked Tfam in the majority of enteric neurons and glia.  
To determine the functional effect of deleting Tfam in the ENS, we next assessed 
mtDNA copy number in YFP-positive enteric neurons and glia from 7 week old 
YFP/Tfam-ENSKO and YFP/control mice. Tfam has an essential role in the maintenance 
and replication of mtDNA [19,20] and previous reports have described severe mtDNA 
depletion following tissue-specific excision of Tfam from a cell of interest [19,21-25]. 
Consistent with this, we found an 80% reduction in total mtDNA content in enteric 
neurons and glia isolated from different regions throughout the gut of YFP/Tfam-ENSKO 
mice (Fig. 1d). 
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In previous studies using Tfam
loxP
 mice, the depletion of mtDNA following Tfam 
excision has been shown to induce severe respiratory chain deficiency, since the 
mitochondrial genome encodes 13 subunits that are essential components of the electron 
transport chain. In addition, Tfam deficiency-induced mitochondrial dysfunction is 
accompanied by abnormalities in mitochondrial morphology [19,21-25,28]. Therefore, to 
further confirm the enteric neuron- and glia-specific disruption of mitochondria in Tfam-
ENSKO mice we examined the enteric nervous system by electron microscopy. 
Abundant abnormal and enlarged mitochondria with distorted cristae were found 
specifically within enteric neurons and glia of Tfam-ENSKOs but not of control 
littermates (Fig. 1e). Together, our results confirm that by deleting Tfam in enteric 
neurons and glia we were able to generate mice with disrupted mitochondria in the ENS.  
 
Tfam-ENSKOs develop progressive gastrointestinal dysfunction characterized by 
intestinal pseudo-obstruction 
Tfam-ENSKO mice were viable and born at the expected Mendelian ratios and, 
for the first 2 weeks of life, they were indistinguishable from their control littermates. 
After 2 weeks of age, however, Tfam-ENSKO mice displayed signs of poor growth and, 
by 4 weeks of age, they were significantly smaller than their control littermates (Fig. 2a). 
In addition, Tfam-ENSKO mice developed abdominal distention at about 6-8 weeks of 
age, which, together with poor growth, suggests gastrointestinal dysfunction. After 8 
weeks of age, the health of Tfam-ENSKO mice deteriorated rapidly and the majority of 
the animals died by 12 weeks of age (Fig. 2b).  
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Dissection of late stage (i.e. 10-12 weeks old) Tfam-ENSKO mice consistently 
revealed massive dilation within the proximal small bowel along with relative contraction 
of the distal small bowel (Fig. 2c). The region of transition from dilated proximal small 
bowel to the narrower distal small bowel was consistently located within the mid-small 
bowel, with variable accumulation of luminal contents in the proximal small bowel and 
stomach.  No stenosis or mechanical cause of the obstruction could be found and the mice 
did not have malrotation or other anatomic explanations for the obstruction.  Proximal to 
the transition zone, in the region of dilation, the bowel was filled with dark-colored 
luminal contents and the bowel wall appeared to be stretched thinner than in controls 
(Fig. 2c).  Luminal contents were absent distally and no stool pellets could be found in 
the colon or rectum.  The distal small intestine and colon in Tfam-ENSKOs generally 
appeared to have a smaller diameter than in control mice. Therefore, we conclude that 
disrupted mitochondrial metabolism in enteric neurons and glia in Tfam-ENSKO mice 
results in significant gastrointestinal dysfunction and dysmotility. 
  
Tfam-ENSKO mice develop progressive neuronal degeneration with distinct 
regional vulnerabilities 
To test the hypothesis that ENS defects underlie the bowel abnormalities and 
early death observed in Tfam-ENSKO mice, we used whole mount immunohistochemical 
methods to evaluate ENS structure. We initially examined total myenteric neuron density 
using immunohistochemistry for HuC/HuD, a widely used pan-neuronal marker that 
labels the cell body of all neurons within the myenteric plexus [29]. 2 week old Tfam-
ENSKO mice had a lower mean neuron density in all regions examined compared to WT 
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animals, but these differences were not statistically significant (p>0.1 in all cases, Fig. 3b 
and Table 1). This is consistent with the healthy appearance of Tfam-ENSKOs at this age 
and suggests that the ENS develops normally in these animals. 
We next examined the myenteric plexus of 7 week old Tfam-ENSKO and control 
mice. At this age, Tfam-ENSKO mice begin to show subtle phenotypic abnormalities (i.e. 
poor growth) but appear healthy, do not display signs of gastrointestinal obstruction, and 
lack intestinal dilation (Fig. 2a and b). Despite their healthy appearance, at 7 weeks of 
age Tfam-ENSKO mice had a 68% decrease in myenteric neuron density in the proximal 
SI, and a 41% decrease in the distal SI (Fig. 3a and b and Table 1).  Surprisingly, even 
though the extent of Tfam excision appeared equal in all regions analyzed at 7 weeks of 
age (Fig. 1), we found no difference in colon total neuron density between Tfam-
ENSKOs and control littermates at this age (Fig. 3a and b and Table 1). In fact, enteric 
neuron density in the colon of Tfam-ENSKOs remained normal even at late pathological 
stages (e.g. 10-12 weeks old), when enteric neurodegeneration in more proximal regions 
was profound (data not shown). Thus, mitochondrial dysfunction in the ENS results in a 
progressive neurodegeneration with marked differences in regional vulnerability to 
neuronal loss.  
 
Glial degeneration parallels that of neurons in Tfam-ENSKOs 
A growing body of literature now implicates glial dysfunction in many 
neurodegenerative diseases traditionally thought to be neuron autonomous. In animal 
models of amyotrophic lateral sclerosis, PD, and Huntington’s disease among others, 
glia-specific abnormalities alter disease onset and progression (for a review see [30]). To 
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address the role of enteric glia in the mitochondria-related gastrointestinal dysfunction of 
Tfam-ENSKO mice, we assessed the effect of Tfam-depletion on enteric glia using Sox-
10 immunohistochemistry. We first examined glial density in the myenteric plexus of 2 
week old mice and observed very little difference between Tfam-ENSKOs and littermate 
controls except in the distal SI (Fig. 3c and Table 1). By 7 weeks of age, however, Tfam-
ENSKO mice had significantly reduced glial cell density in both the proximal and distal 
SI (Fig. 3a and 3c and Table 1). However, as is the case for HuC/HuD
+
 neurons, the glial 
cell density in the colon of Tfam-ENSKO mice remained normal at 7 weeks of age (Fig. 
3a and 3c and Table 1). 
The changes in glial cell density in Tfam-ENSKO mice, therefore, seemed to 
parallel that of neurons, involving the same regions and a similar proportion of cells. We 
examined this in more detail by comparing the ratio of neurons to glia in control and 
Tfam-ENSKO mice. As expected from the absence of either neuron or glial cell loss in 2 
week old Tfam-ENSKOs, we found no difference in the neuron to glia ratio in any of the 
regions examined compared to control animals (Fig. 3d and Table 1). Interestingly, 
despite extensive neuron and glia loss in 7 week old Tfam-ENSKOs, the ratio of neurons 
to glia in all regions examined remained comparable to that of control littermates (Fig. 3d 
and Table 1). These results suggest that enteric neurons and glia are equally susceptible 
to mitochondrial defects in Tfam-ENSKO mice.  
 
Early and differential loss of nitrergic inhibitory neurons in Tfam-ENSKO mice 
Intestinal motility and peristalsis depend on the balance between ENS excitatory 
and inhibitory inputs which together produce the rhythmic coordination of contraction 
139 
 
and relaxation necessary to propel luminal contents [31]. The apparent constriction 
observed in the distal bowel of Tfam-ENSKO mice, as well as the dilation proximal to 
this point (Fig. 2c), suggested the possibility of an imbalance between these inputs. To 
address how enteric neuron loss in Tfam-ENSKO mice affects the balance between 
inhibitory and excitatory inputs, we examined the number and proportion of nitric oxide 
(NO)-producing inhibitory neurons in the myenteric plexus by NADPH diaphorase 
(NADPH-d) staining [32]. The proportion of NADPH-d
+
 neurons in different gut regions 
is normally within a narrow range that maintains the balance between ENS excitatory and 
inhibitory inputs and allows for normal intestinal motility. As early as 2 weeks of age, the 
NADPH-d
+
 neuron density in the proximal and distal SI in Tfam-ENSKO mice was 
significantly lower than in controls (Fig. 4b and Table 1). These data suggest early 
preferential loss of nitrergic inhibitory neurons relative to other neuronal subtypes.  
As the pathologic changes in the ENS of Tfam-ENSKO mice progressed, the loss 
of NADPH-d
+
 neurons became more pronounced and, moreover, by 7 weeks of age the 
percentage of NADPH-d
+
 neurons varied quite dramatically between different regions of 
the gut. NADPH-d
+
 neuron loss was greatest in the distal SI with a 60% decrease, but 
significant decreases were also found in the proximal SI and colon (33% and 25%, 
respectively; Fig. 4a and b and Table 1). Interestingly, the observed loss of nitrergic 
neurons did not parallel the loss of total neurons in each region (Fig. 3a and b), causing 
significant differences in the relative proportion of NADPH-d
+
 neurons to total neurons 
(i.e. changes in inhibitory input) throughout the bowel (Fig. 4c and Table 1). In 7 week 
old Tfam-ENSKOs, NADPH-d
+
 neurons accounted for 75% of total neurons in the 
proximal SI compared to 36% in controls (Fig. 4c and Table 1). In contrast, in the distal 
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SI, the proportion of NADPH-d
+
 inhibitory neurons was lower than in control animals, 
(19% in Tfam-ENSKOs, 28% in controls; Fig. 4c and Table 1). In the colon, there was no 
significant difference in the ratio of nitrergic to total neurons between control and Tfam-
ENSKO mice (Fig. 4c and Table 1). This concurrent increase in relative abundance of 
inhibitory inputs in the proximal SI along with the decrease in the ratio of NADPH-d
+
 to 
total neurons in the distal SI of Tfam-ENSKOs may thus account for the proximal 
dilation and distal constriction observed in the late pathology of these mice (Fig. 4d).  
 
Axonal degeneration is a key feature of enteric neuron loss in Tfam-ENSKOs and 
may precede cell body loss 
During our examination of NADPH-d
+
 neurons, we observed extensive and 
prominent blebbing in neuronal projections in the myenteric plexus of Tfam-ENSKO 
mice (Fig. 5a). In the CNS and PNS, axon blebbing has been recognized as a sign of 
axonal degeneration, a central component of many neurodegenerative diseases, which can 
precede and sometimes cause neuronal death [33]. To assess the role of axon 
degeneration in the neuron loss observed in Tfam-ENSKOs we first examined the 
neuronal projections, or neurites, extending into the villi in the proximal and distal SI. As 
early as two weeks of age, Tfam-ENSKO mice displayed signs of neurite loss within 
intestinal villi, although at this age neurite degeneration was limited to the proximal SI 
(Fig. 5c and Table 2). Neurite loss worsened over time, and by 7 weeks of age the 
number of neurites in the villi of Tfam-ENSKO mice was significantly reduced in both 
the proximal and distal SI (Fig. 5b and c and Table 2) suggesting that loss of neuronal 
projections could contribute to subsequent neuron loss.  
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Because we are unable to easily identify the cell of origin for neurites in the villi, 
we also quantified neuronal fiber density for NADPH-d
+
 fibers in the myenteric plexus of 
7 week old mice. We found no difference in the density of large fiber bundles (i.e., 
primary fibers; [34]) in any region examined between Tfam-ENSKOs and controls (Table 
3). In contrast, small fiber density (i.e., secondary and tertiary fibers; [34]) was 
significantly lower (44%) in the proximal SI of Tfam-ENSKOs mice, but was similar to 
controls in the distal SI and colon (Table 3). Note, however, that what we count as “small 
fibers” or “large fiber bundles” are actually one or more tightly fasciculated neurites. In 
Tfam-ENSKO mice both “small fibers” and “large fiber bundles” appear significantly 
thinner than in control animals at 7 weeks of age (Fig. 4a and 5a), suggesting that our 
counting method for NADPH-d+ neuronal projections significantly underestimates 
neurite loss in the mutant mice. Because of these limitations, we devised an alternate 
method to evaluate the effect of mitochondrial dysfunction on enteric neuron and neurite 
degeneration in vitro. 
E12.5 enteric neurons were cultured from control mouse gut and exposed to 
different inhibitors of the mitochondrial electron transport chain (e.g. rotenone and 
antimycin). Disrupting mitochondrial respiration induced significant neurite degeneration 
within 24 hours, yet did not initially affect neuron viability as measured by ethidium 
homodimer staining (Fig. 5d and e and Table 4). Moreover, even though extended 
exposure to mitochondrial inhibitors eventually induced enteric neuron death, the 
proportion of cells showing axonal degeneration remained larger at every time point 
examined (Table 4). Together, these results suggest that axonal degeneration precedes 
enteric neuron cell body loss induced by mitochondrial defects.  
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Discussion 
The current understanding of how mitochondrial deficits affect enteric neurons 
and contribute to ENS neurodegeneration and gastrointestinal dysfunction has been 
hindered by a lack of animal models. Here we describe a new mouse model with 
disrupted mitochondrial function in enteric neurons and glia. We show that abnormal 
mitochondrial metabolism in the ENS causes widespread enteric neurodegeneration and 
results in severe intestinal pseudo-obstruction, the likely cause of premature death in 
Tfam-ENSKO mice. Remarkably, mitochondrial dysfunction differentially affected 
specific subpopulations of enteric neurons and regions of the gastrointestinal tract. This 
regional and subtype-specific variability resulted in an imbalance of inhibitory and 
excitatory enteric neurons that likely accounts for the observed phenotype in Tfam-
ENSKO mice. Our observations support the hypothesis that damage to the ENS resulting 
from defects in mitochondrial function may underlie some of the pathophysiology 
involved in gastrointestinal abnormalities in many human neurodegenerative diseases. 
Mitochondria are thought to be critical mediators of neuron loss in diverse 
neurodegenerative disorders such as PD or diabetes.  We show that mitochondrial defects 
in the ENS cause both neuron and glia cell loss as well as severe intestinal dysmotility.  
Strikingly, not all regions of the gut were equally affected. The proximal SI suffered the 
most extensive neuron and glial loss whereas the colon was largely spared (Fig. 3). 
Furthermore, we observed differential vulnerability among distinct subtypes of enteric 
neurons. Nitrergic neurons, which are predominantly inhibitory in nature, were lost 
earliest in the progression of the disease in Tfam-ENSKOs (Fig. 4). These findings 
cannot be explained by variations in the efficiency of Tfam excision or in the resulting 
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effect on mitochondria. Cnp1-mediated expression of cre-recombinase (as visualized by 
YFP fluorescence) and mtDNA depletion were comparable throughout the bowel of 
Tfam-ENSKO mice (Fig. 1). The observed variability in sensitivity to mitochondrial 
defects suggests, therefore, that there are regional and cell type specific differences in 
metabolic needs for individual enteric neuron populations.  
In the CNS, regional- and subtype-specific differences in the vulnerability of 
neurons to mitochondrial dysfunction are well established; such differences are thought 
to underlie the preferential loss of striatal neurons in PD or Huntington’s disease [35]. 
Early preferential loss of nitrergic neurons has also been reported in a streptozotocin-
induced rat model of diabetic autonomic neuropathy [36]. Similar differences in 
vulnerability to metabolic insults among enteric neurons had been suggested by an earlier 
study using a rotenone-induced rat model of PD [16]. The enteric nervous system 
abnormalities observed in Tfam-ENSKO mice suggest that regional- and subtype-specific 
differences in the susceptibility of neurons to mitochondrial defects are also present in the 
ENS and may explain the gastrointestinal presentations of neurodegenerative diseases.  
While the mitochondrial dysfunction in Tfam-ENSKO mice is caused by the loss 
of Tfam, the way in which these mice recapitulate gastrointestinal pathological features 
often seen in neurodegenerative disorders indicates that there may be broader 
implications of this work for understanding the bowel dysfunction that accompanies both 
rare and common human disease. For example, Tfam-ENSKO mice consistently 
developed intestinal pseudo-obstruction with dilated proximal small bowel and 
contracted distal bowel reminiscent of that seen in the human mitochondrial disease 
MNGIE. Our results indicate that this pseudo-obstruction could occur because of an 
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imbalance in the ratio of inhibitory to excitatory inputs in the ENS. In Tfam-ENSKOs 
such an imbalance arises from a relative preservation of nitrergic inhibitory neurons in 
the proximal SI and preferential loss of these same neurons in the distal SI of these mice. 
This is of particular interest, because the severe intestinal pseudo-obstruction resulting in 
cachexia and death in MNGIE patients has traditionally been attributed to smooth muscle 
abnormalities, even though mtDNA depletion is also found within enteric neurons in the 
SI of MNGIE patients [37]. Our results demonstrating that mitochondrial dysfunction in 
enteric neurons and glia alone is capable of producing very similar pathology, however, 
suggest that the ENS may play a more prominent role in this mitochondrial disease than 
previously thought.  
While MNGIE is a rare disease, mitochondrial dysfunction is thought to be a 
common underlying mechanism in both normal human aging [38]  as well as in many 
common diseases such as type 2 diabetes [39]. Defects in gastrointestinal motility 
frequently cause serious problems in the elderly and in patients with diabetes [9,40]. 
These motility defects, similar to what we observed in Tfam-ENSKO mice, have been 
attributed to enteric neurodegeneration [9,40]. Moreover, enteric neurodegeneration in 
models of aging, PD and diabetes have been associated with imbalances in inhibitory and 
excitatory neurons [40]. As such, understanding the ENS abnormalities in Tfam-ENSKO 
mice could provide valuable insight into the pathophysiology responsible for 
gastrointestinal motility disorders involved in numerous disease processes and affecting a 
large number of people.  
In summary, Tfam-ENSKO mice are the first genetic model of enteric nervous 
system-specific mitochondrial dysfunction and interestingly recapitulate a number of 
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pathological features often seen in human neurodegenerative diseases with prominent 
gastrointestinal presentations, such as MNGIE, PD or diabetes mellitus. Enteric 
mitochondrial dysfunction in these diseases is therefore likely to contribute to their 
gastrointestinal pathology. Moreover, Tfam-ENSKOs revealed a remarkable region- and 
subtype-specific differential vulnerability of enteric neurons to defects in mitochondrial 
metabolism. Appropriate management of gastrointestinal dysfunction in patients with 
neurodegenerative diseases might thus be facilitated by devising therapeutic strategies 
that improve ENS mitochondrial function and address the differential vulnerability of 
specific enteric neuron populations.  
 
Materials and Methods 
Ethics: All studies were reviewed and approved by the Washington University Animal 
Studies Committee, protocol approval # 20110071 (J.M.) and # 20090190 (ROH). 
 
Matings of transgenic animals: Tfam
loxP/loxP
 mice [19] and CNP-Cre mice [26] in pure 
C57Bl/6 backgrounds were crossed to generate Tfam-ENSKO mice (CNP-Cre
+/-
, 
Tfam
loxP/loxP
) and their control littermates (CNP-Cre
-/-
, Tfam
loxP/loxP
 or CNP-Cre
-/-
, 
Tfam
+/loxP
). For experiments involving YFP fluorescence-based FACS sorting or imaging 
of enteric neurons and glia, Tfam-ENSKO mice were crossed to Rosa26-YFP reporter 
mice [41] to generate YFP/Tfam-ENSKO mice (Rosa26-YFP
+/-
, CNP-Cre
+/-
, 
Tfam
loxP/loxP
). Mice with transgenic Rosa26-YFP and CNP-Cre alleles, but with wild type 
Tfam alleles (YFP/control: Rosa26-YFP
+/-
, CNP-Cre
+/-
, Tfam
+/+
), were used as controls in 
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these experiments. Tfam
loxP/loxP
, CNP-Cre and Rosa26-YFP genotyping were carried out 
as previously described [19,26,41]. 
 
Quantitative ENS analysis:  Mice were euthanized by carbon dioxide asphyxiation 
followed by cervical dislocation.  The gastrointestinal tract was removed and enteric 
whole-mount samples were prepared.  Intestines were flushed with ice cold PBS, then 
opened by cutting along the mesenteric border, flattened and pinned mucosal side down, 
and fixed using 4% paraformaldehyde for 30 minutes.  After fixation, samples were 
washed with ice cold PBS before isolating the myenteric plexus by peeling off the muscle 
layers of the intestine.  A 6 cm-long intestinal sample was isolated from the proximal SI 
(measured from the pylorus), distal SI (measured from the ileocecal junction), and distal 
colon (measured from the anus).  In the 2-week-old mice, 3-4 cm long samples were 
obtained from the same regions as described above.  Samples were then cut into 1 to 2 cm 
segments before storing in 50% glycerol/PBS at -20˚C until staining and analysis. 
 In the 7-week-old mice, sequential 1 cm-long samples of myenteric plexus were 
stained with NADPH-d [42], biotinylated-HuC/HuD (1:250; Invitrogen A21272) and 
Sox-10 (1:250; Santa Cruz). In the 2-week-old mice, sequential 1-1.5 cm long samples of 
myenteric plexus were stained with NADPH-d or biotinylated-HuC/HuD and Sox-10, 
again using the order described above.  For the biotinylated-HuC/HuD and Sox-10 
double labeling, samples were first labeled by HuC/HuD immunohistochemistry (1:250; 
Invitrogen A21272) and then labeled by Sox-10 immunohistochemistry (1:250; Santa 
Cruz). 
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Quantification of neuron or glial cell density was done by counting all cells 
present within the borders of a 0.5 x 0.5 mm grid (20x objective lens).  For instances in 
which the cellular density was very high, counts were done using a 40x objective lens 
(within the borders of a 0.25 x 0.25mm grid).  An attempt was made to stretch all 
segments evenly and equally for all samples.  All analyses used three to six animals, and 
counting was done without knowledge of the mouse genotype.  Twenty (20) randomly 
selected fields were counted for each region and data are presented as neurons/mm
2
.  
Averages for each animal were used to calculate the mean, standard deviation and 
standard error for each genotype.  Neuron-to-glia ratio was determined by dividing the 
number of neurons by the number of glia present within a single field. 
 
Villus neurite quantification: Villus preparations were made by cutting along single 
rows of intestinal villi from full-thickness, pinned samples of proximal and distal small 
intestine in 70% ethanol. These were then labeled by TuJ1 (1:10,000; Covance) 
immunohistochemistry.  Villus neurite quantification was determined by counting all 
TuJ1
+
 projections that crossed a perpendicular line drawn through the middle of each 
villus.  Twenty (20) randomly selected villi were counted for each region and averaged 
for each animal.  At least 3 mice were used to calculate the mean, standard deviation and 
standard error for each genotype. 
 
FACS isolation of enteric neurons and glia: Rosa26-YFP
+
 cells were sorted by flow 
cytometry after isolating and digesting unfixed myenteric plexus from 7-week-old 
YFP/control and YFP/Tfam-ENSKO mice.  A modified version of the protocol published 
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by Schafer et al. [43] was used to isolate adult mouse ENS neurons and glia. Briefly, 
muscle layers of the bowel containing the myenteric plexus were isolated by dissection as 
described above, but were not fixed.  Samples from the proximal SI, distal SI and colon 
were cut into 1 mm
2
 pieces in ice-cold PBS, then treated with collagenase (1 mg/ml in 
DMEM; 37
o
C, 45 min).  After collagenase treatment, tissues were centrifuged at 4,500 
rpm for 2 min and collagenase solution was replaced with 0.25% Trypsin in DMEM.  
Samples were rotated (37
o
C, 20-30 min) and triturated by pipetting before centrifugation 
(4,500 rpm for 2 min) to remove supernatant.  Cells were diluted in 300 μL FACS buffer 
(0.002% BSA, 0.001% Sodium Azide, 1 mM EDTA in PBS) and filtered through 70 
micron MACS separation filters. Cells were then sorted for YFP expression on a MoFlo 
Cell Sorter (Beckman Coulter Corp., Fullerton, CA), using 15 p.s.i. and a 120 μm sorting 
nozzle.  YFP fluorescence was captured with a 525/40 optical filter in the cytometer's FL 
1 channel. Samples were taken from three mice of each genotype (YFP/Ctrl: Rosa26-
YFP
+/-
, CNP-Cre
+/-
, Tfam
+/+
; YFP/Tfam-ENSKO: Rosa26-YFP
+/-
, CNP-Cre
+/-
, 
Tfam
loxP/loxP
) and a non-YFP
+
 littermate (Rosa26-YFP
-/-
, CNP-Cre
+/-
, Tfam
+/+
 or Rosa26-
YFP
-/-
, CNP-Cre
+/-
, Tfam
loxP/loxP
) was used for standardization. 
 
RNA and DNA preparation and quantitative real-time PCR (qRT-PCR): RNA and 
DNA were isolated from FACS sorted enteric neurons and glia from YFP/Tfam-ENSKO 
mice and YFP/Ctrl littermates. For RNA isolation, cells were lysed in Trizol reagent 
(Invitrogen) and total RNA prepared according to the manufacturer’s protocol. For DNA 
isolation, cells were digested and DNA isolated using DNeasy Blood and Tissue Kit 
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(Qiagen) according to the manufacturer’s protocol. DNA and RNA concentration were 
quantified using an ND-1000 spectrophotometer (Nanodrop Technologies).  
For RT-PCR, cDNA was reverse transcribed from total RNA using M-MLV 
reverse transcriptase (Invitrogen) and Tfam or GAPDH mRNA were amplified using the 
following primers  (5’-3’): Tfam: F, CAGGAGGCAAAGGATGATTC; R, 
ATGTCTCCGGATCGTTTCAC; GAPDH:
 
F, TGCCCCCATGTTTGTGATG; R, 
TGTGGTCATGAGCCCTTCC. mtDNA content was quantified by qRT-PCR using a 
SYBR green-based detection system on a 7700 Sequence Detector instrument (Applied 
Biosystems) as described previously [44]. Instead of cDNA, however, 15 ng of total 
DNA were used per reaction. Primers that recognize a region unique to the mitochondrial 
genome were used to determine mtDNA content normalized to nuclear DNA content, as 
determined by a set of primers directed to the genomic locus of Smrt1. The primers used 
were as follows: mtDNA: F, AAGTCGTAACAAGGTAAGCA; R, 
ATATTTGTGTAGGGCTAGGG. Nuc.DNA: F, 
GGGTATATTTTTGATACCTTCAATGAGTTA; R, 
TCTGAAACAGTAGGTAGAGACCAAAGC 
 
Cell culture: Enteric neural crest cells were immunoselected from embryonic day 12.5 
(E12.5) CD1 mice small bowel and colon using p75
NTR
 antibody (Millipore). Bowel was 
dissociated with collagenase (1 mg/ml) and dispase (1 mg/ml) to yield a single cell 
suspension. After p75
NTR
 antibody incubation (Millipore, 1:1000, 1 h, 4°C) in B27 
(Invitrogen) supplemented Neurobasal medium, cells were incubated with goat anti-
rabbit coupled paramagnetic beads (1:50, 1 h, 4°C; Miltenyi Biotec, Bergisch Gladbach, 
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Germany) before separating neural crest-derived cells from unselected cells with a 
positive selection column (MACS separation columns; Miltenyi Biotec). Immunoselected 
crest-derived cells were plated at a density of 500 cells per well on poly-d-lysine/laminin-
coated 24-well plates in B27 supplemented Neurobasal medium plus 50 ng/ml glial cell 
line-derived neurotrophic factor (GDNF). In all experiments, inhibitors were added to the 
medium 24 h after plating using 2.5 μm antimycin (Complex III inhibitor) or 2.5 μm 
rotenone (Complex I inhibitor). Control wells were treated with DMSO vehicle. All 
experiments were performed in triplicate. All analyses were performed blinded.  
 
Neuronal cell body death assay and Immunohistochemistry: Neurons were treated 
with inhibitors or vehicle control and monitored for cell body damage by ethidium 
homodimer exclusion (Biotium, Hayward, CA). Ethidium homodimer was added to the 
cultures at a final concentration of 100 nM and after 30 minutes of incubation cells were 
washed with PBS and fixed 4% paraformaldehyde. After fixation, cells were washed with 
PBS and blocked with 5% normal donkey serum in TBST (Tris-buffered saline plus 0.1% 
Triton X-100) (1 h, 37°C). Cells were incubated in rabbit polyclonal Tuj1 antibody 
(1:1000 at 4°C overnight) and antibody binding was visualized with Alexa Fluor 488 
conjugated anti-rabbit secondary antibodies (Jackson Immunoresearch Laboratory, 1:500, 
25°C, 1 h). 
 
Electron Microscopy: Samples for transmission electron microscopy were obtained 
from 7 week old mice by intracardiac perfusion of Modified Karnovsky’s Fixative (2.5% 
glutaraldehyde, 2% paraformaldehyde in 0.1 mmol/liter cacodylate buffer), followed by 
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isolation of whole mount samples as described above, omitting peeling.  Gut samples 
were pinned in modified Karnovsky’s Fixative and postifixed in 2% OsO4 (in 0.1 mmol/L 
cacodylate buffer). Samples were then dehydrated and embedded in PolyBed 812 
(Polysciences Inc., Warrington, PA). 100 nm sections were cut with a Diatome diamond 
knife and stained with uranyl acetate in 50% methanol and Venable's lead citrate. 
Transmission EM was performed on a JEOL JEM 1200-EX microscope with AMT 
Advantage HR (Advanced Microscopy Techniques Corp., Danvers MA) high-speed, 
wide-angle 1.3 megapixel TEM digital camera. 
 
Light Microscopy and quantification: Samples were counted using a 10 x 10 grid 
counting eyepiece on an Olympus Optical Bx60 microscope or Zeiss Axioskop and an 
Axiocam digital camera and AxioVision imaging software (Zeiss, Germany). Photoshop 
7.0 was used to uniformly adjust contrast and brightness so that digital images appear as 
they did when observed directly through the microscope. 
Statistical analysis: All values are expressed as mean ± SEM.  P values were determined 
by paired Student’s t-test or Mann-Whitney rank sum test using Sigma Plot 11.0 (Systat 
Software, San Jose, CA). In all applicable figures, an asterisk (*) indicates statistical 
significance (p value < 0.05).  
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Figures 
Figure 1. CNP-Cre excises Tfam in enteric neurons and glia and disrupts ENS 
mitochondria in Tfam-ENSKO mice. a) YFP fluorescence in 2-day-old Rosa26-
YFP/CNP-Cre mice overlaps (merge) with enteric neurons (HuC/HuD
+
 cells, Hu, red) 
and glia (Sox-10
+
 cells, Sox, blue). Excision-dependent YFP fluorescence is visible in the 
majority of enteric neurons and glia in all gut regions.  Asterisks indicate the occasional 
non-recombined, non-YFP
+
 cell. Scale bars: 30 μm. b) Quantification of the percent of 
YFP
+
 neurons (% of HuC/HuD
+
 and YFP
+
 cells/total HuC/HuD
+
 cells) and glia (% of 
Sox-10
+
 and YFP
+
 cells/total Sox-10
+
 cells) in different gut regions confirms high 
efficiency of CNP-Cre mediated recombination in the ENS. n=3 mice per genotype. c) 
RT-PCR of Tfam transcript demonstrates the complete excision of Tfam in YFP
+
 FACS 
selected myenteric neurons and glia in YFP/Tfam-ENSKO mice at 7 weeks of age. n=3 
mice per genotype. d) qRT-PCR results show depletion of mtDNA content in YFP
+
 
FACS-selected myenteric neurons and glia in 7 week old YFP/Tfam-ENSKO mice. 
mtDNA content was significantly reduced in YFP/Tfam-ENSKO mice in all regions 
examined at this age (*, p<0.01). Reported values are normalized to nuclear DNA content 
and ratio of mtDNA to nuclear DNA in control animals was set at 100; n=3 mice per 
genotype. e) Electron micrographs of myenteric plexus mitochondria (arrowheads) in 7 
week old control and Tfam-ENSKO mice. Tfam-ENSKO myenteric neurons and glia 
contain abundant abnormal, enlarged mitochondria with dilated and distorted cristae.  
Scale bars, 500 nm. 
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Figure 2. Tfam-ENSKOs develop progressive GI dysfunction characterized by 
intestinal pseudo-obstruction a) Growth curve of Tfam-ENSKO mice and control 
littermates. Tfam-ENSKOs are initially indistinguishable from control mice, but begin to 
exhibit poor growth at 4 weeks of age (n ≥ 10 mice per genotype at each time point). b) 
Survival curve of Tfam-ENSKO mice and control littermates. Tfam-ENSKO mice die 
prematurely beginning at 60 days old.  By 90 days, nearly all Tfam-ENSKO mice are 
dead. n=47 mice. c) Photograph of gastrointestinal tract of 11-12 week old control and 
Tfam-ENSKO mice depicts their typical appearance. Arrowheads indicate regions of 
dilation and accumulation of luminal contents.  St: stomach, SI: small intestine, Co: 
colon. 
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Figure 3. Tfam-ENSKO mice display progressive degeneration of neurons and glia 
with distinct regional vulnerabilities. a) Representative images of HuC/HuD (neurons, 
red) and Sox-10 (glia, green) immunohistochemistry in three regions of myenteric plexus 
of 7 week old control and Tfam-ENSKO mice. Loss of both HuC/HuD
+
 neurons and 
Sox-10
+
 glia is apparent in Tfam-ENSKOs at this age. Scale bars, 100 μm. b) 
Quantification of total myenteric neuron density in Tfam-ENSKOs expressed relative to 
control littermates at 2 and 7 weeks of age. For 2 weeks old, n=6 (Ctrl) and n=4 (Tfam-
ENSKO). For 7 weeks old, n=3 for each genotype. c) Quantification of glial density in 
Tfam-ENSKOs expressed relative to control littermates at 2 and 7 weeks of age. For 2 
weeks old, n=6 (Ctrl) and n=4 (Tfam-ENSKO). For 7 weeks old, n=3 for each genotype. 
d) Neuron-to-glia ratio in ENS of Tfam-ENSKOs and control littermates at 2 and 7 weeks 
of age demonstrates that relative cell loss is equivalent for both neurons and glia. For 2 
weeks old, n=6 (Ctrl) and n=4 (Tfam-ENSKO). For 7 weeks old, n=3 for each genotype. 
PSI: proximal small intestine, DSI: distal small intestine, Co: colon. 
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Figure 4. Early and differential loss of nitrergic inhibitory neurons in Tfam-ENSKO 
mice. a) Representative images of NADPH-d stained myenteric plexus show inhibitory 
neurons in the proximal SI and distal SI in 7 week old Tfam-ENSKO mice. Scale bar, 
150 μm. b) Quantitative analysis of NADPH-d+ neuron density in Tfam-ENSKOs relative 
to control littermates at 2 and 7 weeks of age. n=3 for each genotype at each age. c) Ratio 
of nitrergic neurons to total neurons in 7 week old Tfam-ENSKO and control mice. n=3 
for each genotype.  PSI: proximal small intestine, DSI: distal small intestine, Co: colon. 
d) Diagram depicting how the imbalance of inhibitory neurons to excitatory neurons in 
each region in Tfam-ENSKOs could produce the observed proximal SI dilation and distal 
SI constriction. In Tfam-ENSKO mice, greater total neuron loss (Tfam-ENSKO top 
panel) relative to NADPH-d
+
 neuron loss (Tfam- ENSKO middle panel) would result in 
increased inhibitory input and dilation of the proximal SI (Tfam-ENSKO bottom panel). 
Greater NADPH-d
+
 neuron loss (Tfam-ENSKO middle panel) relative to total neuron 
loss (Tfam-ENSKO top panel) would result in decreased inhibitory input and constriction 
(and pseudoobstruction) of the distal SI of Tfam-ENSKO mice (bottom panel). Color 
intensity represents neuronal density with WT density set as the most intense color in all 
regions of the bowel. 
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Figure 5. Axonal degeneration is present in Tfam-ENSKO mice and may precede 
enteric neuron loss. a) Tfam-ENSKO mice show noticeable neurite blebbing 
(arrowheads) in the proximal and distal SI at 7 weeks of age.  Scale bars, 25 μm. b, c) 
Representative images (b) and quantification (c) of TuJ1
+
 neurites extending into SI villi 
of 7 week old control and Tfam-ENSKO mice. n=3 for each genotype.  Scale bars, 40 
μm. d, e) Representative images (d) and quantification (e) of axonal fragmentation (TuJ1, 
green) and cell body loss (ethidium homodimer, staining not shown) in cultured enteric 
neurons after treatment with the mitochondrial inhibitors rotenone or antimycin. Images 
correspond to untreated or rotenone-treated enteric neurons. n= duplicate wells for each 
condition from 3 independent assays. Scale bars, 100 μm. 
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Tables 
Table 1. Myenteric Plexus Cell Density 
Region Age 
(weeks) 
Total neuron density 
(Cells/mm
2
) 
Glial cell density 
(Cells/mm
2
) 
Neuron-to-Glia Ratio 
(Neurons/Glia) 
NADPH-d+ Neuron 
Density (Cells/mm
2
) 
% of total neurons that 
are NADPH-d
+
 
Ctrl Tfam-
ENSKO 
% of 
Ctrl 
p 
value 
Ctrl Tfam-
ENSKO 
% of 
Ctrl 
p 
value 
Ctrl Tfam-
ENSKO 
% of 
Ctrl 
p 
value 
Ctrl Tfam-
ENSKO 
% of 
Ctrl 
p 
value 
Ctrl Tfam-
ENSKO 
% of 
Ctrl 
p 
value 
PSI 2 1221 
± 156 
839 
± 148 
 0.133 2316 
± 126 
1831 
± 216 
 0.071 0.54 
± 0.09 
0.49 
± 0.12 
 0.706 303 
± 24 
188 
± 26 
62% 0.030 25 22   
DSI 2 2355 
± 381 
1747 
± 461 
 0.339 3142 
± 239 
2094 
± 176 
67% 0.012 0.77 
± 0.14 
0.83 
± 0.18 
 0.794 574 
± 28 
350 
± 46 
61% 0.014 24 20   
Co 2 2113 
± 286 
1879 
± 317 
 0.607 3633 
± 372 
3117 
± 268 
 0.343 0.61 
± 0.11 
0.60 
± 0.08 
 0.961 578 
± 73 
557 
± 93 
 0.860 27 30   
PSI 7 235 
± 23 
74 
± 5 
31% 0.003 479 
± 31 
250 
± 31 
52% 0.007 0.49 
± 0.02 
0.32 
± 0.06 
 0.054 82 
± 6 
55 
± 4 
67% 0.021 36 
± 5 
75 
± 12 
208% 0.038 
D SI 7 329 
± 18 
194 
± 14 
59% 0.004 744 
± 55 
515 
± 38 
69% 0.027 0.45 
± 0.03 
0.38 
± 0.04 
 0.400 91 
± 9 
36 
± 5 
40% 0.007 28 
± 2 
19 
± 2 
68% 0.035 
Co 7 548 
± 85 
426 
± 33 
 0.258 1409 
± 48 
1153 
± 87 
 0.062 0.37 
± 0.06 
0.35 
± 0.06 
 0.782 147 
± 8 
110 
± 7 
75% 0.027 21 
± 4 
26 
± 1 
 0.288 
 
Table 1. Myenteric Plexus Cell Density. Myenteric plexus neuron and glial cell density and ratios in 2 and 7-week-old Tfam-ENSKO 
and control mice. n= 3 for each genotype for all analyses of 7 week old mice. For 2 week old mice, n=6 (Ctrl) or 4 (Tfam-ENSKO) for 
total neuron density, glial density, and neuron to glia ratio and n=3 for NADPH-d
+
 neuron density. N/A, not applicable; due to small size 
of tissue samples at 2 weeks of age, staining for both HuC/HuD
+
 (total) and NADPH-d
+
 (nitrergic) could not be performed on a single 
animal and therefore statistical analysis of the proportion of total neurons that are NADPH-d
+
  was not possible. PSI: proximal small 
intestine, DSI: distal small intestine, Co: colon. 
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Table 2. Villus Neurite Density 
Region Age  
(weeks) 
Neurites/villus 
Ctrl Tfam-ENSKO % of Ctrl p value 
PSI 2 4.25 ± 0.18 2.72 ± 0.09 64% 0.002 
DSI 2 3.63 ± 0.25 3.18 ± 0.2  0.235 
PSI 7 10 ± 1.3 2.6 ± 0.23 26% 0.006 
DSI 7 12 ± 1.6 4.1 ± 0.35 34% 0.011 
 
Table 2. Villus Neurite Density. Density of neuronal projections in intestinal villi in 2 and 7 week old Tfam-ENSKO and control mice. 
n= 3 for each genotype and age. PSI: proximal small intestine, DSI: distal small intestine, Co: colon. 
 
Table 3. Nitrergic Fiber Density 
Region Age  
(weeks) 
NADPH-d
+
 Bundles/mm
2
 NADPH-d
+
 Fibers/mm
2
 NADPH-d
+
 Fibers/neuron 
Ctrl Tfam-
ENSKO 
% of 
Ctrl 
p value Ctrl Tfam-
ENSKO 
% of 
Ctrl 
p value Ctrl Tfam-
ENSKO 
% of 
Ctrl 
p value 
PSI 7 19 ± 0.5 14 ± 2  0.073 312 ± 18 174 ± 32 56% 0.020 3.9 ± 0.6 3.1 ± 0.5  0.208 
DSI 7 22 ± 3 19 ± 0.5  0.700 298 ± 25 233 ± 6  0.100 3.4 ± 1.4 6.8 ± 4.8  0.098 
Co 7 25 ± 1 25 ± 1  0.844 583 ± 56 527 ± 5  0.378 4.0 ± 0.7 4.8 ± 0.2  0.099 
 
Table 3. Nitrergic Fiber Density. Myenteric NADPH-d
+
 fiber density and number of NADPH-d
+
 fibers per neuron in 7 week old Tfam-
ENSKO and control mice. n= 3 for each genotype. PSI: proximal small intestine, DSI: distal small intestine, Co: colon. 
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Table 4. In vitro Mitochondrial Inhibitor Assay Results 
Time Neurons with fragmented 
axons (%/well) 
% of Control p value Et2D
+
 (dead) Neurons (%/well) % of Control p value 
Veh Rot Antim Rot Antim Rot Antim Veh Rot Antim Rot Antim Rot Antim 
24 hrs 7.3 ± 1.2 26.3 ± 3 15 ± 3.6 360% 205% 0.004 0.03 5.7 ± 0.3 8 ± 1.15 6.3 ± 1.5   0.124 0.5 
48 hrs 6.7 ± 1.2 51.7 ± 6.7 12 ± 1 772% 179% 0.003 0.01 6.7 ± 0.3 31 ± 3.6 12  ± 2.6 463% 179% 0.002 0.01 
72 hrs 7.7 ± 1.2 83.7 ± 4.7 32 ± 6.8 1087% 416% <0.001 0.003 7 ± 0.6 58.7 ± 5.2 19.3  ± 3.2 839% 276% <0.001 0.003 
 
Table 4. In vitro Mitochondrial Inhibitor Assay Results. In vitro mitochondrial inhibitor assay results from cultured E12.5 
immunoselected enteric neurons. n= duplicate wells for each condition from 3 independent assays. Veh=Vehicle; Rot=Rotenone; 
Antim=Antimycin 
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CHAPTER 5 
 
 
microRNAs modulate Schwann Cell response to nerve injury by reinforcing 
transcriptional silencing of dedifferentiation-related genes 
 
 
 
 
 
 
 
Adapted from: Viader A, Chang LW, Fahrner T, Nagarajan R, Milbrandt J. (2011) 
miRNAs modulate Schwann Cell response to nerve injury by reinforcing transcriptional 
silencing of dedifferentiation-related genes. Schwann cell mitochondrial metabolism 
supports long-term axonal survival and peripheral nerve function. Journal of 
Neuroscience. 31(48):17358-69.  
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Abstract 
In the peripheral nervous system, Schwann cells (SCs) surrounding damaged 
axons undergo an injury response that is driven by an intricate transcriptional program 
and is critical for nerve regeneration. To examine whether these injury-induced changes 
in SCs are also regulated post-transcriptionally by miRNAs, we performed miRNA 
expression profiling of mouse sciatic nerve distal segment after crush injury. We also 
characterized the SC injury response in mice containing SCs with disrupted miRNA 
processing due to loss of Dicer. We identified 87 miRNAs that were expressed in mouse 
adult peripheral nerve, 48 of which were dynamically regulated after nerve injury. Most 
of these injury-regulated SC miRNAs were computationally predicted to inhibit drivers 
of SC dedifferentiation/proliferation and thereby re-enforce the transcriptional program 
driving SC re-myelination. SCs deficient in miRNAs manifested a delay in the transition 
between the distinct differentiation states required to support peripheral nerve 
regeneration. Among the miRNAs expressed in adult mouse SCs, miR-34a and miR-140 
were identified as functional regulators of SC dedifferentiation/proliferation and re-
myelination, respectively. We found that miR-34a interacted with positive regulators of 
dedifferentiation and proliferation such as Notch1 and Ccnd1 to control cell cycle 
dynamics in SCs. miR-140 targeted the transcription factor Egr2, a master regulator of 
myelination, and modulated myelination in DRG/SC co-cultures. Together, these results 
demonstrate that SC miRNAs are important modulators of the SC regenerative response 
after nerve damage. 
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Introduction 
Neuronal regeneration in adult vertebrates is largely limited to the peripheral 
nervous system (PNS). Unlike neurons in the central nervous system (CNS), PNS 
neurons are capable of long-distance axonal regeneration. Central to the differential 
plasticity of peripheral neurons are Schwann cells (SCs), the glial cells of the PNS. SCs 
have the striking ability to dedifferentiate and revert back to an immature-like state 
following axonal loss (Jessen and Mirsky, 2008). After a transient phase of proliferation, 
dedifferentiated SCs help support axonal regeneration by clearing myelin debris, forming 
tubular structures known as bands of Bungner, and upregulating the synthesis of a 
number of neurotrophic factors. As peripheral axons regenerate, SCs re-differentiate to 
form mature Remak bundles or new myelin sheaths, helping to restore, in this way, 
peripheral nerve function (Geuna et al., 2009). Greater insight into this highly 
orchestrated process of SC-mediated support of axonal regeneration could be harnessed 
to improve the treatment of peripheral and central neurodegenerative diseases 
characterized by axonopathy, including diabetic neuropathy and amyotrophic lateral 
sclerosis (Coleman, 2005).  
Micro-RNAs (miRNAs) are small (around 22 nucleotides) non-coding RNAs 
capable of postrancriptionally regulating protein expression. miRNAs have emerged as 
ubiquitous regulators of developmental timing and cellular differentiation (Flynt and Lai, 
2008). The central role of miRNAs in cell fate determination suggests that they could 
modulate the transcriptional program responsible for the dedifferentiation and 
redifferentiation of SCs following nerve injury (Jessen and Mirsky, 2008). This idea is 
supported by zebrafish studies implicating miRNAs in the regulation of tissue 
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regeneration (Thatcher et al., 2008; Yin et al., 2008; Ramachandran et al., 2010). 
Moreover, miRNAs are essential for the normal development of SCs, as miRNA-
deficient SCs are unable to differentiate past an immature state (Bremer et al., 2010; 
Pereira et al., 2010; Yun et al., 2010). The behavior, identity, and potential role of 
miRNAs in the regenerative response of adult SCs after nerve injury, however, remain 
unexplored.  
In this study we examined the dynamics of miRNA expression in mouse sciatic 
nerve following crush-induced axonal loss. We identified 87 miRNAs consistently 
expressed in adult peripheral nerve. Most of these SC miRNAs were computationally 
predicted to inhibit drivers of SC dedifferentiation/proliferation and their expression was 
dynamically regulated after injury to potentially re-enforce the transcriptional program 
driving the SC regenerative response. Accordingly, miRNA-deficient SCs had delayed 
transitions between the distinct differentiation states involved in the SC injury response. 
Among the miRNAs consistently expressed in SCs, miR-34a and miR-140 were 
characterized as functional regulators of two distinct processes carried out by SCs 
following peripheral nerve damage: proliferation and myelination. Together, our results 
demonstrate that miRNAs are important modulators of the SC regenerative response after 
nerve damage. 
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Results 
Dynamics of SC miRNA expression after injury are consistent with a modulatory 
role in the SC regenerative response  
To study the potential regulatory role of miRNAs in the SC regenerative response 
after peripheral nerve injury, we carried out miRNA microarray expression profiling of 
mouse sciatic nerves after crush-induced axonal degeneration. In previous work 
examining mRNA expression profiles during the SC injury response (Nagarajan et al., 
2002; Araki et al., 2001; Bosse et al., 2006), we and others found that expression of 
regulators of SC dedifferentiation/proliferation and myelination peaks 4 (C4) and 14 
(C14) days after nerve crush, respectively. In the present study we therefore profiled 
miRNA expression in the distal stump of injured nerves at C4 and C14, as miRNAs that 
are differentially expressed at these two time points are likely to be involved in the 
regulation of the SC regenerative response.  
We identified 87 miRNAs that were reproducibly detected in the adult peripheral 
nerve (Fig. 1a). Given that SCs constitute greater than 80% of the cells in mouse sciatic 
nerves (King RH, 2005), the detected miRNAs primarily represent the microRNAome of 
these glia. Indeed, over one third of the miRNAs detected by our microarray analysis 
were previously found to be expressed in cultured isolated SCs (Verrier et al., 2009). 
Moreover, several of the most highly expressed miRNAs identified, including let-7f, 
miR-138, miR-145, and miR-16, have been previously related to the postnatal 
development of SCs (Bremer et al., 2010; Yun et al., 2010; Verrier et al., 2010). 
Remarkably, the expression of over half of the detected miRNAs was up- or down-
regulated in the distal nerve segment following crush injury (48 of 87; C4 vs. Ctrl 
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p<0.05), suggesting that miRNAs may indeed play a role in modulating the processes of 
SC dedifferentiation and remyelination after injury. 
Genes involved in the dedifferentiation/proliferation and remyelination of SCs 
following crush-induced axonal degeneration are dynamically regulated and have 
reciprocal patterns of expression (Nagarajan et al., 2002). We reasoned that miRNAs 
involved in the SC injury response would be dynamically regulated in a manner similar to 
genes known to be important for the regulation of this process. We applied k-means 
clustering to our previous SC mRNA expression profiling datasets (see Methods), and 
identified gene clusters containing known regulators of SC dedifferentiation/proliferation 
(proliferation profile) or differentiation/myelination (myelination profile) after injury 
(Fig. 2a) (Nagarajan et al., 2002). Of the 48 miRNAs differentially regulated following 
nerve crush injury, 31 of them were expressed in a pattern that was highly correlated with 
either the myelination or proliferation profile (with a Pearson's correlation 
coefficient>0.8). Interestingly, 21 of these miRNAs were regulated similarly to genes in 
the myelination cluster; their expression was inhibited immediately after injury and 
increased as remyelination ensued (Fig. 2a). The expression of a significant portion of SC 
miRNAs, therefore, is dynamically regulated after crush injury in a manner consistent 
with them playing a critical role in modulating the SC regenerative response. 
 
Target bias analysis suggests that SC miRNAs modulate the injury response by 
repressing positive regulators of SC dedifferentiation/proliferation 
miRNAs often act in concert with transcriptional control to regulate target gene 
expression more efficiently (Hornstein and Shomron, 2006). For this reason, biologically 
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relevant miRNAs tend to be either co-expressed (positive target bias) or negatively 
correlated (negative target bias) with their predicted targets to either fine-tune or inhibit 
their activity, respectively (Tsang et al., 2007). We hypothesized that miRNAs could 
modulate the SC injury response in a similar manner by cooperating with the 
transcriptional regulatory program that controls this process. A miRNA whose expression 
profile is correlated with that of myelination-associated genes (Fig. 2a) could thus 
reinforce the transcriptional program driving remyelination by inhibiting positive 
regulators of SC dedifferentiation/proliferation (demonstrating a negative target bias) or 
by modulating myelination-associated genes (demonstrating a positive target bias). 
Conversely, a miRNA whose expression is correlated with that of 
proliferation/dedifferentiation-associated genes could coordinate with the transcriptional 
regulatory program by inhibiting drivers of myelination (negative target bias) or by fine-
tuning proliferation-related genes (positive target bias). To begin to address the biological 
function of SC miRNAs in modulating the injury response we therefore studied their 
target bias as well as examined their correlation with the proliferation and myelination 
expression profiles.  
We first used the TargetScanS algorithm (Grimson et al., 2007) to identify SC 
expressed genes that were predicted targets of the 87 miRNAs we detected in SCs. We 
found that 59 of the 87 miRNAs detected by our microarray analysis had predicted 
targets among the ~8000 transcripts detected in our previous SC mRNA expression 
profiling datasets (Nagarajan et al., 2002 and unpublished data). TargetScanS is a 
relatively stringent miRNA target prediction algorithm, which requires an exact match 
between the miRNA seed sequence and any predicted sites. The 59 miRNAs we 
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identified (subset 1) therefore represent a high-confidence set of modulators of the SC 
injury response and were further examined in our functional analysis.  
We then used a Mann-Whitney U-test to determine if the expression of each 
miRNA in subset 1 had a higher positive or negative correlation with the expression of its 
predicted targets than with that of predicted non-target genes (indicative of a target bias, 
see Methods). We found that 25 miRNAs in subset 1 had a significant target bias. 
Remarkably, 23 out of these 25 miRNAs had a negative target bias, meaning that when 
the expression of a given miRNA was high the mRNA level of its putative targets tended 
to be low and vice versa. This prevalence of a negative target bias is in agreement with 
previous studies (Farh et al., 2005; Lau et al., 2008), and suggests that the majority of SC 
miRNAs reinforce rather than fine-tune the concurrent transcriptional regulatory 
processes (Tsang et al., 2007).  
Finally, the extent of target bias for each miRNA in subset 1 (measured by a 
Mann-Whitney z-score, See Methods) was plotted against the correlation of its 
expression with the myelination or proliferation profile (measured by CC, the difference 
in correlation coefficients with the proliferation profile and the myelination profile). 
Interestingly, when plotted in this manner, the majority of SC miRNAs clustered in the 
top left quadrant of the graph, indicative of a negative target bias and an expression 
pattern that correlated with that of genes in the myelination cluster (Fig. 2b). Only six 
miRNAs had a negative target bias and a high correlation with the expression pattern of 
genes in the proliferation cluster. Similarly, very few miRNAs showed a positive target 
bias (Fig 2b). Importantly, these results suggest that SC miRNAs are likely to modulate 
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the injury response primarily through their inhibition of positive regulators of SC 
dedifferentiation/proliferation.  
To further validate this conclusion we carried out gene ontology enrichment 
analysis for the putative targets of miRNAs that were: 1) differentially regulated after 
injury (C4 vs. Ctrl p<0.05); 2) demonstrated a statistically significant target bias; and, 3) 
had a high correlation with the myelination or proliferation clusters (CC>1.6). We 
reasoned that miRNAs that met these three criteria were more likely to be direct 
regulators of the SC injury response. Using these rigorous criteria, six miRNAs were 
identified.  Interestingly, these miRNAs all had a negative target bias and an expression 
pattern that correlated with the myelination profile (Fig. 2c). Gene ontology enrichment 
analysis showed that the predicted targets of these miRNAs were enriched for genes 
involved in cellular processes that are normally more active in immature or proliferating 
SCs. These processes included cell cycle regulation, cell migration, and regulation of 
transcription or chromatin organization (Fig. 2d), and genes such as SC mitogens (e.g. 
fibroblast growth factor), oncogenes (e.g. Kras) or cyclins (e.g. cyclin E2). These results 
indicate that SC miRNAs regulate the injury response primarily by inhibiting positive 
regulators of SC dedifferentiation/proliferation, and reinforce the transcriptional program 
that keeps these dedifferentiation/proliferation genes quiescent in mature or 
differentiating SCs. This reinforcement likely facilitates rapid and robust transitions 
between the distinct differentiation states involved in the SC injury response (Farh et al., 
2005; Stark et al., 2005). 
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SCs with disrupted miRNA processing show delays in cycling between 
differentiation states after peripheral nerve injury  
The results described above suggest that miRNAs work in concert with 
transcriptional controls in order to ensure the correct extent and timing of the SC 
dedifferentiation and subsequent remyelination following nerve injury. To more directly 
examine this idea, we carried out nerve lesion studies on mice in which mature miRNA 
synthesis was disrupted in SCs through the targeted deletion of Dicer1¸ a gene encoding 
an essential enzyme in miRNA biosynthesis (Bartel and Chen, 2004). Mice harboring 
loxP-flanked Dicer1 alleles (Cobb et al., 2005) were crossed to mice expressing a 
tamoxifen-inducible form of Cre-recombinase in both myelinating and non-myelinating 
SCs under the control of the proteolipid protein promoter (PLP-CreERT) (Doerflinger et 
al., 2003). The resulting PLP-CreERT:Dicer fl/fl mice were aged to 1 month and then 
-SCKOs) or vehicle (Ctrl) for 10 
consecutive days (see Methods). Eight weeks after exposure to tamoxifen, a majority of 
SC nuclei (82% +/- 5.1%, identified morphologically) in PLP-CreERT mice carrying a 
copy of a Cre-inducible Rosa26-YFP reporter exhibited YFP fluorescence (Fig. 3a). 
Accordingly, Dicer mRNA levels as well as the basal levels of a number of highly 
expressed miRNAs were significantly reduced in the sciatic nerves of Dicer-SCKO vs. 
Ctrl mice (Fig. 3b and data not shown). However, at 8 weeks and for as long as 14 weeks 
after tamoxifen treatment, nerves from Dicer-SCKO mice showed no apparent pathology 
and were indistinguishable from Ctrl nerves, indicating that disruption of miRNA 
processing in SCs after peripheral nerve myelination was fully completed was well 
tolerated (Fig. 3g and h and data not shown).  
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To determine whether miRNA deficiency led to deficits in the SC injury response 
and re-myelination, sciatic nerves of Dicer-SCKO and Ctrl littermates were crushed 8 
weeks after tamoxifen administration. We first examined the response of SCs to axonal 
degeneration by assessing changes in SC proliferation and in their ability to break down 
existing myelin (Geuna et al., 2009). The rate of myelin loss, a measure of SC 
dedifferentiation, was similar between Dicer-SCKO and Ctrl mice, with no differences 
observed in the amount of myelin debris (Fig. 3c) or of myelin basic protein (MBP) 
immunofluorescence in the nerves after injury (data not shown). Similarly, 
immunostaining of the nerve distal stump 4 days after injury using an antibody against 
the proliferation marker phospho-histone 3 (PH3) showed that, following axonal loss, 
miRNA-deficient SCs were able to re-enter the cell cycle to the same extent as Ctrl SCs 
(% of PH3 positive cells Ctrl= 12.37 +/- 0.47; Dicer-SCKO= 13.12 +/- 0.69; Fig. 3d and 
e). Depletion of miRNAs, therefore, did not interfere with the ability of SCs to 
dedifferentiate and proliferate after injury.  
We next studied the late phase of the SC-injury response, during which these glia 
exit the cell cycle and redifferentiate to restore peripheral nerve function. PH3 
immunostaining was initially used to assess the proportion of proliferating SCs 14 days 
after crush, a time when SCs have normally exited cell cycle and are actively 
differentiating. Interestingly, PH3 immunoreactivity showed that while the number of 
proliferating SCs in Ctrl nerves had returned to pre-injury levels, significantly more SCs 
in Dicer-SCKO nerves were still actively proliferating at this time (% of PH3 positive 
cells Ctrl= 0.93 +/- 0.08; Dicer-SCKO= 4.47 +/- 0.32; p<0.001; Fig. 3d and e). 
Consistent with the reduced ability of miRNA-deficient SCs to exit cell cycle in a timely 
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manner, nerves from Dicer-SCKO mice showed reduced remyelination compared to 
nerves from Ctrl mice, as indicated by a decrease in the total number of myelinated axons 
14 days after injury (Fig. 3g and h). Note that this difference in remyelination after injury 
in Dicer-SCKO mice was not due to changes in the overall number of SCs (SC 
number/50K 
2
: Ctrl=183.4 +/- 33.7; Dicer-SCKO=203.5 +/- 18.9; p=0.6). An 
examination of electron micrographs of injured sciatic nerves from Ctrl and Dicer-SCKO 
mice revealed equivalent total numbers of regenerated axons (remyelinated and non-
remyelinated
2
: Ctrl=525 +/- 46.2; Dicer-SCKO=576.9 +/- 2.5; p=0.3) 
(Fig. 3f). Interestingly, 28 days after nerve injury the total number of myelinated axons in 
nerves from Dicer-SCKO and Ctrl mice were similar (Fig. 3g and h), but the axons in 
Dicer-SCKO nerves remained more thinly myelinated (G-ratio (axon area/fiber area) 
Ctrl= 0.41 +/- 0.016; Dicer-SCKO= 0.46 +/- 0.012; p=0.05; Fig. 3h). Together these 
results support that SC miRNAs modulate the injury response by cooperating with 
transcriptional controls to ensure the correct extent and timing of SC dedifferentiation, 
cell cycle re-entry/exit, and subsequent differentiation and re-myelination after nerve 
injury. 
 
miR-34a is a potential regulator of SC dedifferentiation and proliferation after 
peripheral nerve injury 
Cellular differentiation is tightly linked to exit from the cell cycle. Therefore, the 
influence of miRNAs on cell fate decisions is often linked to their ability to modulate cell 
cycle regulators (Ivey and Srivastava, 2010). Given that SCs need to dedifferentiate and 
temporarily re-enter the cell cycle in order to support axonal regrowth after injury (Geuna 
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et al., 2009), we hypothesized that the regulation of SC cell cycle entry/exit by miRNAs 
could underlie their influence on the injury response. Among the miRNAs identified as 
most likely play a role in the SC injury response (Fig. 2c), we identified miR-34a as a 
particularly good candidate to regulate the competency of SCs to proliferate or 
differentiate. miR-34a is a tumor suppressor gene whose ectopic expression can induce 
cell cycle arrest (Hermeking, 2010). Moreover, Notch1 and cyclin D1 (Ccnd1), two 
important mediators of SC dedifferentiation, proliferation, and cell cycle entry/exit, after 
peripheral nerve injury (Woodhoo et al., 2009; Kim et al., 2001) are targets of miR-34a in 
cancer cells (Pang et al., 2010; Sun et al, 2008). In addition, we identified a negative 
target bias for miR-34a in SCs for genes in the proliferation cluster (Fig. 2c), suggesting 
that miR-34a is a modulator of cell cycle regulators in SCs.  
To verify a potential role of miR-34a in the regulation of cell cycle entry in SCs 
we first examined the expression of this miRNA in more detail. Quantitative RT-PCR 
confirmed that miR-34a is highly expressed in adult peripheral nerves (Ctrl) but that its 
expression level drops sharply after nerve crush (C4) or transection (Trx14) when SCs 
dedifferentiate and re-enter the cell cycle. miR-34a expression, however,  is restored to 
pre-injury levels as SCs exit the cell cycle and redifferentiation ensues (C7, C14) (Fig. 
4a). The expression pattern of miR-34a before and after injury is consistent with a role in 
the modulation of cell cycle regulators in SCs.  
We next assessed the effect of the differential expression of miR-34a after nerve 
injury on Notch1 and Ccnd1, two putative targets relevant to SC 
dedifferentiation/proliferation and the injury response (Woodhoo et al., 2009; Kim et al., 
2001; Atanasoski et al., 2001). We overexpressed miR-34a in HEK293T cells together 
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with a luciferase construct containing the 3’-UTR of either Notch1 or Ccnd1 and 
confirmed that, as previously reported (Pang et al., 2010; Sun et al., 2008), miR-34a 
directly recognized and interacted with the transcripts of these two genes (Figure 4b). 
Consistent with direct targeting of Notch1 and Ccnd1 by miR-34a, the expression pattern 
of these two genes was reciprocally correlated with that of miR-34a following axonal 
degeneration (i.e., miR-34a expression decreased after injury as Notch1 and Ccnd1 
expression increased). The converse expression pattern was observed as SC 
redifferentiation took place (Fig. 4c). Furthermore, when miR-34a was overexpressed in 
isolated SCs, Ccnd1 and Notch1 were downregulated at both the transcript and protein 
levels (Fig 4d and e). In SCs, therefore, miR-34a directly targets at least two positive 
regulators of SC dedifferentiation and proliferation (Notch1 and Ccnd1). In addition to 
Notch1 and Cnd1, other potentially relevant targets to SC dedifferentiation and 
remyelination (e.g. YY1) could also mediate some of the effects of miR-34a on the injury 
response (Chen et al., 2011; He et al., 2010)  
Finally, to directly determine whether miR-34a regulates cell cycle entry and exit 
in SCs we assessed the effect of overexpressing this miRNA on the axon-induced 
proliferation of SCs in vitro. When isolated SCs are cultured in the presence of dorsal 
root ganglion (DRG) neurons, contact with axons initially induces SCs to enter the cell 
cycle and proliferate. We found that ectopic expression of miR-34a did not affect SC 
health and viability, but severely inhibited DRG axon-induced proliferation of SCs in 
vitro (Fig. 4f).  Together our results indicate that mir-34 can directly interact with 
positive regulators of dedifferentiation and proliferation in SCs to control cell cycle 
dynamics in these peripheral glial cells, thus providing a mechanism by which miRNAs 
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could modulate proper cycling of SCs between the distinct differentiation states that 
support nerve regeneration after injury.  
 
miR-140 targets Egr2, a master regulator of myelination, to help modulate SC 
redifferentiation after nerve injury 
 The differentiation status of SCs after injury is determined by the balance between 
signaling systems that drive SC maturation/myelination vs. those that induce SC 
dedifferentiation/proliferation (Jessen and Mirsky, 2008). While we initially found that 
most SC miRNAs interact with targets involved in SC dedifferentiation/proliferation (see 
above), we also searched for miRNAs that targeted positive regulators of myelination. To 
this end, we focused on identifying miRNAs that interact with Egr2, a transcription factor 
that is required for the formation and maintenance of myelin and that is often mutated in 
patients with peripheral myelinopathies (Svaren and Meijer, 2008).  
In silico analysis using PicTar (Krek et al., 2005), TargetScanS (Grimson et al., 
2007) and miRanda (John et al., 2004) algorithms identified a putative binding site for 
miR-140 in the 3’-UTR of Egr2 (Fig. 5a). This binding site has an exact match to the 2-
8bp seed sequence of mouse miR-140 (AGUGGUU), which is highly conserved in 
human, rat, dog and horse, and thus this miRNA was selected for further testing. 
Although our microarray analysis detected expression of miR-140* (which originates 
from the opposite arm of the pre-miRNA for mir-140) rather than miR-140 in nerve 
samples (Fig. 1), qRT-PCR confirmed that miR-140 is also expressed in adult peripheral 
nerve. Moreover, we found that miR-140 expression was dynamically regulated after 
peripheral nerve injury, i.e. its expression level was significantly decreased immediately 
186 
 
after nerve crush (C4) and remained low until at least C7 (Fig. 5b). miR-140 expression 
was restored to pre-injury levels once SC redifferentiation ensued (C14) (Fig. 5b). 
Interestingly, the identified expression pattern of miR-140 after peripheral nerve injury is 
positively correlated with that of its putative target Egr2 (Fig. 5c), suggesting that miR-
140 influences the injury response by fine-tuning the steady-state level of Egr2 in SCs 
that are actively forming or maintaining myelin (Tsang et al., 2007).  
The dynamic regulation of miR-140 during active myelin remodeling prompted us 
to further examine this miRNA in SCs. To confirm that Egr2 is a target of miR-140, we 
first co-transfected HEK293T cells with plasmids encoding either pre-mir-140 or a 
control pre-miRNA together with a luciferase reporter construct carrying the 3’UTR of 
Egr2. Co-expression of this reporter plasmid with miR-140 decreased luciferase activity 
in these cells, indicating that miR-140 can directly recognize and interact with the Egr2 
3’UTR (Fig. 5d). This interaction was dependent on the computationally predicted miR-
140 binding site in this region, as a 3’UTR fragment containing a mutant site was no 
longer responsive to co-expression of pre-mir-140 (Fig. 5d). Consistent with results from 
these luciferase reporter assays, Egr2 protein levels were reduced 2.8-fold in cultured SCs 
overexpressing miR-140 (Fig. 5e). These results identify Egr2 as a new target of miR-140 
and indicate that this miRNA directly interacts with Egr2 via a highly conserved site in 
its 3’UTR to regulate the expression of this transcription factor in SCs.  
Finally, we examined whether miR-140 affected the ability of SCs to differentiate 
and myelinate in vitro. In the absence of neurons, prolonged exposure to cAMP-
stimulating agents can promote SC growth arrest and differentiation and induce 
expression of genes typically associated with myelinating SCs (e.g. Mpz and Pmp22) 
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(Jessen et al., 1991; Monje et al., 2009). Using this system, we evaluated the effect of 
miR-140 overexpression on SC differentiation. Consistent with the down-regulation of 
Egr2 protein by mir-140 in SCs (Fig. 5e), cAMP-induced, Egr2-mediated upregulation of 
myelin markers in cultured SCs was inhibited in the presence of this miRNA (cAMP-
induced gene expression fold induction, MPZ: Ctrl miR= 4.7 +/- 0.51; miR-140= 2.09 +/- 
0.35; p<0.05; PMP22: Ctrl miR= 1.5 +/- 0.06; miR-140= 0.9 +/- 0.06; p<0.05) 
When SCs are cultured together with dorsal root ganglion neurons (DRGs) in the 
presence of ascorbic acid, DRG axons will support the differentiation of SCs and the 
formation of myelin (Wood et al., 1990). Myelination can be monitored in this system by 
using myelin basic protein (MBP) immunostaining as a marker. We found that 
overexpression of miR-140 in SCs co-cultured with DRGs inhibited the expression of 
Egr2 as well as a number of myelination markers (Fig. 5f). Most importantly, miR-140 
overexpression inhibited myelination in this in vitro assay as evidenced by the decreased 
number of myelin segments detected by MBP immunostaining (Fig. 5g). Together, our 
results indicate that miR-140 can directly interact with Egr2 and modulate the level of 
this transcription factor to regulate myelination. This suggests another mechanism by 
which miRNAs may modulate the injury-induced regenerative process of SCs in 
peripheral nerves.  
 
Discussion 
 Following axonal loss, SCs mount a regenerative response involving coordinated 
dedifferentiation, proliferation and redifferentiation that helps restore peripheral nerve 
function. Extensive work has established that this SC injury response is driven by an 
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intricate transcriptional program controlling the balance between positive and negative 
regulators of SC differentiation (Jessen and Mirsky, 2008).  The present study describes a 
new regulatory layer of the SC injury response involving post-transcriptional regulation 
by miRNAs. We show that SC miRNAs modulate the injury response by targeting 
primarily positive regulators of SC dedifferentiation/proliferation, cooperating with 
transcriptional controls to ensure rapid and robust transitions between the distinct 
differentiation states that support nerve regeneration. Moreover, we also identify miR-34a 
and miR-140 as important functional regulators of SC proliferation and myelination, two 
central processes of the SC regenerative response after injury. miRNAs therefore appear 
to be important modulators of the SC regenerative response after peripheral nerve injury. 
miRNAs are thought to have evolved to canalize the genetic network and confer 
robustness to gene expression programs (Hornstein and Shomron, 2006). miRNAs 
achieve this by integrating into the pre-existing genetic network in two ways. On the one 
hand, miRNAs can wire into coherent feed-forward loops (FFLs) such that high 
expression of a given miRNA is induced at a time or location when the transcription of its 
predicted targets is repressed (negative target bias) (Hornstein and Shomron, 2006; Tsang 
et al., 2007). This type of network motif functions as a post-transcriptional failsafe and 
results in mutually exclusive expression domains for the miRNA and its putative targets 
(Stark et al., 2005; Mansfield et al., 2004). On the other hand, miRNAs can wire into 
incoherent FFLs, which would promote high expression of a given miRNA at a time or 
location where its predicted targets are also abundant (positive target bias) (Hornstein and 
Shomron, 2006; Tsang et al., 2007). Biological examples of incoherent FFLs (Karres et 
al., 2007) have shown that in this type of network motif miRNAs have a fine-tuning 
189 
 
action and keep protein levels in the correct functional range. Our work demonstrates that 
SC miRNAs show a prevalence of negative target biases during the SC injury response. 
This indicates that SC miRNAs primarily participate in coherent FFLs. Moreover, the 
expression of most SC miRNAs after injury was negatively correlated with that of 
positive regulator of SC dedifferentiation/proliferation.  Interestingly, we also found that 
predicted targets of SC miRNAs are enriched for genes active in immature or 
proliferating SCs that are quiescent in adult, differentiated SCs. Together these 
observations indicate that SC miRNAs regulate the injury response primarily by 
inhibiting positive regulators of SC dedifferentiation/proliferation and thereby reinforcing 
a preexisting transcriptional silencing mechanism that keeps 
dedifferentiation/proliferation-related genes quiescent in differentiated SCs yet allows 
their induction following axonal degeneration. 
The above results imply that the majority of miRNAs expressed in mature SCs are 
involved in maintaining the differentiated state. In accordance, we found that 
immediately after injury most SC miRNAs are down-regulated, which allows for the 
transcriptionally driven dedifferentiation of SCs. We also observed that, similar to what 
has been reported for SC postnatal development (Bremer et al., 2010; Pereira et al., 2010; 
Yun et al., 2010),  the expression of most SC miRNAs is up-regulated once again shortly 
after axonal regrowth. Because most SC miRNAs target positive regulators of SC 
dedifferentiation/proliferation that must be repressed for proper SC differentiation to 
occur (Le et al., 2005), this serves to facilitate redifferentiation and stabilization of the 
mature SC phenotype. This observation is consistent with studies showing that miRNAs 
are generally expressed at lower levels in immature or dedifferentiated tissues than in 
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differentiated ones (Wienholds et al., 2005; Lu et al., 2005), and with the idea that 
miRNAs are largely involved in promoting, inducing, and stabilizing differentiated 
phenotypes (Wienholds and Plasterk, 2005). It is possible that manipulation of SC 
miRNAs could be used therapeutically to facilitate SC differentiation after injury or 
reverse the effects of neuropathy.  
The therapeutic modulation of SC miRNAs, however, requires the identification 
of specific miRNAs playing critical roles in the establishment and maintenance of SC 
differentiation as well as in the modulation of the SC injury response. We identify miR-
34a as one such candidate. We found that miR-34 was able to critically regulate SC cell 
cycle exit by directly interacting with Ccnd1 transcripts and impinging on Notch 
signaling, a central modulator of SC dedifferentiation after injury (Woodhoo et al., 2009). 
Other miRNAs are likely to play similar roles; for example, let-7 family members 
enhance differentiation and inhibit stem-cell self-renewance (Melton et al., 2010). 
Moreover, this family of miRNAs participates in regenerative processes in zebrafish 
(Ramachandran et al., 2010). Intriguingly, our microarray analysis found that several 
members of the let-7 family were differentially regulated in SCs after peripheral nerve 
injury.  
While our work shows that most SC miRNAs interact with targets involved in SC 
dedifferentiation/proliferation, we also identified miR-140 as a potential regulator of Egr-
2. Egr2 is an essential transcription factor for myelinogenesis and is often mutated in 
patients with peripheral myelinopathy (Svaren and Meijer, 2008). Accordingly, we found 
that overexpression of miR-140 in SCs impaired their ability to form myelin in vitro. 
Interestingly, the expression pattern of miR-140 and Egr2 indicates the presence of an 
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incoherent FFL (Hornstein and Shomron, 2006; Tsang et al., 2007) in which both 
transcript and miRNA are co-expressed at the same time in SCs. This suggests that miR-
140 may act to maintain Egr2 expression within precise functional levels. This is 
particularly interesting because myelin formation and maintenance is very sensitive to 
gene dosage effects. In fact, both abnormally low or high levels of specific myelin 
proteins can cause peripheral neuropathy in humans (Meyer zu Horste et al., 2006). 
Regulation of expression thresholds could therefore be a second mechanism, together 
with reinforcement of transcriptional silencing, by which SC miRNAs modulate the 
injury response of these glia and promote regeneration of peripheral nerves.  
In summary, through miRNA expression profiling after nerve damage and 
examination of the effects of impaired miRNA processing on the SC injury response, the 
present study establishes a critical role for miRNAs in the modulation of the SC 
regenerative response in peripheral nerves. We demonstrate that SC miRNAs ensure 
rapid and robust transitions between the distinct differentiation states necessary to 
support nerve regeneration by reinforcing the transcriptional silencing of 
dedifferentiation and proliferation-related genes. Modulation of SC miRNAs could offer 
therefore a new therapeutic avenue to enhance nerve regeneration and improve the 
treatment of neurodegenerative diseases characterized by axonopathy 
 
Materials and Methods 
Animals and matings: All animal experiments were carried out in compliance with 
institutional animal protocols. For all nerve lesion studies, except those involving mice 
lacking Dicer specifically in SCs (Dicer-SCKOs), C57Bl6 mice of either gender were 
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used. Dicer-SCKO mice were generated by crossing Dicer 
loxP/loxP 
mice (Cobb et al., 
2005) to PLP-CreERT
+/-
 mice (Doerflinger et al., 2003). Compound heterozytoges (PLP-
CreERT
+/-
, Dicer
+/loxP
) were then backcrossed to homozygous Dicer 
loxP/loxP 
to generate 
PLP-CreERT
+/-
, Dicer
loxP/loxP
 mice. One-month-old PLP-CreERT
+/-
, Dicer
loxP/loxP
 mice of 
either gender were injected daily with 100 g/g of tamoxifen (10 mg/ml stock dissolved 
in a 10:1 peanut oil/ethanol mixture) for a total of 10 days (with a 2 day break after day 
5) to generate Dicer-SCKOs. Ctrl mice were injected in the same way with vehicle alone 
(10:1 peanut oil/ethanol mixture). PLP-CreERT
+/-
 were also crossed to Rosa26-YFP
+/- 
mice to generate PLP-CreERT
+/-
, Rosa26-YFP
+/-
 mice, which were treated with tamoxifen 
in an analogous manner. 
 
Surgical procedures: For lesion studies, adult mice (2-3 months of age) were 
anaesthetized by intraperitoneal injection of avertin. The sciatic nerve was exposed at the 
hip and either crushed using #5 jeweler’s forceps for 30 sec or transected using small 
scissors. In the case of transection, the distal stump was deflected onto an adjacent 
muscle to prevent regeneration. When necessary, the site of injury was marked with a 
single 10-0 nylon epineural suture. Nerve lesions were produced on the right side
 
and the 
intact contralateral nerve served as the
 
uninjured control. At the appropriate time points 
nerves were harvested and processed for histology or immediately frozen in liquid 
nitrogen for subsequent extraction of RNA.  
RNA preparation, and quantitative real-time PCR: Total RNA was isolated after 
homogenization (for sciatic nerves) or lysis (for cultured SCs) in Qiazol lysis reagent 
(Qiagen) using a miRNeasy Minikit (Qiagen) according to the manufacturer’s protocol. 
193 
 
RNA concentration was quantified using an ND-1000 spectrophotometer (Nanodrop 
Technologies). mRNA was reverse transcribed from 100 ng of total RNA using qScript 
cDNA SuperMix (Quanta Biosciences) while miRNA was reverse transcribed from 100 
ng of total RNA using NCode Vilo miRNA cDNA Synthesis kit (Invitrogen). mRNA 
qRT-PCR was performed using a SYBR green-based detection system on a 7900 HT 
Sequence Detector instrument (Applied Biosystems) as described previously (Nagarajan 
et al., 2001). GAPDH expression was used to normalize samples and obtain relative 
expression values that were used to calculate percent changes. miRNA qRT-PCR was 
carried out in an analogous manner but cycling conditions were adapted as per NCode 
Vilo miRNA qRT-PCR kit (Invitrogen) recommendations. U6 snRNA was used for 
normalization. The sequences of the qRT-PCR primers used are as follows (5’-3’): Dicer: 
F,  AATTGGCTTCCTCCTGGTTAT; R, GTCAGGTCCTCCTCCTCCTC. mir-34a: F, 
GGCAGTGTCTTAGCTGG TTGT. mir-26a: F, 
GATTTCAAGTAATCCAGGATAGGCT. mir-140: CAGTGGTTTTACCC 
TATGGTAG. All miRs R, NCode Vilo Universal Primer. Egr-2: F, 
CATGGGCAAATTCTCCATTGA; R, TTGCAAGATGCCCGCAC. MPZ: F, 
CCCTGGCCATTGTGGTTTAC; R, CCATTCACTGGACCAGAAGGAG. MBP: F, 
CCAGTAGTCCATTTCTTCAAGAACATT; R, AGCTAAATCTGCTGAGGGACAGG. 
Ccnd1: F, GCGTACCCTGACACCAATCT; R, GAACCGGTCCAGGTAGTT CA; 
Notch1: F, TGACCTGCTCACTCTCACAGA GTAC; R, 
CGACAGATGTATGAAGACT CAAAGG.  
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Microarray and computational analysis: SC microarray gene expression profiling 
experiments were performed in previous studies using Affymetrix MU74v2 chips 
(Nagarajan et al., 2002). Expression data were processed and normalized using 
Affymetrix MAS5 algorithm. A SC expressed gene was defined as one that was called 
present in at least one time point during SC regeneration. k-means clustering was used to 
cluster genes based on their expression profiles, and gene clusters that had an expression 
pattern similar to the previously identified myelination or proliferation profile (Nagarajan 
et al., 2002) based on the Pearson correlation coefficient were identified and merged. The 
average expression profile, i.e. the centroid, was calculated as the final myelination or 
proliferation profile. 
For miRNA expression profiling, total RNA samples were prepared by isolating 
and pooling RNA from at least 3 different mice at the appropriate times after nerve crush. 
Replicates were prepared entirely independently from two separate pools of at least three 
animals each. 2 replicates were used for hybridization onto HTG Molecular qNPA 
miRNA microarrays (HTG Molecular) according to the manufacturer’s protocol, and 
microarray images were obtained and background substracted as per HTG Molecular 
recommendations. Scanned miRNA microarray expression data were first processed 
using the software provided by the manufacturer of the array. This microarray platform 
includes duplicate probesets for 1046 miRNAs. miRNA expression data were further 
filtered using the following criteria: 1) the average of the expression of control miRNA 
probesets on the array was used as a cutoff to remove miRNAs that have low or no 
expression, and 2) miRNAs for which the expression of one duplicate probeset at all time 
points are significantly higher than that of the other duplicate probeset were also removed 
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for further analysis, based on a Mann-Whitney U test. Expression data were then Z-score 
normalized for each miRNA, and at each time point the average expression of the two 
duplicate probesets was calculated. These miRNA expression profiles were compared to 
the previously identified myelination or proliferation profiles in the following target bias 
analysis. 
 TargetScanS, PicTar, and miRanda algorithms were used to predict potential 
miRNA regulatory targets. miRNA targets predicted by these programs were downloaded 
from the program websites. miRNA target bias analysis was performed as follows: for 
each miRNA, SC expressed genes that have a miRNA seed sequence match in the 3’UTR 
were identified using TargetScanS. The Pearson’s correlation coefficient of gene and 
miRNA expression profiles was calculated for each target and non-target. The Mann-
Whitney test P-value was calculated to test if miRNA target genes tend to have higher 
expression correlations with miRNA than non-target genes, i.e. a positive target bias.  
 
Immunohistochemistry: The following primary and secondary antibodies were used: 
chicken anti-GFP (1:1000, Aves), rabbit anti-βIII tubulin (1:1000, Covance), rabbit anti-
phospho histone 3 (1:200, Millipore), rat anti-MBP (1:100, Millipore), anti-rabbit Cy3 
(1:500, Jackson ImmunoResearch Laboratories), anti-rat Cy3 (1:500, Jackson 
ImmunoResearch Laboratories),  and anti-chicken Alexa 488 (1:500, Jackson 
ImmunoResearch Laboratories).   
For immunohistochemical analysis of sciatic nerves, nerves were dissected, 
immersion fixed in 4% paraformaldehyde for 2 h, rinsed with PBS, and cryoprotected in 
30% sucrose. Sciatic nerves were then embedded in Tissue-Tek OCT Compound (Sakura 
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Finetek) and sectioned at 6 m. All frozen sections were immunostained by post-fixing in 
ice-cold acetone at -20°C for 10 min and blocking in 5% fish skin gelatin in PBS-0.2% 
Triton for 1 h at room temperature. Sections were then incubated with primary antibody 
diluted in blocking buffer overnight at 4°C. Secondary antibody incubation was 
performed at room temperature for 1 h also in blocking buffer. After all stainings, 
sections were mounted with Vectashield Mounting Medium with DAPI (Vector 
Laboratories) for microscopic visualization. Images were captured using an upright 
microscope equipped
 
for epifluorescence microscopy (Nikon 80i; CoolSnapES camera)
 
and were processed using MetaMorph, Image-J and Gimp software
 
using global 
adjustments in brightness and contrast. All cell number quantifications were carried out 
by counting the cells of interest in 4 randomly selected regions in longitudinal nerve 
sections from each animal assessed (at least 3 mice per genotype at each time point) at a 
20x magnification. The area covered by MBP immunostaining was determined using 
Image-J after automated background adjustment and binarization (Sasaki et al., 2009), 
from 4 randomly selected fields at a 20x magnification in longitudinal nerve sections. 
MBP area was normalized to total nerve area and results represent the average of at least 
3 mice per genotype.  
 
Nerve light and electron microscopy and morphometry: Sciatic nerve segments from 
Dicer-SCKO or Ctrl mice were dissected at the appropriate times after injury and placed 
in 3% glutaraldehyde overnight. The isolated nerve segments were approximately 15 mm 
in length and, in the case of crush-injured nerves, included the distal regenerated stump. 
After washing with phosphate buffer, nerves were postfixed in 1% osmium tetraoxide in 
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phosphate buffer overnight at 4°C. Specimens were then dehydrated in graded alcohols 
and embedded in 100% epoxy (Araldite 502). One-micrometer-thick plastic embedded 
sections were prepared and stained with toluidene blue for light microscopy. For electron 
microscopy, thin sections were prepared, stained with uranyl acetate and lead citrate, and 
photographed with a JEOL (Akishima) 1200 electron microscope. All nerves underwent 
qualitative assessment of neural architecture followed by detailed histomorphometric 
analysis carried out in a blinded fashion as previously described (Hunter et al., 2007), 
using at least three mice per genotype at each time point. For injured nerves, 
histomorphometric analysis was carried out 5 mm distal to the crush site. Total 
regenerated axon counts were determined by counting both remyelinated and non-
remyelinated axons in Ctrl and Dicer-SCKO nerves 14 days after injury from electron 
micrographs taken at 5000x magnification.  
 
Plasmids: miRNAs were obtained by PCR amplifying individual miRNA precursors 
from genomic DNA. The resulting fragments were cloned between the BamHI and Nhe I 
sites in the miRNASelect pEP-MIR Cloning and Expression Vector (Cell Biolabs) using 
the InFusion HD cloning system (Clonetech) according to the manufacurer’s 
recommendations. Pre-miRNAs included the miRNA stem loop and ~100 nt of flanking 
sequence on either side and were amplified using the following primers: pre-mir-34a: F, 
TAGTTCTCGAGGATCCCCAGCTGAATCCCGACTA GT; R, 
AAAAGCTCGAGCTAGCTCTCTTAGCCAGAAGTGCTC. pre-mir-140: F, TAGTTC 
TCGAGGATCCGCCTCTGACCCTGCTTGCTGGTGGTGTA; R, 
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AAAAGCTCGAGCTAGC CCAACACCCACCCAATAGACGCCT. pEP-mir Null 
Vector (Cell Biolabs) was used as Ctrl.  
A lentiviral miRNA expression vector was made by PCR amplifying the pEP-
MIR expression cassette (promoter, miR processing portion, and mCherry reporter; F, 
AGATCCAGTTTGGTTAATTAAGTGAGG CTCCGGTGCCCGTCA; R, TAGAG 
TCGCGGCCGCTTTACTTGTACAGCTCGTCCATGCCGCCGGTGGA) and 
subcloning it between the PacI and BsrgI sites of an FCIV lentiviral vector (Araki et al., 
2004) using the InFusion HD cloning system (Clonetech) according to the manufacurer’s 
recommendations. For luciferase assays, the 3’UTR regions of Egr2, Notch1 and Ccnd1 
were PCR amplified from genomic DNA using the following primers: Ccnd1 3’UTR: F, 
AAAGCTGCGCACTAGTGGG CCACCGGGCAGGCGGGAGCCA; R, 
ATCCTTTATTAAGCTTTGAGATTTTACCAATTT TATTT; Notch1 3’UTR: F, 
AAAGCTGCGCACTAGTACAGAGATGTGGGATGCAGGACC; R, 
ATCCTTTATTAAGCTTGTTTAGCAAAATGTGGACAACCA; Egr2 3’UTR: F, 
AAAGCT GCGCACTAGTGATGAAGCTCTGGCTGACACACCA; R, 
ATCCTTTATTAAGCTTACCA TAGTCAATAAGCCATCCAT. DNA fragments were 
cloned downstream of the luciferase gene between the HindIII and SpeI sites in the 
pMIR-REPORT miRNA Expression Reporter Vector (Ambion). The 3’UTR of Egr2 
lacking the miR-140 landing pad was cloned in an analogous manner using the following 
sets of overlapping primers: F1, 
AAAGCTGCGCACTAGTGATGAAGCTCTGGCTGACACACCA R1, 
ACAGCCATACTTA 
AACCCAAGTCTCGAGCTCGCGGCGCCTCTAGAAAGGCATCCTGTACACATGC
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A F2, 
TGCATGTGTACAGGATGCCTTTCTAGAGGCGCCGCGAGCTCGAGACTTGGGT
TTAAGTATGGCTGT R2 
AAAGATCCTTTATTAAGCTTACCATAGTCAATAAGCCATCCATTAT 
CTGAACTCCAGTTTCAAAGCTTGGCGCGCCAGAATAGATTGTTTCTCTCT. 
pRL-CMV Renilla Luciferase Reporter vector (promega) was used as a transfection 
control.   
 
Lentivirus production: Lentiviruses expressing miR-34a, miR-140 or a Ctrl miRNA 
were produced in HEK293T cells as previously described (Sasaki et al., 2006).  
 
Luciferase assays: HEK293T cells were seeded at a density of 50,000 cells/well in 24 
well plates in DMEM media (Invitrogen) supplemented with 10% fetal bovine serum 
(FBS), 2 mM L-glutamine. Cell were transfected 24 h later, with either a pEP-MIR vector 
expressing a pre-miRNA or with the pEP-mir Null control and with the pMIR-REPORT 
luciferase reporter vector containing the appropriate 3’UTR linked to luciferase. pRL-
CMV Renilla Luciferase Reporter vector (Promega) was used as a transfection control. A 
total of 200 ng of plasmid DNA/well were transfected at a ratio of 50:1:0.5 (miRNA : 
luciferase reporter : transfection Ctrl). Cells were harvested 48 h post-transfection and 
assayed using a Dual-Luciferase Reporter Assay System (Promega) according to the 
manufacturer’s protocol.  
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Primary SC cultures and lentiviral infection: Primary rat SCs were cultured from 
postnatal day1 to day3 rat pups sciatic nerves as previously described (Nagarajan et al., 
2001). Established SC cultures were then transduced at an early passage (<passage 3) 
with a lentiviral vector expressing miR-34a, miR-140 or a Ctrl miRNA. Efficiency of 
infection was confirmed by visualization of expression of mCherry fluorescent reporter in 
the pEP-MIR cassette in almost 100% cells.  
 
SC in vitro proliferation, differentiation, or myelination assays: For SC in vitro 
differentiation assays, Ctrl or miR-140 overexpressing SCs were initially seeded onto 
collagen coated 24-well plates (~75,000 cells/well) in 10% FBS-DMEM media and 24 
hours later cells were switched to 1% FBS-DMEM media for 2 days. SCs were then 
induced to differentiate by adding 1% FBS-DMEM media containing 250 M 8-(4-
 Chlorophenylthio) adenosine-3',5' cyclic monophosphate (cpt-cAMP, Biolog). RNA was 
isolated 72 h later. Reported results are from duplicated wells from two independent 
assays. For SC proliferation and in vitro myelination assays, dorsal root ganglion neurons 
were dissected from E14 rat embryos, dissociated, and seeded onto Matrigel-coated (BD 
Biosciences) 4-well plates in Neurobasal media (Invitrogen) containing 2% B27 
(Invitrogen) and 50 ng/ml NGF. Glia were eliminated by addition of 20 μM 5-fluoro-2-
deoxyuridine (Sigma) and 20 μM uridine (Sigma) to the media for 4 days. Seven days 
after seeding DRGs were switched to F-12/DMEM media supplemented with 15% FBS, 
2mM L-glutamine and 50 ng/ml NGF, and Ctrl or miR overexpressing SCs were added to 
each well. To examine SC proliferation, 25,000 Ctrl or miR-34a overexpressing SCs/well 
were plated onto DRG neurons and growth curves were generated by monitoring changes 
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in cell number over 5 days. mCherry positive cells expressing miR-34a were visualized at 
a 20x magnification and quantified from 5 randomly selected fields. Results are averages 
from triplicate wells from 2 independent assays. For in vitro myelination assays, 50,000 
Ctrl of miR-140 overexpressing SCs/well were plated onto DRG neurons and allowed to 
proliferate and ensheath axons for 7 days. At this point, myelination was induced by 
adding 50 μg/ml of ascorbic acid. Myelination was allowed to proceed for 14 days and 
myelinated segments were visualized through MBP immunostaining at a 20x 
magnification as previously described (Ryu et al., 2008). The number of myelinated 
segments was quantified by averaging five different fields from triplicate wells in 3 
independent assays.  
 
Western Blotting: Ctrl and miRNA overexpressing SCs were lysed in 200 l of buffer 
containing  150 mM sodium chloride, 50 mM Hepes, 1% NP-40, 1 mM EDTA, 1 mM 
sodium fluoride, 1 mM sodium orthovanodate, and complete protease inhibitor cocktail 
(Roche Applied Science). Lysates were clarified by centrifugation at 14,000 rpm for 10 
min and quantified using the MicroBCAProtein Assay kit (Pierce). For Western blotting, 
the proteins were separated by SDS-PAGE and transferred to a PVDF membrane 
(Millipore). Membranes were blocked in 5% milk in 0.1% TBS-Tween and incubated 
overnight with the appropriate primary antibody. Following incubation with secondary 
antibodies conjugated to HRP (GE Healthcare), membranes were developed with 
SuperSignal West Dura substrate (Pierce). The primary antibodies used were mouse anti-
Ccnd1 (1:1000, Cell Signaling), anti-Notch1 (1:1000, Cell Signaling) and rabbit anti-
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Egr2 (1:1000, Covance). The secondary antibodies used were anti-mouse and anti-rabbit 
HRP (1:5000; Jackson ImmunoResearch Laboratories). 
 
Statistical analysis: All values are expressed as mean ± SEM. If not stated
 
otherwise, p 
values were determined by unpaired, two-tailed
 
Student's t test. All statistical analyses 
were performed using
 
Microsoft Excel 2007. 
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Figures 
Figure 1: Expression profiles of 87 miRNAs expressed in SC. a) Z-score normalized 
miRNA expression levels 4 days (C4) and 14 days (C14) after nerve crush injury as well 
as in uninjured nerves (Ctrl) are shown in a heatmap. Red indicates higher expression 
than the average across all samples while green indicates lower expression. mmu refers to 
the standard abbreviation used to designate miRNAs of mouse origin. 
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Figure 2: Target bias analysis suggests that SC miRNAs modulate the injury 
response by repressing positive regulators of SC dedifferentiation/proliferation. a) 
mRNA expression profiles of gene clusters containing known regulators of SC 
dedifferentiation/proliferation (the proliferation profile) or differentiation/myelination 
(the myelination profile) after injury. b) Graph plotting the target bias for each miRNA in 
subset 1 (measured by a Mann-Whitney z-score) against the correlation of its expression 
with the myelination or proliferation profile (measured by CC, the difference in 
correlation coefficients with the proliferation profile and the myelination profile). 
Biological functions of miRNAs in regulating the SC injury response may be inferred 
from their correlation with the proliferation or myelination gene clusters and by their 
positive or negative target bias. The majority of SC miRNAs cluster in the top left 
quadrant of the graph (negative target bias, correlation with the myelination profile), 
suggesting that SC miRNAs are likely to modulate the injury response primarily through 
their inhibition of positive regulators of SC dedifferentiation/proliferation. Dotted and 
dashed lines represent statistical significance cutoffs.  miRNAs differentially regulated 
after injury (C4 vs. Ctrl p<0.05), with a statistically significant target bias and a high 
correlation with the myelination or proliferation clusters (CC>1.6) are represented by 
triangles.  Empty dots represent miRNAs that met statistical significance cutoffs for 
target bias and high correlation with the myelination or proliferation clusters, but were 
not differentially regulated after injury. c) miRNAs likely to be direct regulators of the 
SC injury response (represented as triangles in b) based on their differential regulation 
after injury, significant target bias and a high correlation with the myelination or 
proliferation clusters. d) Predicted targets for miRNAs in (c) are enriched for genes 
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involved in cellular processes that are normally inhibited in adult or differentiating SCs 
but are active in immature or proliferating SCs.  
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Figure 3: SCs with disrupted miRNA processing have delayed cycling between 
differentiation states after peripheral nerve injury. a) YFP fluorescence in SCs 
(arrowheads) of longitudinal sciatic nerve sections of Rosa26-YFP/ PLP-CreERT mice 8 
weeks after injection with tamoxifen. PLP-CreERT induces specific and efficient 
recombination in most SCs and excision-dependent YFP fluorescence is localized to 
regions of SC cytoplasm but not to axons (Tuj1; note non-overlapping Tuj1 and YFP 
staining). Scale Bars: 50 m. b) qRT-PCR results show efficient depletion of Dicer1 
mRNA and of mature miRNAs in Dicer-SCKO sciatic nerves 8 weeks after tamoxifen-
induced recombination. Dicer mRNA levels and the levels of miR-34a and miR26a in the 
sciatic nerve of Dicer-SCKO mice at this time were decreased by over 60% (p<0.001 in 
all three cases, two-tailed Student’s t-test) compared to Ctrl littermates. Reported values 
are normalized to GAPDH for mRNA and U6 for miRNAs; error bars, SEM; n=5 mice 
per genotype. c) Quantification of the amount of myelin debris present in Ctrl and Dicer-
SCKO nerves 14 days after crush injury shows no impairment in the ability of Tfam-
deficient SCs to break down existing myelin. Error bars, SEM; n=3 mice per genotype. d 
and e) Pictures (d) and quantification (e) of phospho-histone 3 (PH3) immunostaining 
between sciatic nerves of Ctrl and Dicer-SCKO mice collected 4 (C4) or 14 (C14) days 
after crush injury. No difference in the number of proliferating SCs between Ctrl and 
Dicer-SCKO sciatic nerves was observed 4 days after crush injury. At C14, however, 
there were significantly more PH3 positive SCs in the sciatic nerves of Dicer-SCKO vs. 
Ctrl mice (p<0.05, two-tailed Student’s t-test), indicating exit from cell-cycle was 
delayed in SCs with disrupted miRNA processing. Scale Bar: 25 m. Error bars, SEM; 
n=3 mice per genotype. f) At C14, electron micrographs of sciatic nerves from Ctrl and 
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Dicer-SCKO mice show equivalent numbers of regenerated axons (remyelinated, arrows; 
non-remyelinated, arrow heads). Note the increased number of non-remyelinated axons 
(arrowheads) in Dicer-SCKO nerves. Scale Bar: 2 m. g and h) Pictures (h) and 
quantification (g) of myelinated profiles in nerves from Ctrl and Dicer-SCKO mice 
before crush injury, or at C14 or C28. There is no difference in total number of 
myelinated axons in nerves from Dicer-SCKO vs. Ctrl mice before crush injury. 
However, examination of toluidene-blue stained plastic sections revealed a significant 
decrease (p<0.05, two-tailed Student’s t-test) in the number of myelinated profiles at C14 
in nerves from Dicer-SCKO mice. By C28 there is no longer a difference in total number 
of myelinated profiles between Dicer-SCKO and Ctrl nerves, however nerves in Dicer-
SCKO mice are more thinly myelinated. Scale Bar: 25 m. Error bars, SEM; n=3 or 4 
mice per genotype at each time point. 
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Figure 4: miR-34a targets Notch-1 and Ccnd1 to regulate SC proliferation in vitro. 
a) The dynamic regulation of miR-34a expression in sciatic nerves after crush injury 
suggests a potential role in the modulation of cell cycle regulators. miR-34a levels are 
significantly decreased 4 days after crush injury (p<0.01, two-tailed Student’s t-test) but 
recover as re-differentiation ensues (C14). After nerve transection (Trx), an injury 
paradigm in which remyelination does not occur, mir-34a levels remain low compared to 
uninjured nerves even 14 days after injury (p<0.05, two-tailed Student’s t-test). Reported 
values are normalized to U6; error bars, SEM; n=3-6 mice at each time point. b) miR-34a 
directly interacts with the 3’UTRs of Ccnd1 (top) and Notch1 (bottom).  Overexpression 
of miR-34a but not of a Ctrl miRNA in HEK293T cells expressing a luciferase reporter 
construct carrying the 3’UTR of either Notch1 or Ccnd1 results in significantly decreased 
luciferase activity (p<0.01 in both cases, two-tailed Student’s t-test). Error bars, SEM; 
n=3 independent assays c) qRT-PCR measurements show that the expression pattern of 
Ccnd1 (top) and Notch1 (bottom) after injury is inversely correlated with that of miR-
34a, suggesting a direct targeting of these transcripts by miR-34a. Reported values are 
normalized to GAPDH for mRNA and U6 for miRNAs; error bars, SEM; n=3-6 mice at 
each time point. d, e) Lentivirus-mediated mir-34a overexpression (≈ 3-fold) in cultured 
SCs significantly reduces Notch1 and Ccnd1 mRNA (d; p<0.05, in both cases, two-tailed 
Student’s t-test) and protein levels (e, ≈ 2.5-fold decrease; Notch FL, Full-length; Notch 
NTM, cleaved transmembrane/intracellular region). qRT-PCR reported values are 
normalized to GAPDH; error bars, SEM; n=duplicate wells from three independent 
assays. f) Lentivirus-mediated mir-34a overexpression (≈ 3-fold) impairs the ability of 
SCs to proliferate in the presence of DRG axons. miR-34a expressing SCs have a 
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significantly decreased axon-induced proliferation in vitro compared to control SCs (no 
significant difference at day 1; p<0.01 at days 3 and 5; two-tailed Student’s t-test). Error 
bars, SEM; n=triplicate wells from two independent assays. 
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Figure 5: miR-140 directly interacts with Egr2 to regulate SC myelination in vitro. 
a) PicTar, TargetScanS, and miRanda  algorithms all identify a putative binding site for 
miR-140 in the 3’-UTR of Egr2. b) qRT-PCR results show that miR-140 is expressed in 
mouse sciatic nerves and that its expression is dynamically regulated after injury. miR-
140 expression is significantly decreased after injury (C4 and C7 p<0.05; two-tailed 
Student’s t-test) but recovers as re-differentiation ensues (C14 no significant difference). 
Reported values are normalized to U6; error bars, SEM; n=3-6 mice at each time point. c) 
qRT-PCR measurements show that the expression pattern of Egr2 is correlated with that 
of miR-140. Reported values are normalized to GAPDH for mRNA and U6 for miRNAs; 
error bars, SEM; n=3-6 mice at each time point. d) Luciferase assays confirm a direct 
interaction between miR-140 and the 3’-UTR of Egr2.  Overexpression of miR-140 but 
not of a Ctrl miRNA in HEK293T cells expressing a luciferase reporter construct 
carrying the 3’-UTR of Egr2 results in significantly decreased luciferase activity (p<0.05, 
two-tailed Student’s t-test). Mutating the predicted landing pad for miR-140 in the 3’-
UTR of Egr2 disrupts the interaction between miR-140 and the Egr2 3’-UTR luciferase 
construct and restores luciferase activity.  e) Western blot analysis shows that 
overexpression of miR-140 in cultured SCs reduces the levels of Egr-2 protein ≈ 2.8 fold. 
f) Overexpression of miR-140 in SCs significantly decreases the levels of Egr2 as well as 
of a number of myelin markers when these cells are co-cultured with DRGs and induced 
to myelinate ( in all cases p<0.05, two-tailed Student’s t-test). Reported values are 
normalized to GAPDH; error bars, SEM; n=duplicate wells from two independent assays. 
g) Similarly, miR-140 overexpression significantly inhibits the ability of SCs to form 
myelin in vitro in co-cultures with DRG neurons as visualized by MBP immunostaining 
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(p<0.05, two-tailed Student’s t-test). Error bars, SEM; n=triplicate wells from three 
independent assays. 
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CHAPTER 6 
 
 
An integrated approach to infer transcription factor and microRNA regulatory 
networks 
 
 
 
 
 
 
 
Adapted from: Chang LW, Viader A, Payton JE, Varghese N, Milbrandt J, Nagarajan R. 
2011. An integrated approach to infer transcription factor and microRNAs regulatory 
networks. Nucleic Acid Research. Submitted.  
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Abstract 
Regulation of cell fate and developmental timing as well as maintenance of 
cellular and tissue homeostasis requires precise spatiotemporal control of gene 
expression, which is modulated by key transcription factors (TF) and microRNAs 
(miRNA) via a complex gene regulatory network. Elucidation of TF and miRNA 
regulatory networks is crucial to understand how normal gene regulatory mechanisms are 
disrupted in human disease. Computational methods have been developed to infer TF or 
miRNA mediated gene regulation, but few methods integrate these results to construct 
integrated TF and miRNA gene regulatory networks. In this study we present a 
systematic approach, IntegraNet, which combines mRNA and miRNA expression data, 
chromatin immunoprecipitation with sequencing (ChIP-Seq) data and computation TF 
and miRNA target prediction to build integrated TF and miRNA gene regulatory 
networks. We applied IntegraNet to expand a previously published miRNA-mRNA 
regulatory network as well as to infer the TF and miRNA regulatory network involved in 
Schwann cell (SC) response to nerve injury. Further analysis of regulatory network 
motifs in this SC injury response network provided insight on cooperative regulation of 
this process by TFs and miRNAs. This work demonstrates a systematic method for gene 
regulatory network inference that may be used to gain new insights on local and global 
features of gene regulation by TFs and miRNAs.       
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Introduction 
Regulation of cell fate and developmental timing as well as maintenance of 
cellular and tissue homeostasis requires precise spatiotemporal control of gene 
expression. It is now apparent that such intricate control mechanisms are regulated by 
transcription factors (TFs) and microRNAs (miRNAs), which organize into exquisitely 
coordinated gene regulatory networks (Tsang et al. 2007; Martinez and Walhout 2009; 
Shalgi et al. 2009). Alteration or disruption of these regulatory networks often results in 
disease, including cancer and developmental disorders (Tenen 2003; Villard 2004; Zeng 
et al. 2010). Comprehensive delineations of how TFs and miRNAs cooperate in specific 
genetic programs are thus critical to understanding physiological and pathological 
processes.  
Systematically inferring TF and miRNA regulatory networks is difficult to 
achieve by experimental methods and has motivated development of computational 
approaches. Thus, computational tools have been created to construct TF and miRNA 
regulatory networks using information such as gene expression profiling, miRNA 
expression profiling, and predicted TF and miRNA binding sites (Joung et al. 2007; 
Bandyopadhyay and Bhattacharyya 2009; Lionetti et al. 2009; Peng et al. 2009; Wang et 
al. 2009). Few studies, however, have combined all of these data to infer an integrated 
network of TFs and miRNAs. Particularly, transcriptional regulation of miRNAs is often 
excluded in these analyses due to the challenge in reliable prediction of miRNA 
promoters (Shalgi et al. 2007; Guo et al. 2010). In addition, chromatin 
immunoprecipitation with sequencing (ChIP-Seq) data for TFs, which experimentally 
characterizes TF regulatory targets and provides critical information for understanding 
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gene regulation, is seldom incorporated. These limitations highlight the need for new 
tools for gene regulatory network construction.  
In this study we developed a novel approach (IntegraNet) to inferring human or 
mouse gene regulatory networks, which include TF-mRNA, TF-miRNA and miRNA-
mRNA interactions. This method integrates mRNA and miRNA expression data, ChIP-
Seq data, and computational TF and miRNA target predictions. Starting with a set of 
genes or miRNAs obtained from expression profiling analysis, our approach initially 
constructs a network by using TF targets identified from ChIP-Seq experiments. This 
network is then expanded to include additional regulatory targets of TFs and miRNAs by 
using genome-wide target prediction.  To demonstrate the utility of our approach, we first 
applied IntegraNet to expand a published miRNA regulatory network involved in 
Hepatitis C Virus (HCV) infection (Peng et al. 2009). In addition, we used IntegraNet to 
construct the regulatory network involved in Schwann cell (SC) response to injury, a 
process driven by TFs and modulated by miRNAs. Using this network, we study 
cooperative TF/miRNA regulation in this regenerative process. This work demonstrates a 
systematic approach to infer TF and miRNA regulatory networks, which may be used to 
better understand coordinated gene regulation by TFs and miRNAs in complex biological 
systems.  
 
 Results 
Overview of TF and miRNA regulatory network inference 
We developed a systematic approach for TF and miRNA regulatory network 
inference. This approach, termed IntegraNet, integrates mRNA and miRNA expression 
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profiling data, chromatin immuneprecipitation with sequencing (ChIP-Seq) data, and 
computational TF and miRNA target predictions (Fig. 1). Two major applications of gene 
expression profiling analysis (including microarrays or RNA-Seq experiments) in order 
to understand gene regulation involve identification of differentially expressed genes 
between two conditions (e.g., disease vs. normal and mutant vs. wild type) or 
characterization of gene clusters that share a specific expression profile (over a time 
course or across multiple samples). Therefore, our approach for regulatory network 
inference starts with sets of coherently expressed or differentially expressed genes 
(termed core gene clusters, CGCs) and/or miRNAs (termed core miRNA clusters, CMCs) 
(Step 0). TF genes in CGCs and miRNAs in CMCs constitute the initial set of potential 
regulators in the gene regulatory network. In the first step, ChIP-Seq data is used to 
identify regulatory interactions between TFs and CGC mRNAs and between TFs and 
CMC miRNAs (Step 1). Additional mRNAs and miRNAs regulated by these TFs, as well 
as other TFs without ChIP-Seq data, are identified by genome-wide analysis of TFBS 
enrichment (Step 2). Next, genes in CGCs that may be regulated by miRNAs in CMCs 
are identified using computational miRNA target prediction (Step 3). The resulting 
regulatory network is further expanded to include TFs that, although not included in 
CGCs in the initial expression data analysis, are master regulators of genes in CGCs or 
miRNAs in CMCs (Step 4). Similarly, miRNAs that are not included in CMCs in the 
expression analysis but whose predicted targets are enriched in CGCs are identified (Step 
5). Finally, upstream or downstream regulatory interactions of additional TFs and 
miRNAs added in Steps 4 and 5 are identified using ChIP-Seq data (as described in Step 
1) and computational predictions (as described in Step 2) (Step 6). This final step 
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completes the regulatory network inference. In these steps, we have compiled and 
precalculated datasets of experimentally characterized and computationally predicted TF-
mRNA, TF-miRNA, and miRNA-mRNA interactions, which are available as 
supplementary files and may be queried by an API to our in-house database upon request. 
Each step of IntegraNet is described in detail as follows. 
 
Step 1: Identification of TF targets using ChIP-Seq data 
To find TF-mRNA interactions among CGCs genes, IntegraNet first used 
experimentally validated TF targets characterized by ChIP-Seq results. We compiled a 
compendium of publicly available TF ChIP-Seq data, which included 47 independent 
datasets on 78 TFs (24 human TFs and 54 mouse TFs) (Supplementary Table 1). To use 
this dataset to identify TF targets conserved between human and mouse, we mapped the 
identified ChIP-Seq peak locations across the human and mouse genomes (see Methods). 
To assemble a high-confidence and high-quality TF target dataset and to reduce false-
positive targets introduced by this mapping, we only used ChIP-Seq peaks that contained 
at least one match to one the TF's position weight matrix binding models. Additionally, 
we only included peaks that were located between -10kb and +5kb from the transcription 
start sites (TSSs) of annotated genes. After this filtering, 19.9% of the original ChIP-Seq 
peaks were retained in the list of high confidence TF target list, which consists of a total 
of 71,346 mouse and 64,367 human TF-mRNA interactions (Supplementary Files 1 and 
2). 
In addition to TF-mRNA interactions, the genome-wide mapped reads of ChIP-
Seq data may be used to identify TF-miRNA interactions. Performance of such analysis 
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depends on accurate characterization of pri-miRNA promoters. Several studies have 
developed computational methods to predict pri-miRNA TSSs using several promoter 
features (Marson et al. 2008; Ozsolak et al. 2008; Saini et al. 2008; Corcoran et al. 2009). 
However, given that many of these methods rely on limited experimental datasets, they 
tend to only predict TSSs for a subset of miRNAs. To address this limitation we 
developed a new voting algorithm (TSSvote) for predicting human and mouse miRNA 
TSSs, which uses a comprehensive set of transcription-related sequence features (Fig. 
2A, see Methods). These included mapping of known transcripts/ESTs, CpG islands, 
CAGE tags, H3K4me3 marks, and evolutionary conservation. Using TSSvote's predicted 
pri-miRNA TSSs, we defined the promoter sequences of miRNAs as the genomic region 
between -5kb and +1kb from the predicted TSS. We then identified ChiP-Seq peaks of 
TFs located within these predicted miRNA promoters. Only peaks that contained at least 
one sequence match to the TF's binding model were retained, so as to obtain high 
confidence TF target predictions. This analysis generated a high quality list of 1,183 
mouse and 1,511 human TF-miRNA interactions (Supplementary Files 3 and 4). 
Note, that the performance of TSSvote was tested by a compiled benchmark set of 
21 experimentally determined human and mouse miRNA TSSs (Supplementary Table 2). 
TSSvote predicted 52% of these test TSSs within 500bp and 81% of them within 2500bp, 
outperforming all other currently available methods tested (as measured by the number of 
miRNA TSSs predicted within a given error range; Fig. 2B). The predictions of TSSvote 
were further supported by the fact that a large proportion of miRNAs (63% of intergenic 
and 45% of intragenic miRNAs in mouse) were located within 10kb from the pre-miRNA 
sequence (Fig. 2C, Supplementary Table 3). Furthermore, the miRNA promoter 
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sequences (as defined above) were more conserved than randomly selected intergenic 
sequences of the same length (Chi-square P-value=1.45E-51) (Fig. 2D) and contained 
significantly more TF binding sites than random sequences (Chi-square P-value=1.28E-
34) (Fig. 2E).  
 
Step 2: TF target prediction using genome-wide TFBS enrichment analysis 
Although ChIP-Seq data of TFs allowed the extraction of experimentally 
characterized TF-target interactions, this information was only available for a subset of 
TFs. Moreover, because ChIP-Seq experiments might have been performed under 
different conditions, some transcriptional regulatory interactions critical to the CGCs 
under study might not be identified. To address this shortcoming our IntegraNet 
algorithm included computationally predicted genome-wide TF regulatory interactions 
based on an improved version of a previously developed statistical model for TF binding 
site (TFBS) enrichment (Chang et al. 2008). This approach calculated a binding 
probability score for a TF-gene pair using conserved TF binding sites in proximal 
promoters and evaluated a P-value using TFBS permutation (See Methods, 
Supplementary Fig. 1). In this study, the model was improved by using a phylogenetic 
tree-based scoring function to incorporate evolutionary conservation information from 
more species. Using this model, we predicted 108,204 mouse and 132,516 human TF-
mRNA interactions (Supplementary Files 5 and 6). By applying this model to the miRNA 
promoters predicted by TSSvote (Supplementary Fig. 1) we also predicted a total of 
2,658 mouse and 5,395 human TF-miRNA interactions (Supplementary Files 7 and 8).  
233 
 
We validated this computational model using the compendium of ChIP-Seq 
datasets for 78 TFs described earlier. In this validation, we tested if the target genes 
identified by ChIP-Seq tended to have significantly higher scores for binding among all 
the genes in the genome, based on a Mann-Whitney U-test (Fig. 3A). We found that 
ChIP-Seq identified mouse and human mRNA targets had significantly higher scores in 
94% and 93% of the ChIP-Seq datasets, and ChIP-Seq identified mouse and human 
miRNA targets had significantly higher scores in 55% and 64% of the datasets (Fig. 3B). 
This analysis showed that our computational TF-target prediction was consistent with 
experimental results, for both TF-mRNA and TF-miRNA regulation. 
 
Step 3: Identification of miRNA targets using computational prediction 
 The previous ChIP-Seq data analysis and genome-wide TF target prediction 
identified TF-mRNA and TF-miRNA interactions. To identify miRNA-mRNA 
interactions we performed computational miRNA target prediction. A recent study 
showed that better performance of miRNA target prediction may be achieved by 
combining multiple currently available algorithms in order to reach reasonable specificity 
while minimizing loss of sensitivity (Sethupathy et al. 2006). Therefore we chose to 
combine TargetscanS (Lewis et al. 2005) and pictar (Krek et al. 2005), which provides 
higher specificity, with miRanda (John et al. 2004), which provide higher sensitivity, to 
identify targets of miRNAs. Only targets of miRNAs predicted by at least two of these 
three methods were included in the network construction. Using this approach, we 
identified 57,980 mouse and 75,570 human miRNA-mRNA interactions (Supplementary 
Files 9 and 10). The average number of targets is 250 genes per miRNA, respectively, 
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which is close to the speculated number of targets per miRNA (Martinez and Walhout 
2009).  
 
Step 4: Expanding networks by adding master TF regulators of CGC and CMC 
genes  
Up to this step, TFs included in the regulatory network were identified either by 
their correlation with expression profiles of interest or by their differential expression. 
However, master regulators of genes in the CGCs may share a coherent expression 
profile but with a lag time (hence not being identified by cluster analysis of expression 
data). Alternatively, they may be modulated by mechanisms other than transcriptional 
control and have similarly expression under two experimental conditions (hence not 
being identified by differential expression). These TFs could be identified by 
computational tools such as PAP (Chang et al. 2006), oPOSSUM (Ho Sui et al. 2007), 
and ToppGene (Chen et al. 2009), which predict common regulators of gene sets based 
on enriched TBFS in proximal promoters. To ensure that the final regulatory networks 
contain all important TFs, the IntegraNet algorithm incorporated the PAP algorithm. 
 
Step 5: Expanding networks by adding master miRNA regulators of CGC genes 
Similar to TFs, common miRNA regulators of genes in the CGCs may not have 
expression profiles that are tightly correlated/anti-correlated with their mRNA targets or 
may not have significant differential expression. Therefore, to ensure that the regulatory 
networks inferred by IntegraNet contain all critical miRNAs, we identified miRNAs 
whose predicted targets were enriched among CGC genes using a hypergeometric 
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distribution (see Methods). This target enrichment analysis may also identify miRNA 
regulators whose expression is not accurately measured on microarray.  
 
Step 6: Identifying regulatory interactions for master TF and miRNA regulators 
After additional TF and miRNA regulators found in Steps 4 and 5 were added to 
the network, additional TF-mRNA, TF-miRNA, and miRNA-mRNA interactions were 
characterized using ChIP-Seq data of TFs (Step 1) and computational predictions (Steps 2 
and 3). This final step completed the regulatory network construction.  
 
Application of IntegraNet to expand a previously identified miRNA regulatory 
network 
 To demonstrate the utility of IntegraNet, we first applied our approach to analyze 
a published dataset of mRNA and miRNA expression profiling data from Hepatitis C 
Virus (HCV) negative or positive human liver biopsy samples (Peng et al. 2009). The 
goal of this study was to identify miRNA regulatory networks that were associated with 
HCV infection. The authors found that 54 miRNAs were differentially expressed between 
HCV positive and negative samples. The study then constructed a miRNA-target 
regulatory network using computationally predicted miRNA-mRNA interactions. We 
expanded this network by applying IntegraNet to add TF-mRNA and TF-miRNA 
interactions.  
Using the 54 differentially expressed miRNAs as the CMC, we found 773 genes 
whose expression was correlated or anti-correlated with CMC miRNAs (based on a 
cutoff of CC=0.65). These genes were defined as the CGC. These 773 genes contain 5 
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TFs with available ChIP-Seq data and 18 TFs with available binding profiles. Using 
enrichment of TFBS, we identified 14 additional TFs as master regulators of the CGC or 
CMC. Using enrichment of miRNA targets in the CGC, we added 5 miRNAs to the 
network (using a hypergeometric P-value cutoff of 0.01). Overall, we identified 32 TFs 
and 5 additional miRNAs as important regulators of the previously characterized miRNA 
regulatory network. We identified and predicted a total of 55 TF-TF and 45 TF-miRNA 
regulatory interactions (Supplementary Fig. 2, Supplementary Table 4). This analysis 
demonstrated that IntegraNet can be adopted to extract additional biological information 
using previously collected genomic profiling datasets. 
 
Application of IntegraNet to identify TF and miRNA regulation networks involved 
in Schwann cell response to peripheral nerve injury 
In the peripheral nervous system (PNS), Schwann cells (SCs) surrounding 
damaged axons undergo an injury response that is critical for nerve regeneration. This 
regenerative process relies on the unique ability of SCs to dedifferentiate/proliferate to 
support axonal re-growth and to subsequently re-differentiate to restore peripheral nerve 
function (Geuna et al. 2009). The cycling between the different SC differentiation states 
after injury are controlled by an intricate regulatory program that involves TFs and 
miRNAs (Jessen and Mirsky 2008; Bremer et al. 2010; Pereira et al. 2010; Yun et al. 
2010), but the interactions between them are unknown. Therefore, we applied IntegraNet 
to study the TF and miRNA regulatory networks governing the SC injury response.  
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Identification of important TFs and miRNAs in the SC injury response network 
To identify important regulators involved in SC response to injury, we first 
reanalyzed a published gene expression profiling dataset on a mouse nerve injury model 
(Nagarajan et al. 2002). Using unsupervised k-means clustering, we identified co-
expressed gene clusters that were differentially expressed after nerve injury and that 
contained known myelination genes (see Methods). Four coexpressed core gene clusters 
for injury response (CGCIR) were identified (Supplementary Table 5). Two of the 
clusters included genes that were downregulated immediately after crush and returned to 
pre-injury levels as the nerve regenertated (CGCIRs 1 and 2), while the other two 
displayed the reciprocal expression pattern (CGCIRs 3 and 4) (Supplementary Fig. 3A). 
Gene Ontology analysis showed that CGCIRs 1 and 2 contain genes related to 
myelination and CGCIRs 3 and 4 were enriched for proliferation related genes 
(Supplementary Fig. 3B). In total, these CGCIRs contained 35 TFs.  
Next, we identified core miRNA clusters for SC injury response (CMCIRs) by 
profiling nerve miRNA expression before and after crush injury (A Viader, L Chang, T 
Fahrner, R Nagarajan, J Milbrandt, in press). We focused on miRNAs whose expression 
was correlated or anti-correlated with one of the four CGCIRs. Overall, this analysis 
identified 30 miRNAs that were expressed similar to genes in CGCIRs 1 and 2 and 
identified 6 miRNAs that were expressed similar to genes in CGCIRs 3 and 4 
(Supplementary Table 6, Supplementary Fig. 3C). 
Applying IntegraNet, we first identified 37 TF-TF and 15 TF-miRNA regulatory 
interactions for 8 TFs from the compiled ChIP-Seq datasets (Step 1). We then used 
computational TF target predictions and expanded the network to include 79 TF-TF and 
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70 TF-miRNA interactions (Step 2). Using miRNA target prediction we next added 43 
miRNA-TF interactions (Step 3). Furthermore, using the Promoter Analysis Pipeline 
(PAP) (Chang et al. 2006), we identified 12 and 1 TFBS significantly enriched in 
CGCIRs and CMCIRs, respectively (Step 4). We also identified 7 miRNAs with 
significantly enriched targets in CGCIRs (Step 5). Overall, the final TF and miRNA 
network for SC injury response included 146 TF-TF, 117 TF-miRNA, and 71 miRNA-TF 
interactions, connecting 48 TFs and 32 miRNAs (Fig. 4, Supplementary Table 7).  
 
Regulatory network for SC injury response inferred by IntegraNet is consistent 
with current knowledge 
The regulatory network constructed above provided a global view of TF and 
miRNA mediated gene regulation in SC injury response. When we organized the SC 
injury response regulatory network to show its cluster structures (using the "organic 
layout" in Cytoscape (Shannon et al. 2003)), one of the nodes in the center of the network 
was Egr2, the early growth response 2 (Egr2/Krox-20) transcription factor. Egr2 is 
required for peripheral nerve myelin formation and maintenance and it is often mutated in 
patients with peripheral myelinopathies (Svaren and Meijer 2008). Five TFs were 
predicted to regulate the expression of Egr2 (Fig. 5A), two of which (Nfkb1 and Fos) 
have been previously associated with SC myelination (Nickols et al. 2003) and 
dedifferentiation (Stevens and Fields 2000; Parkinson et al. 2008). In addition to TFs, two 
miRNAs, miR-140 and miR-124, were found to target Egr2. Additional experimental 
studies confirmed these interactions and showed that these two miRNAs contribute to the 
modulation of the expression of Egr2 (Supplementary Fig. 4, A Viader, L Chang, T 
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Fahrner, R Nagarajan, J Milbrandt, in press). Egr2 was in turn predicted to directly 
regulate the expression of the TF Hic1 and 3 miRNAs (let-7f, let-7a, and miR-22) (Fig. 
5A). The tumor suppressor miR-22 has been shown to target the 3’UTR of Pten and 
modulate Akt signaling, which critically determines the extent of SC myelination (Ogata 
et al. 2004; Cotter et al. 2010). These results showed that our method to delineate the 
genetic networks driving the SC injury response elucidated Egr2 regulatory pathways that 
were consistent with current knowledge on the regulation of SC differentiation.  
 
TF and miRNA feedforward loops in the SC injury response network 
The importance of transcriptional and post-transcriptional control in the SC injury 
response as well as the reciprocal nature of the genetic programs driving this process 
make SC recovery after injury an ideal system for studying the cooperation of TF and 
miRNA mediated gene regulation. TFs and miRNAs form cooperative regulatory 
network motifs to reinforce (via coherent loops) or modulate (via incoherent loops) the 
expression of target genes (Tsang et al. 2007; Martinez and Walhout 2009; Shalgi et al. 
2009). In the regulation of SC injury response, an incoherent or coherent feedforward 
loop may target genes that are correlated with the expression of 
differentiation/myelination genes (i.e., genes in CGCIRs 1 and 2) or with the expression 
of proliferation genes (i.e., genes in CGCIRs 3 and 4), with the participating miRNA 
acting as a reinforcer or modulator (Fig. 5B). Thus, to understand the coordinated 
regulation of TFs and miRNAs we examined the regulatory network inferred by 
IntegraNet for the presence of coherent and incoherent loops (Supplementary Table 8). 
When we categorized all the regulatory loops based on the target gene's expression and 
240 
 
the type of the feedforward loop, we found a significantly higher frequency of 
myelination genes in the incoherent loops than in the coherent loops (Fig. 5B, I1 as 
opposed to C1). In contrast, there was a significantly higher frequency of proliferation 
genes in the coherent loops than in the incoherent loops (Fig. 5B, C2 as opposed to I2). 
These results suggest that in SC injury response, regulation of myelination gene 
expression tends to be modulated or carefully controlled by miRNAs in incoherent 
feedforward loops, whereas regulation of proliferation gene expression tends to be 
reinforced by miRNAs in coherent feedforward loops. This analysis demonstrated that 
the gene regulatory networks inferred by IntegraNet may provide new insights on the 
cooperative gene regulation by TF and miRNA in complex biological systems.  
 
Discussion 
In this study, we developed the IntegraNet algorithm for TF and miRNA 
regulatory network inference that integrates expression profiling data of mRNAs and 
miRNAs, TF regulatory targets derived from ChIP-Seq data, and computational TF and 
miRNA target prediction. IntegraNet takes a step-wise, bottom-up approach that starts 
with clusters of dynamically regulated or differentially expressed genes or miRNAs as 
the basic network node set and sequentially adds TFs and miRNAs and their regulatory 
interactions to the network. We applied IntegraNet to reanalyze a published dataset of 
mRNA and miRNA expression profiling and expanded a previously identified miRNA 
regulatory network to include TF regulation. By applying IntegraNet to comprehensively 
delineate the gene regulatory network underlying the Schwann cell response to nerve 
injury, we showed that IntegraNet allows integrated inference of gene regulation by TFs 
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and miRNAs in complex biological settings. Our method was able to provide valuable 
new insights into fundamental aspects of the SC regenerative response, indicating its 
potential to help elucidate the complexities of biological processes governed by intricate 
networks of TFs and miRNAs.  
Importantly, the design of IntegraNet took into account the confidence level of 
multiple types of gene regulation information. For example, experimentally identified 
transcriptional regulatory interactions derived from ChIP-Seq datasets were added before 
the regulatory interactions for correlated or anti-correlated regulators, which are followed 
by interactions for regulators with enriched binding sequences but without observed 
coordinated expression (Fig. 1). To further ensure the quality of the network construction, 
the computational predictions used in our method were tested and verified in several 
ways. The computational model for TF target prediction was previously validated using 
ChIP-chip data (Chang et al. 2006). This model was further validated in this study using a 
much larger set of ChIP-Seq experiment data for 70 TFs. When we applied IntegraNet to 
study the gene regulatory network involved in SC response to nerve injury, we compared 
the inferred subnetwork around Egr2, a well-known transcription regulator of 
myelination, to current knowledge of gene regulation in SC and found high consistency. 
Finally, the post-transcriptional regulation of Egr2 by two miRNAs, miR-124 and miR-
140, identified in our network were validated experimentally using luciferase assays 
(Supplementary Fig. 4, A Viader, L Chang, T Fahrner, R Nagarajan, J Milbrandt, in 
press). These results suggest that our method produced an informative and reliable 
regulatory network for SC injury response. 
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An important step in our approach was to use available Chip-Seq data to derive 
mRNA and miRNA targets of TFs. While a significant number of transcription factor 
ChIP-Seq data has been accumulated, only few studies have combined these datasets and 
used this resource to study transcriptional regulation of mRNAs (Hannah et al. 2011), and 
no studies have co-analyzed these datasets to infer transcriptional regulation of miRNAs. 
This is partly due to the lack of reliable prediction of miRNA promoters. By developing a 
new miRNA TSS prediction algorithm, TSSvote, we were able to circumvent this 
problem. Our prediction algorithm incorporates several sequence features that imply TSS 
and our method does not rely on experimental data that probe promoter usage, which may 
be dependent on the experimental conditions. Testing our algorithm using experimentally 
validated miRNA TSS sites showed that the accuracy of our prediction was within 
2500bp in 81% of the cases and the performance was better than current methods (Fig. 
2B). These predicted miRNA TSS allowed for the identification of ChIP-Seq peaks that 
were located within miRNA promoters. The identified miRNA promoters also allowed 
for the computational prediction of TFs that regulate miRNAs (Supplementary Fig. 1). 
Our computational predictions are expected to be more accurate than previously reported 
methods (Shalgi et al. 2007; Guo et al. 2010) due to the more accurate miRNA promoter 
annotation and a more robust TF binding site analysis model.      
A notable strength of our methods is that while it integrates multiple types of 
experimental and computational data, it is also modular in its design. Thus, individual 
components of the network inference pipeline may be improved or replaced separately, 
and additional information about TF or miRNA regulation may be added to the prediction 
model. For example, the computational prediction of TF targets may be further improved 
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by incorporating epigenetic information (Ramsey et al. 2010). Also, additional regulatory 
mechanisms, such as regulation by non-coding RNAs and by RNA binding proteins 
(Viswanathan et al. 2008), may be added into the network once experimental data or 
computational prediction become available for these interactions.    
miRNAs and TFs tend to cooperate in coherent or incoherent feed-forward loops, 
in which miRNAs may function as either a reinforcer or a modulator, to control the 
expression of a target gene (Tsang et al. 2007; Martinez and Walhout 2009; Shalgi et al. 
2009). In our analysis of network motifs in the SC injury response network, we found 
that genes involved in proliferation tend to be regulated by coherent loops, where their 
repression during SC injury response is reinforced by miRNAs. Genes involved in 
myelination, on the other hand, tend to be regulated by incoherent loops, where their 
activation during SC injury response is “fine-tuned” by miRNAs (Fig. 5B). This suggests 
that fast and precise timing of the activation/inactivation of genes associated with the 
immature state of SCs is most critical for the dedifferentiation of these glia after nerve 
injury. In contrast, proper remyelination seems not to require as carefully controlled 
timing of gene expression, but instead depend mostly on achieving precise functional 
levels of myelin-related proteins. This is particularly interesting because myelin 
formation and maintenance is very sensitive to gene dosage effects. In fact, both 
abnormally low or high levels of specific myelin proteins can cause peripheral 
neuropathy in humans (Meyer zu Horste et al. 2006). 
To conclude, we present in this work a new algorithm, IntegraNet, for TF and 
miRNA regulatory network inference. Our approach systematically integrates multiple 
types of experimental data and computational prediction on gene regulation and thus 
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produces more reliable gene regulatory networks. Applying our approach to the SC injury 
response dataset demonstrates that our method may be used to gain new insight on the 
local and global features of gene regulation by TFs and miRNAs.      
 
Methods 
Analysis of ChIP-Seq datasets: Publicly available ChIP-Seq datasets for human and 
mouse transcription factors were compiled and collected from literature search. Peak 
locations identified in the original studies were used if they are available. When peak 
locations were not available, Partek Genomic Suite with default parameters was used to 
identify peaks using raw alignment data. All peak locations were converted to genomic 
coordinates of human genome build hg18 or mouse genome build mm9. Peak locations of 
human datasets were then mapped to the mouse genome using UCSC’s liftover tool and 
vice versa. ChIP-Seq peaks that contained binding sites of a TF were identified using the 
position weight matrix models of TFs available in the TRANSFAC, JASPAR and 
UniPROBE databases (Newburger and Bulyk 2009). Peaks that were located near 
mRNAs or miRNAs were identified using NCBI’s gene annotation for mRNAs and 
computationally predicted miRNA TSS (see below).       
 
Computational prediction of miRNA TSS: To predict miRNA TSS, all human and 
mouse miRNAs were categorized as intergenic or intragenic miRNAs. Intragenic 
miRNAs were defined as miRNAs located between the start and end of a protein coding 
gene that is on the same strand (termed the host gene). miRNAs that are not intragenic 
were defined as intergenic. For intergenic miRNAs, the TSS search range was defined as 
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the genomic sequence between the end of the upstream gene and the start of the pre-
miRNA. For intragenic miRNAs, the TSS search range was defined as the genomic 
sequence between the start of the host gene and the start of the pre-miRNA. To predict 
miRNA TSS, a new algorithm, TSSvote, was developed to score each 100bp window 
within the TSS search range based on transcription related sequence features. Mapping 
locations of known transcripts or ESTs and CpG islands were downloaded from the 
UCSC genome browser. CAGE tags were downloaded from the FANTOM project 
(Severin et al. 2009). H3K4me3 histon modification marks were collected from a 
compiled set of H3K4me3 ChIP-Seq studies (Barski et al. 2007; Mikkelsen et al. 2007; 
Pan et al. 2007; Zhao et al. 2007; Robertson et al. 2008; Araki et al. 2009; Wei et al. 
2009; Cheung et al. 2010; Guenther et al. 2010). Conservation score was calculated as the 
number of aligned species in the 100bp sequence window divided by the number of 
species in which the pre-miRNA was conserved. Using these sequence features, TSSvote 
calculated the score of each sequence window by                             
                            where         equals one if a given feature is 
located within the sequence window. Otherwise,         equals zero. For each miRNA, 
the sequence window within the TSS search range that had the highest score was 
predicted as the miRNA TSS. When multiple sequence windows had the same score, the 
sequence window closest to the miRNA was assigned as the predicted TSS. 
 
Computational prediction of TF regulatory targets: To predict TF regulatory targets, 
we applied a previously developed computational model of transcription factor binding 
site (TFBS) enrichment to the mouse genome (Chang et al. 2008). This approach 
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calculated a binding probability score for a TF-gene pair using all the TF binding sites in 
the proximal promoters of protein coding genes. In this study, we improved this model by 
including 10 mammalian species, whose genomes were completely sequenced with a 
good coverage (>6x). Using NCBI’s mouse genome annotation (build 37.1), for each 
mouse gene the multiple alignments of genomic sequence (downloaded from the UCSC 
genome browser site) from -100kb of the TSS to the end of the gene itself were extracted. 
Within this range, the sequence between -10kb and +5kb of the TSS and the sequence 
regions that have a regulatory potential (RP) score (Kolbe et al. 2004) larger than 0.1 
were identified and collected as the TFBS search space. To search for TFBS, a total of 
867 vertebrate position weight matrix models (PWMs) of TFs were compiled from the 
TRANSFAC, JASPAR, and UniProbe (Newburger and Bulyk 2009) databases. Using 
these PWMs, putative TFBS were identified in the TFBS search space, and the 
evolutionary conservation of each site was determined using multiple sequence 
alignments.  
The original PAP model only considered TFBS conserved in human, mouse and 
rat. Therefore, transcriptional regulation based on non-conserved sites was not accurately 
modeled, and the regulation of non-conserved genes was neglected. To overcome these 
limitations of the original model, we developed a phylogenetic tree-based scoring 
function to weight the contribution of each TFBS by the total tree branch length of all the 
species in which the TFBS is conserved. Thus, TFBS that are conserved in a distantly 
related species will gain a higher weight than those conserved in a closely related species.  
Using this scoring model, for each TF-gene pair, the probability score for binding 
and the P-value were calculated based on all the identified TFBSs. Regulatory targets of 
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TFs were identified using a P-value cutoff of 0.005, which was determined by comparing 
the number of computationally predicted targets to the number of ChIP-Seq identified 
targets for available TFs. The same analysis was applied to identify TFs that regulate 
miRNAs using miRNA promoters, which were defined as the sequence between -5kb and 
+1kb of the miRNA TSS predicted by TSSvote. 
 
Identification of master TF regulators CGC mRNAs or CMC miRNAs: Common TF 
regulators of coexpressed mRNAs were identified by the previously developed Promoter 
Analysis Pipeline tool (Chang et al. 2006), which searches for the enriched TF binding 
sites in the promoter sequences of coexpressed mRNAs or miRNAs. Briefly, an R-score 
was calculated for each gene in the mouse genome based on the ranking of the 
probability score for binding. Genes that are more likely to be regulated by a TF will 
have a higher R-score for that TF. For a set of coexpressed genes, the average of the R-
scores of the member genes were calculated for each TF. The P-value for a given R-score 
was then calculated by using randomly selected gene clusters of the same size. A 
Bonferroni corrected P-value cutoff of 0.05 was used to identify TFs that had 
significantly higher average R-scores as common regulators. The same analysis was 
applied to identify common TF regulators of coexpressed miRNAs based on miRNA R-
scores, which were calculated using the probability score for binding for miRNAs. 
 
 Identification of master miRNA regulators of CGC mRNAs: Common miRNA 
regulators of coexpressed mRNA genes were identified by the enrichment of miRNA 
targets in the coexpresed genes. The hypergeometric P-value for enrichment was 
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calculated for a miRNA using the total number of nerve expressed genes that were 
predicted as targets of any miRNA (population size), the number of coexpressed mRNA 
genes (sample size), the number of nerve expressed genes that were predicted as targets 
of the miRNA (number of successes in population), and the number of coexpressed genes 
that were predicted as targets of the miRNA (number of successes in sample). Common 
miRNA regulators were identified using a hypergeometric P-value cutoff of 0.05. 
 
Analysis of the mRNA and miRNA expression profiling data in HCV infection: Raw 
data of mRNA and miRNA expression profiling data were downloaded from GEO 
(GSE15387). For miRNA microarray data, the total gene signal was used. The expression 
data was normalized across arrays using median centered approach and log2-transformed, 
as described in the original study (Peng et al. 2009). For mRNA microarray data, log-
transformed signal ratios from replicates of the same sample were averaged and used as 
the expression level of the sample. Processed expression data were used to calculate the 
correlation coefficients between the expression profiles of mRNAs and miRNAs. 
 
Identification of core gene clusters for SC injury response (CGCIRs): SC mRNA 
expression profiling before and after crush and transection injury were performed using 
Affymetrix MU74Av2 chips in a previous study (Nagarajan et al., 2002). Gene 
expression levels were measured for uninjured nerves, on days 4, 7 and 10 after crush 
injury, and on days 1, 4, 7, and 10 after transection injury. Mouse gene expression 
profiling data during SC development were collected from an independent study 
(Verheijen et al. 2003). This dataset profiled mRNA expression on days 0, 2, 4, and 10 
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after birth. Expression data were processed and normalized using Affymetrix MAS5 
algorithm. k-means clustering was used to cluster genes based on the combined 
expression profiles of injury response and development. Gene clusters that contained 
known myelin genes and that were differentially expressed before and after crush injury 
based on a t-test were identified. Clusters with similar expression profiles based on the 
Pearson correlation coefficient were identified and merged. The average expression 
profile, i.e. the centroid, was calculated for each cluster. Nerve-expressed genes that were 
correlated with the centroids based on a Pearson correlation coefficient cutoff of 0.8 were 
identified as the final CGCIRs.  
 
Identification of core miRNA clusters for SC injury response (CMCIRs): SC miRNA 
expression profiling before and after crush injury were performed using HTG Molecular 
qNPA miRNA microarrays in a previous study (A Viader, L Chang, T Fahrner, R 
Nagarajan, J Milbrandt, unpublished). Expression of 1046 miRNAs was profiled using 
this microarray platform on days 0, 4 and 14 after crush injury. miRNA expression data 
were filtered using the following criteria: miRNAs that had an expression level lower 
than the average expression of the control miRNA probesets were removed from further 
analysis. miRNAs for which the expression of one duplicate probeset at all time points 
were significantly higher than that of the other duplicate probeset based on a Mann-
Whitney U test were also removed from further analysis. After this filtering procedure, 
the average expression of the two duplicate probesets at each time point was used as the 
expression at that time point. miRNAs that were correlated or anti-correlated with the 
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expression of one of the four CGCIRs were identified as CMCIRs using crush injury 
mRNA expression data on days 0, 4, and 10. 
 
Experimental validation: Plasmids: pre-mir-124 was obtained through PCR 
amplification from genomic DNA. The resulting fragment was cloned between the 
BamHI and Nhe I sites in the miRNASelect pEP-MIR Cloning and Expression Vector 
(Cell Biolabs) using the InFusion HD cloning system (Clonetech) according to the 
manufacurer’s recommendations. Pre-mir-124 included the miRNA stem loop and ~100 
nt of flanking sequence on either side. For luciferase assays, the 3’UTR region of Egr2 
was PCR amplified from genomic DNA using the following primers: Egr2 3’UTR: F, 
AAAGCT GCGCACTAGTGATGAAGCTCTGGCTGACACACCA; R, 
ATCCTTTATTAAGCTTACCA TAGTCAATAAGCCATCCAT. DNA fragments were 
cloned downstream of the luciferase gene between the HindIII and SpeI sites in the 
pMIR-REPORT miRNA Expression Reporter Vector (Ambion). The 3’UTR of Egr2 
lacking the miR-124 pad was cloned in an analogous manner. pRL-CMV Renilla 
Luciferase Reporter vector (promega) was used as a transfection control.   
Luciferase assays: HEK293T cells were seeded at a density of 50,000 cells/well in 
24 well plates in DMEM media (Invitrogen) supplemented with 10% fetal bovine serum 
(FBS), 2 mM L-glutamine. Cell were transfected 24 h later, with either a pEP-MIR vector 
expressing a pre-miRNA or with the pEP-mir Null control and with the pMIR-REPORT 
luciferase reporter vector containing the appropriate 3’UTR linked to luciferase. pRL-
CMV Renilla Luciferase Reporter vector (Promega) was used as a transfection control. A 
total of 200 ng of plasmid DNA/well were transfected at a ratio of 50:1:0.5 (miRNA : 
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luciferase reporter : transfection Ctrl). Cells were harvested 48 h post-transfection and 
assayed using a Dual-Luciferase Reporter Assay System (Promega) according to the 
manufacturer’s protocol.  
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Figures 
Figure 1. The IntegraNet algorithm for gene regulatory network construction. 
Starting with TFs and miRNAs that are correlated with particular expression profiles or 
differentially expressed between two conditions, IntegraNet takes sequential steps in this 
workflow to integrate multiple types of experimental and computational information. In 
each step, nodes and interactions identified from earlier steps are placed in the 
background. Circles: TFs. Hexagons: miRNAs. Blue or red nodes: TFs or miRNAs that 
are identified by expression analysis. Grey nodes: master TF or miRNA regulators 
identified by enrichment of binding sites or targets. 
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Figure 2. A new computational method, TSSvote, predicts the TSS of miRNAs 
reliably. (A) Illustration of the TSSvote algorithm. For intergenic miRNAs (top sequence 
bar), the TSS search range is defined as the genomic sequence between the end of the 
upstream gene and the start of the pre-miRNA. For intragenic miRNAs (bottom sequence 
bar), the TSS search range is between the TSS of the host gene and the start of the pre-
miRNA. TSSvote calculates a score for each 100bp sequence window within the TSS 
search range based on five supporting sequence features of TSS. The sequence window 
that is “voted” by the most features is predicted as the miRNA TSS. (B) Benchmarking 
computational methods for miRNA TSS prediction using a set of 21 experimentally 
validated miRNA TSS. For each method, the percentage of test cases where the distance 
between the predicted TSS and the true TSS is with a given distance is plotted. (C) The 
distribution of the distance between the predicted miRNA TSS and the pre-miRNA. (D) 
The distribution of the percentage of sequence conservation in predicted miRNA 
promoters versus random sequences. (E) The distribution of the number of TF binding 
sites found in predicted miRNA promoters versus random sequences. In (C), (D), and 
(E), mouse data were used, while using human data produced similar results. 
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Figure 3. Validating computational TF target prediction using the compendium of 
TF ChIP-Seq datasets. (A) ChIP-Seq identified TF binding locations (peaks) near 
annotated mRNA transcription start sites (TSS) or predicted miRNA TSS were identified. 
Peaks that also contained TF binding sites (TFBS) based on known TF binding profiles 
were used to identify regulatory targets of TFs. Mann-Whitney U test was used to test if 
identified targets have higher binding scores calculated by the computational model. (B) 
Percent of ChIP-Seq datasets that were consistent with computational TF target 
prediction when tested using mouse or human mRNAs or miRNAs.    
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Figure 4. The SC injury response regulatory network inferred by integrating 
experimental data and computational prediction. Circles: TFs. Hexagons: miRNAs. 
Blue nodes: TFs or miRNAs correlated with myelination gene clusters. Red nodes: TFs 
or miRNAs correlated with proliferation gene clusters. Grey nodes: master TF or miRNA 
regulators of coexpressed genes. Black edges: regulatory interactions derived from TF 
ChIP-Seq data. Grey edges: regulatory interactions inferred by computational prediction. 
Arrowed edges: activation by TFs. T-shaped edges: repression by TFs or miRNAs.  
 
 
 
267 
 
 
 
 
 
 
 
 
 
 
 
268 
 
Figure 5. Local and global analysis of the SC injury response regulatory network. 
(A) Upstream regulators and downstream targets of Egr2 and regulatory interactions 
among them. (B) Biased usage of incoherent and coherent feedforward loops in the SC 
injury response network. Feedforward loops are divided into four categories according to 
the expression pattern of its target gene: I1: an incoherent loop regulating myelination 
genes, I2: an incoherent loop regulating proliferation genes, C1: a coherent loop 
regulating myelination genes, and C2: a coherent loop regulating proliferation genes. For 
each category, the number of network motifs in the SC injury response network and the 
number of TFs, miRNAs, and targets that participate in those motifs are shown, with 
more prevalent network motifs highlighted in grey. Circles: TFs. Hexagons: miRNAs. 
Rectangles: target mRNAs. Blue nodes: TFs or miRNAs correlated with myelination 
gene clusters. Red nodes: TFs or miRNAs correlated with proliferation gene clusters. 
Grey nodes: master TF or miRNA regulators. White boxes: downstream target genes not 
included in the network. Arrowed edges: activation by TFs. T-shaped edges: repression 
by TFs or miRNAs.   
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Supplementary Figure 1. Workflow of the computational method for predicting TFs 
that regulate mRNAs, using NCBI’s TSS annotation, or miRNAs, using 
computational TSS prediction. 
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Supplementary Figure 2. The hepatitis C virus (HCV) associated gene regulatory 
network. Circles: TFs. Hexagons: miRNAs. Blue nodes: TFs or miRNAs over-expressed 
in HCV-positive samples. Red nodes: TFs or miRNAs over-expressed in HCV-negative 
samples. Grey nodes: master TF or miRNA regulators of differentially expressed genes. 
Black edges: regulatory interactions derived from TF ChIP-Seq data. Grey edges: 
regulatory interactions inferred by computational prediction. Arrowed edges: activation 
by TFs. T-shaped edges: repression by TFs or miRNAs.  
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Supplementary Figure 3. CGCIRs and CMCIRs dynamically regulated in SC injury 
response. (A) Expression profiles of the four CGCIRs. (B) Gene Ontology terms enriched 
in each of the four CGCIRs. Color coding of bars matches that of the expression profiles 
shown in (A). (C) Expression profiles of miRNAs that are correlated with CGCIRs 1 or 2 
(blue) and miRNAs that are correlated with CGCIRs 3 or 4 (red).  
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Supplementary Figure 4. Luciferase assays confirm a direct interaction between 
miR-124 and the 3’-UTR of Egr2. Overexpression of miR-124 but not of a Ctrl miRNA 
in HEK293T cells expressing a luciferase reporter construct carrying the 3’-UTR of Egr2 
results in significantly decreased luciferase activity (p<0.05, two-tailed Student’s t-test). 
Mutating the predicted landing pad for miR-124 in the 3’-UTR of Egr2 disrupts the 
interaction between miR-124 and the Egr2 3’-UTR luciferase construct and restores 
luciferase activity.   
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Conclusions and Future Directions 
Mitochondria are critical mediators of disease progression in peripheral 
neuropathies. Mitochondrial dysfunction, for example, is thought to be largely 
responsible for peripheral nerve diseases associated with systemic metabolic disorders 
such as diabetes (Fernyhough et al., 2010). Similarly, abnormalities in mitochondrial 
metabolism ultimately account for the presentation of some forms of CMT in which 
mitochondrial proteins are mutated (Niemann et al., 2006). With the hope of developing 
new therapies much effort is being devoted to understanding how mitochondrial 
deficiencies influence nerve function. To date, most work has focused on clarifying the 
role played by neuronal/axonal mitochondria (Baloh, 2008). The contribution of SC-
specific mitochondrial deficits to the pathophysiology of peripheral neuropathy, however, 
has remained largely unexplored. Given that SCs intimately associate with and critically 
support all peripheral nerve axons (Chen et al., 2003; Meyer zu Horste et al., 2007; 
Reddy et al., 2003), greater insight into the biology and pathology of SC mitochondrial 
metabolism could be relevant to the treatment of peripheral neuropathies. In the present 
thesis we addressed the contribution of mitochondrial deficits specifically in SCs to 
disease progression in peripheral nerve disease. We also explored some of the 
mechanisms by which mitochondrial metabolism abnormalities in SCs may contribute to 
axonal degeneration and damage peripheral nerves. Finally, we examined the gene 
regulatory network that is important for peripheral nerve regeneration after injury and in 
disease states.    
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Mitochondrial derangements in SCs are underappreciated contributors to the 
pathology of peripheral neuropathies 
With the goal of understanding whether SC mitochondrial abnormalities affect 
axonal survival and peripheral nerve function, we generated and characterized the first 
mouse model useful in directly interrogating the contribution of SC mitochondrial 
dysfunction to peripheral neuropathy (Chapter 2) (Viader et al., 2011). These mice 
(Tfam-SCKOs), were produced through the tissue-specific deletion of the mitochondrial 
transcription factor A gene (Tfam), which is required for mtDNA transcription and 
replication and when excised induces progressive defects in the mitochondrial electron 
transport chain (Larsson et al., 1998)  Interestingly, we found that the induction of 
mitochondrial dysfunction specifically in SCs did not affect their survival; instead it 
resulted in a severe, progressive peripheral neuropathy characterized by extensive axonal 
degeneration. These results showed that disrupted mitochondrial function specifically in 
SCs can itself cause axonal degeneration and peripheral nerve disease. Moreover, these 
results highlighted that much of the pathology present in peripheral neuropathies may 
primarily reflect metabolic abnormalities in SCs. This is in agreement with previous work 
examining the role of the polyol pathway in diabetic neuropathy (Tomlinson and 
Gardiner, 2008), and emphasizes the potential of targeting metabolic abnormalities that 
affect SCs as a way to treat peripheral neuropathies.  
Importantly, Tfam-SCKO mice generated in our study recapitulated a number of 
critical pathological features of human peripheral neuropathies. Disrupting mitochondrial 
metabolism specifically in SCs was sufficient to induce both axonal degeneration as well 
as demyelination. Tfam-SCKOs also displayed distal weakness and sensory deficits, two 
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common problems in human patients. Finally, Tfam-SCKOs suffered preferential early 
loss of unmyelinated C fibers followed by the degeneration of large-caliber myelinated 
axons. This was of particular interest because preferential loss of small-caliber 
unmyelinated fibers is characteristic of peripheral and optic neuropathies associated with 
systemic diseases such as diabetes or with exposure to environmental toxins (Kennedy et 
al., 1996; McArthur et al., 2005; Sadun, 2002). Together, our results indicated that key 
pathological features commonly encountered in human peripheral nerve disease can 
potentially be explained by SC-specific mitochondrial dysfunction. Moreover, our 
observations suggested that Tfam-SCKO mice may be particularly useful in 
understanding some of the pathophysiology of diabetic and other mitochondria-related 
neuropathies, as these mice are one of few metabolic mutants (Sullivan et al., 2007) that 
strongly recapitulate some of the pathology of human peripheral nerve diseases. 
 
Role of SC mitochondrial metabolism in the biology of these glia and the metabolic 
support of axons 
Unexpectedly, severe respiratory chain abnormalities in the SCs of Tfam-SCKO 
mice did not affect their survival. This observation suggested that SCs have an adaptable 
energy metabolism. In fact, we observed that following Tfam-depletion and inhibition of 
mitochondrial respiration SCs induced mitochondrial biogenesis and increased 
glycolysis. These two metabolic adaptations that often follow mitochondrial deficits 
(Chabi et al., 2005; Piao et al., 2010), likely account for the relative preservation of 
energy levels in Tfam-SCKO nerves as well as the limited or largely delayed death of 
SCs. Our current knowledge of the basic energy metabolism and requirements of SCs, 
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however, is still very rudimentary. SCs, for example, have been hypothesized to be 
largely glycolytic and rely on the non-oxidative catabolism of glucose to meet their 
energy needs (Pellerin and Magistretti, 2003). This idea is supported by the observation 
that in explant systems SCs take up a disproportionately large amount of glucose (Vega et 
al., 2003). The fact that disruption of mitochondrial energy metabolism in Tfam-SCKO 
mice did not affect SC survival and resulted in increased glycolysis provided indirect 
support for this hypothesis. At the same time, increased mitochondrial biogenesis in 
Tfam-deficient SCs suggested that these glia still depend on mitochondria to meet some 
of their metabolic needs.  Future work aimed at understanding the basic metabolic 
requirements of SCs and the adaptations that follow disturbances of specific energy 
metabolism pathways (e.g. OXPHOS, glycolysis, fatty acid oxidation…) should provide 
valuable insight into both the biology and pathology of SCs. 
One of the more intriguing aspects of the pathology in Tfam-SCKO nerves is that 
it may reflect a disruption of SC-mediated metabolic support of axons. SCs have a 
primary role in supporting axonal function and survival (Chen et al., 2003; Meyer zu 
Horste et al., 2007; Reddy et al., 2003), and metabolic support of axons by ensheathing 
glia is hypothesized to be critical to this function of SCs (Nave and Trapp, 2008). Similar 
to what happens in the CNS between neurons and astrocytes, SCs may support axons 
through the transfer of metabolites or by helping axons eliminate certain toxic species 
(Benarroch, 2005). Tfam-SCKO mice provide an in vivo system in which begin to 
address some of the details of the mechanisms behind the putative metabolic support of 
axons by SCs. Tfam-SCKO mice may be a particularly valuable model when combined 
with other systems designed to more directly examine the transfer of specific energy 
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metabolites likely to shuttle between SCs and neurons (e.g. lactate, glutamine, 2-
oxoglutarate, malate) (Miller et al., 2002). In this context, the generation of new 
transgenic mice lacking certain metabolite transporters specifically in SCs or axons could 
prove especially informative (Voutsinos-Porche et al., 2003). Mechanistic inside derived 
from such studies will complement our basic observation of that SC mitochondria are 
essential for the SC-mediated support of axonal function and survival; it should also be 
important in identifying new potential therapeutic targets for peripheral neuropathy.  
 
The integrated stress response as a common maladaptive mechanism in peripheral 
neuropathies 
Having established the relevance of the characterization Tfam-SCKO mice to 
understanding and potentially treating peripheral neuropathies, chapter three in this thesis 
described our efforts aimed at discovering the mechanisms underlying the nerve 
pathology in these mice. Our examination of Tfam-SCKO mice uncovered the activation 
of the ISR in Tfam-deficient SCs secondary to mitochondrial dysfunction. The ISR is an 
evolutionarily conserved, “stress”-activated, gene expression program centered on 
phosphorylation of eIF2. Activation of this program is meant to promote a cellular 
stress-resistant state by global attenuation of protein synthesis, which reduces the ER load 
and diverts amino acids from energetically costly protein synthesis to other metabolic 
pathways (Ron and Walter, 2007). Activation of this program in SCs, however, is 
particularly maladaptive and is thought to cause some of the pathology present in 
neuropathies associated with mutations to structural myelin proteins (Pennuto et al., 
2008). In this context, induction of the ISR in SCs is associated with the accumulation of 
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mutant myelin proteins in the ER and an unfoled protein response (Lin and Popko, 2009). 
Activation of the ISR in Tfam-SCKO, mice, however, was not associated with ER stress 
or an unfolded protein response. The maladaptive induction of the ISR in SCs could 
therefore be a common pathological mechanism in different forms of peripheral 
neuropathy, including those associated with mutations to structural myelin as well as 
metabolic abnormalities. 
While the idea that ISR activation may be a common pathological mechanism in 
peripheral neuropathies of diverse etiology is attractive, this hypothesis would be greatly 
strengthened by evidence that confirms the role of this pathway in the pathology of Tfam-
SCKO mice. This evidence could come from the examination of nerve disease 
progression in Tfam-SCKOs that also lack the key downstream mediator of the ISR 
Chop, as previously done by Pennuto and colleages in another neuropathy model 
(Pennuto et al., 2008). Intriguingly, neuropathy-causing chemotherapy drugs have also 
been shown to activate the ISR in cell lines in vitro (Gately et al., 1996). Experiments 
that explore whether chemotherapy drugs activate the ISR in SCs would also provide 
further credit to our hypothesis.  
 
A shift in SC lipid metabolism as a key driver of the pathology of Tfam-SCKO 
nerves 
Lipids play a crucial role in the normal biology of SCs; they are required for 
myelin assembly and maintenance, regulate the differentiation status of these glia, and 
may also be important for SC-mediated metabolic support of axons (Chrast et al., 2010). 
Our work identified a shift in lipid metabolism early in the disease progression of Tfam-
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SCKO nerves. This alteration in SC lipid metabolism was characterized by a decreased 
flux of fatty acids towards new lipid synthesis and a concomitant increase in lipid 
oxidation. Importantly, this shift in SC lipid metabolism secondary to mitochondrial 
dysfunction in Tfam-deficient SCs preceded much of the nerve pathology in Tfam-
SCKOs and could thus ultimately account for the disease phenotype in these mice. 
Abnormalities in nerve lipid composition are present in a number of peripheral 
neuropathies in which mitochondrial dysfunction is known to occur (Chrast et al., 2010; 
Navarro et al., 2010; Niemann et al., 2006). Our results suggested therefore that 
alterations in SC lipid metabolism may be at the center of the pathology of 
mitochondrial-related neuropathies modeled in Tfam-SCKO nerves. 
The shift in the lipid metabolism in Tfam-deficient SCs resulted in depletion of 
sulfatides and cerebrosides, key myelin lipid components that together represent almost 
30% of all myelin lipid content (Garbay et al., 2000). The early reduction of these lipids 
likely accounted for the prominent demyelinating phenotype apparent in late stages of 
disease in Tfam-SCKO mice (Viader et al., 2011). Interestingly, sulfatides and 
cerebrosides also have an important role in maintaining axon-glial contact (Dupree et al., 
1998; Hoshi et al., 2007). Depletion of these galactolipids could thus also drive some of 
the later axon loss in Tfam-SCKO nerves by disrupting the ability of SCs to properly 
associate with and support axons. As our understanding of SC-mediated metabolic 
support of axons expands it will be interesting to examine how this support is affected by 
depletion of sulfatides and cerebrosides and disruption normal axon-glial interactions.  
We also observed a significant accumulation of acylcarnitines in Tfam-SKCO 
nerves. Our work provided initial evidence that such accumulation of fatty acid -
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oxidation intermediates in SCs following mitochondrial deficits could also be 
contributing to axonal degeneration in peripheral neuropathies. We found that long-chain 
acylcarnitines could be released from SCs, disrupt the membrane properties of axons, and 
induce their degeneration. These results are in agreement with the fact that neuropathy is 
among the long-term complications of genetic disorders leading to buildup of 
acylcarnitines (Schaefer et al Turnbull, 1996; Tyni & Pihko, 1999). To unequivocally 
link acylcarnitine accumulation to axonal degeneration in Tfam-SCKO nerves, however, 
one will need to assess the benefits of preventing the increase of these lipid intermediates 
in Tfam-SCKOs. Etomoxir treatment, an inhibitor of the acylcarnitine synthesizing 
enzyme Cpt1, could be useful in pursuing this line of investigation, particularly as 
etomoxir has shown therapeutic potential in the treatment of other neurodegenerative 
conditions (Shriver et al., 2011). Crossing Tfam-SCKOs to mice lacking malonyl-coA 
decarboxylase, an enzyme that degrades the natural CPT1 inhibitor malonyl-CoA, could 
provide an alternative genetic model to further asses the role of acylcarnitine 
accumulation in peripheral neuropathy. Intriguinly, malonyl-coA decarboxyalse deficient 
mice are protected against diet induced glucose-intolerance (Koves et al., 2008)  
 
miRNAs modulate the ability of SCs to support peripheral nerve regeneration 
To complement the work describe in the first part of this thesis, which aimed at 
understanding the basic pathological mechanism that drive peripheral nerve disease, we 
also  examined the transcriptional and post-transcriptional gene regulatory networks that 
are responsible for the regenerative response of Schwann cells (chapters 5 and 6). Greater 
insight into this highly orchestrated process could be harnessed to help restore function in 
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peripheral and central neurodegenerative diseases characterized by axonopathy, including 
diabetic neuropathy and amyotrophic lateral sclerosis (Coleman, 2005). We explored 
whether injury-induced changes in SCs were orchestrated post-transcriptionally by 
microRNAs (miRNAs). Interestingly, we found that SC miRNAs modulated the injury 
response largely by targeting positive regulators of SC dedifferentiation/proliferation. SC 
miRNAs cooperated with transcriptional controls to promote rapid and robust transitions 
between the distinct differentiation states necessary to support nerve regeneration. Our 
results suggested, therefore, that that manipulation of SC miRNAs could be used 
therapeutically to facilitate SC differentiation after injury or reverse the effects of 
neuropathy.  
The therapeutic modulation of SC miRNAs, however, requires the identification 
of specific miRNAs playing critical roles in the establishment and maintenance of SC 
differentiation as well as in the modulation of the SC injury response. We identified miR-
34a and miR-140 as two such candidates that critically regulate SC proliferation and 
myelination, respectively. mir-34a and mir-140 deficient mice have been generated (Choi 
et al., 2011; Miyaki et al., 2010) and examination of the SC injury response in these mice 
could be especially useful in determining the therapeutic value of these two miRNAs. 
Future experiments that examine some of the other miRNAs identified in this thesis to be 
potentially important for the SC regenerative response (e.g. let-7 familiy members, mir-
22, mir-26a…) could also be interesting.  
 
In conclusion, the results described in the present thesis expand our understanding 
of how mitochondrial abnormalities specifically in SCs contribute to the clinical 
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impairment in patients afflicted with peripheral neuropathy. Our findings emphasize that 
future therapies for peripheral neuropathy will need to address metabolic abnormalities in 
SCs and not just in axons if they hope to effectively prevent disease progression. More 
importantly, our work identifies new potentially important therapeutic targets that may 
eventually enhance the quality of life of patients with peripheral nerve diseases.  
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